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Biopharmaceuticals represent a variety of biological products for diagnostic and therapeutic 
purposes, of which developments are driven by the recent advances in biotechnology. However, 
oral administration of biopharmaceuticals is challenging due to the low absorption of 
macromolecules and the potential degradation that occurs in the harsh environment of the 
gastrointestinal tract. Various strategies have been explored to improve the bioavailability of these 
therapeutic agents, and some strategies have the potential to protect these fragile proteins from 
the harsh environment. The low permeability of these macromolecules across the intestinal 
epithelium remains the main challenge.  
This work focuses on providing a strategy to increase the intestinal epithelium permeability of 
biopharmaceuticals. In nature, bacterial toxins, such as Pseudomonas aeruginosa exotoxin A 
(PE), are able to travel across the intestinal epithelium and target the immune cells underneath. 
The hypothesis of this study is that these toxins can facilitate the trans-epithelial transport of toxin-
conjugated nanoparticles. Two biodegradable and mucoadhesive polymers, alginate and chitosan, 
were selected for the preparation of nanoparticles.   
Alginate-chitosan nanoparticles had a diameter of 179 ± 3 nm and a zeta potential of 17 ± 5 
mV. After the conjugation with ntPE, the size and zeta potential changed to 202 ± 20 nm and -6 
± 5 mV, respectively. Transcytosis of ntPE-coupled nanoparticles was evaluated on Caco-2 cell 
monolayers in vitro. The transport rate was 4.36 ± 2.24 %, compared to 4.18 ± 2.05 % for 
nanoparticles conjugated with bovine serum albumin (BSA) and 2.83 ± 1.29 % for unmodified 
ones. The trans-epithelial transport of ntPE-coupled nanoparticles was then examined in the living 
rat small intestine. Nanoparticles coupled with ntPE were found to accumulate in the lamina 
propria of the rat small intestine, while no BSA-coupled nanoparticles or unmodified 
nanoparticles were found in the tissue sections. Finally, green fluorescent protein served as a 
model for biopharmaceuticals, and was loaded into alginate-chitosan nanoparticles to study the 
trans-epithelial delivery ability of these nano-carriers.     
Overall, this thesis tests the feasibility of using a bacterial toxin to facilitate the trans-epithelial 
transport of nano-carriers loaded with biopharmaceuticals. Results support this hypothesis and 
suggest these alginate-chitosan nanoparticles are worthy of continued work to develop into nano-
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Chapter 1    Introduction  
 
Overview:  The field of biopharmaceuticals is growing fast with emerging biotechnology, 
unfortunately, most of the therapeutic proteins on the market are restricted to the injection route, 
which is invasive and has low patient compliance. The clinical potential of biopharmaceuticals 
would therefore be greatly expanded by the ability to deliver these therapeutics as oral dosage 
forms. However, biopharmaceuticals are vulnerable to the acidic and enzymatic environment in 
the gastrointestinal (GI) tract, and the therapeutic effect is also extremely limited by their low 
permeability across the intestinal epithelium.  
In order to provide a successful oral delivery strategy, approaches must be developed to 
overcome these issues of instability and poor uptake following oral dosing. This chapter gives a 
brief description of the anatomy of the GI tract, emphasising its characteristics that hinder the 
administration of biopharmaceuticals. In this respect, strategies based on absorption enhancers, 
enzyme inhibitors, chemical conjugation, and nano-carriers are discussed. In addition, this chapter 
describes different transport routes for nano-carriers, including the paracellular pathway, and 
transcytosis via M cells or absorptive epithelial cells (enterocytes). The approach of modifying 
nano-carriers with ligands to facilitate their transcytosis is the subject of this thesis.  
The specific approach examined in this thesis involves ligand-mediated nano-carrier uptake 
where the ligand used is a non-toxic version of Pseudomonas exotoxin A (ntPE). Finally, the main 

















1.1 Challenges and advantages of oral biopharmaceutical delivery 
 
Biopharmaceuticals (i.e. protein, peptide, or nucleic acid-based agents) are manufactured by 
using biotechnology or synthetic methods for the purpose of therapeutic or diagnostic 
applications. In particular, the development and commercialisation of protein-based 
biopharmaceuticals has changed the direction of healthcare. This area has undergone a boom since 
two discoveries were reported in the mid-1970s: hybridoma technology for producing large 
numbers of identical antibodies, and genetic engineering for the large-scale production of proteins 
(11). The first recombinant protein drug (human insulin) was approved by the US Food and Drug 
Administration in 1982, and the proportion of biopharmaceuticals on the market has been 
increasing ever since. By 2016, around 650 protein drugs had been approved worldwide, and over 
1300 recombinant pharmaceuticals are under development (12). Biopharmaceuticals have been 
used for treating different types of cancer, autoimmune diseases, as well as various genetic and 
metabolic diseases (13, 14). Overall, the annual market for biopharmaceuticals is predicted to 
reach $386.7 billion by the end of 2019 globally (15).   
Compared to conventional small drug molecules, therapeutic proteins offer several distinct 
advantages: 1) the unique structure and function allows for a highly specific pharmacological 
effect, thereby, interfering less with normal biological processes (16); 2) since the body produces 
many of the proteins used as therapeutics, these agents are well tolerated and less immunogenic; 
3) the specific structures and effects of proteins enable pharmaceutical companies to gain far-
reaching patent protection, providing critical financial benefits for the companies developing 
them (17).   
While recombinant proteins have been used clinically for more than ~35 years, their 
administration is still restricted largely to the parental route (i.e. intravenous, intramuscular, and 
subcutaneous injection). Frequent injections might cause reactions at the site of administration, 
and reduce patient compliance (18). On the other hand, injections also carry the risk of infection 
resulting from inappropriate use or reuse of needles; there is also a social stigma associated with 
injecting drugs (19). Delivering biopharmaceuticals via the oral route is a very attractive 
alternative to parental delivery, but this approach is severely limited by the physical, chemical 
and biological barriers established by the GI tract. 
The oral route presents several advantages over other means of administration, not only 
because it is the most convenient way of delivering drugs compared to other non-invasive routes 
(i.e. pulmonary, intranasal, and transdermal), but also has high patient compliance (20). From a 






care professionals, which makes it cheaper compared to parenteral administration (21). 
Further, an oral dosage form must be aseptic, but not sterile in the same way as a parenteral 
formulation, which saves manufacturing costs (21). Finally, there is a number of 
biopharmaceuticals that could have improved benefit by oral administration. For example, insulin 
delivered orally results in its direct targeting to the liver via hepatic portal circulation, replicating 
its physiological direct targeting to the liver after its release from the pancreatic beta cells. The 
current form of subcutaneous injection of insulin delivers the dose to the systemic circulation 
firstly with only a fraction (10 – 20 %) reaching the liver. By better mimicking this physiological 
route, oral insulin is likely to bring additional advantages on clinical effects, including reducing 
the risk of hypoglycaemia, weight gain associated with systematic insulin therapy, and reduction 
of hyperinsulinemia (22).  
 
1.2 Anatomy and physiology of the gastrointestinal tract 
 
The GI tract is composed of the mouth, oesophagus, stomach, small and large intestine; its 
primary role is to macerate and digest foodstuffs with the goal of nutrient absorption (Figure 1-1). 
The stomach is a muscular, hollow organ that secretes gastric acid and digestive enzymes to break 
down substances such as carbohydrates, proteins, and fats. The absorption of these nutrients takes 
place primarily in the small intestine, which is composed of the duodenum, jejunum, and ileum. 
The large intestine is mainly responsible for extracting water and salts from solid wastes before 
the elimination from the body, and working together with resident bacteria to derive nutrients 
from materials poorly digested in the upper GI tract.  








Figure 1-1: Diagram of the human GI tract. The GI tract is an organ system 
that digests food and absorbs nutrients, as well as expels the remaining waste. 
It is composed of the mouth, oesophagus, stomach, small intestine and large 
intestine. The image is modified from (1). 
Liver 
Stomach: acidic environment, pH 1-2 
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The innermost layer of the GI tract is called the epithelium, which acts as a physical and 
biological barrier separating the body from the lumen that is contiguous with the external 
environment. The luminal space is enriched with many digestive enzymes, ingested compounds 
in various states of degradation, and potentially noxious substances (23). The small intestinal 
epithelium is responsible for selectively absorbing major nutrients from the lumen as well as for 
maintaining the homeostatic conditions in the small intestine, while restricting the uptake of 
unwanted or dangerous materials. Underlying the epithelium is the lamina propria; this tissue 
functions as scaffold, in turn the lamina propria is supported by a thin layer of smooth muscle, 
called the muscularis mucosa (23).   
Numerous finger-like structures called villi protrude into the lumen (~0.5 – 1.6 mm), which 
increase the surface area for nutrient absorption by ~30-fold (Figure 1-2) (24). The intestinal villi 
mainly consist of a monolayer of columnar absorptive epithelial cells (named enterocytes) that 
are interspersed with goblet cells. Blood and lymphatic vessels (termed lacteals) are connected 
with the villi, for the purpose of absorbing nutrients from the lumen. 






Figure 1-2: Illustration of the small intestine. The innermost layer of the small intestine is the epithelium, 
and it is supported by a layer of connective tissue named lamina propria. Numerous finger-like structures 
(called villi) extend toward the lumen, and a network of capillaries and lacteal vessels are the routes for 








At the base of villi are crypts (Figure 1-3), which contain Paneth cells, stem cells and 
enteroendocrine cells. Epithelial stem cells are constantly proliferating to renew the epithelial 
cells in the crypts that then work their way up to the tip of each villus. Paneth cells, named after 
physiologist Joseph Paneth in the 1880s, secrete anti-bacterial products such as lysozyme and 
defensins that help to protect the intestinal epithelium from pathogens (25). Enteroendocrine cells 
are specialised cells for producing gastrointestinal hormones, which function as intercellular 
messengers for regulation of the nervous-immune responses to specific stimuli (26).  
 
     
Enterocytes are the most abundant cells in the GI tract. These polarised cells are known for 
their actions in metabolism and nutrient absorption. Each enterocyte has numerous hair-like 
structures that extend into the lumen known as microvilli (~1 µm by length), expanding the 
membrane surface available for absorption by 600-fold (27). These cells have an apical-basal 
polarity; the apical membrane faces the intestinal lumen, and the basolateral membrane is 
connected to the basement membrane (28). The apical and basolateral membranes are composed 
of different types of proteins and lipids; sphingolipids and cholesterol are enriched in the apical 





Figure 1-3: Diagram of small intestinal epithelium. The surface of the epithelium is covered by a 
mucus layer as a protective barrier for the underlying epithelial cells. The folded epithelium, villi, 
are composed of a single layer of enterocytes interspersed with goblet cells. Paneth cells, entero-
endocrine and epithelial stem cells are found in the crypts, which are important for the regulation 
of the small intestine. Peyer’s patches are aggregations of lymphatic tissue, their surfaces are 
covered by follicle-associated epithelial cells mainly consisting of M (for microfold) cells. Image is 
from (2) .  





enterocytes contain a primary cilium which is a long, thin extension of the plasma membrane 
(Figure 1-4). The segregation of apical from basolateral plasma membrane is controlled and 
stabilised by lateral cell-cell adhesion junctions, containing desmosomes, gap junctions, adherens 
junctions, and tight junctions shown in Figure 1-4.  
    
Desmosomes are adhesive intercellular junctions that are critical for maintaining stable cell-
cell adhesion (29); gap junctions form cell-to-cell channels that only allow the diffusion of small 
molecules (< 1 kDa) between adjacent enterocytes. Adherens junctions are cytoskeletal-
membrane microdomains located the basal side of tight junctions, which provide adherent 
strength at cell-cell contacts (8). Tight junctions consist of a network of transmembrane proteins 
involving claudins, occludin, tricellulin and junctional adhesion molecules. The function of tight 
junctions is not only preventing the mixing of apical and basolateral membrane components, but 
also restricting the movement of solutes, ions, and water between adjacent cells via the so-called 
paracellular route (30). Extracellular domains of occludin can regulate the paracellular 
permeability between adjacent enterocytes, but the properties of this regulation are dominated by 
the actions of claudins.  
Tight junction proteins can be a target for manipulating the paracellular permeability in order 
to enhance trans-epithelial drug absorption (31). Claudin proteins constitute a family of 24 
transmembrane proteins, of which claudin-2, -4, -7, and -15 are predominantly expressed in the 
intestinal epithelium (32). Interactions between claudins and ZO proteins are required for the 
assembly of tight junction structures. ZO-1, ZO-2 and ZO-3 are members of the family of zona 
 
 
Figure 1-4: Illustration of the polarised enterocytes. Different proteins and lipids are located on the 
apical and basolateral membranes. This segregation of apical from basolateral membrane is 
stabilised by the lateral cell-cell adhesion junctions, containing tight junctions, adherens junctions, 




















occludens proteins, which bind to adherens and tight junction proteins in addition to the actin 
cytoskeleton (30).  
Another type of cell in small intestinal villi is the goblet cell, which functions to produce 
mucin, a substance used to maintain a hydration layer over the surface of the epithelium and to 
entrap bacterial and viral pathogens (33). The GI tract also contains gut-associated lymphoid 
tissue (GALT), which consists of isolated or aggregated lymphoid follicle-associated epithelium 
(Peyer’s patches) (Figure 1-3). M (microfold) cells are located within Peyer’s patches. In contrast 
to enterocytes, M cells lack an extensive mucus layer and display poorly organised and irregular 
shaped microvilli (34). These specialised cells play an important role in immune surveillance as 
they internalise antigens from the intestinal lumen via endocytosis, and deliver them to the 
underlying lymphoid tissue in the lamina propria (35).  
 
1.3 Anatomical, biochemical, and physiological barriers  
 
Although the oral route is attractive for delivering biopharmaceuticals, there are still 
challenges to overcome for efficient delivery of therapeutic proteins: 1) the harsh environment in 
the GI tract; 2) the defensive mucus layer; and 3) the low permeability of intact proteins across 
the epithelium. 
 
Acidic and enzymatic environment in the GI tract 
The acidic environment (pH ~1 – 2) in the stomach alters the ionisation state of amino acids, 
which acts to unfold proteins through the disruption of interactions involved in secondary or 
tertiary structures (36). Additionally, such acidity can also break some peptide bonds (37). All of 
these effects could cause a loss of specific structure and function for a biopharmaceutical. In 
general, four categories of digestive enzymes are present in the GI tract: lipases, proteases, 
amylases, and nucleases, which are responsible for breaking down fats, proteins/peptides, 
carbohydrates, and nucleic acids, respectively. Exposure of therapeutic proteins to proteases, such 
as trypsin and chymotrypsin released from the pancreas into the duodenum, may lead to the 
hydrolysis of peptide bonds or the chemical modification of the functional groups, for example, 
oxidation and de-phosphorylation. All these biochemical reactions will denature or degrade 
proteins, which may change their pharmacological effects (38).  
 
 





The Mucus layer 
Mucus is a viscous material that is adherent to the surface of the intestinal epithelium. It is 
composed predominantly of secretions released from specialised goblet cells. Mucus is a complex 
hydrogel composed of proteins, carbohydrates, lipids, salts, antibodies, bacteria, and cellular 
debris; but the main protein component of mucus is the glycoprotein mucin that is viscous and 
has elastic gel-like properties (39). Mucus is responsible for lubricating the GI tract to assist the 
passage of substances as well as providing a barrier to protect the epithelium from pathogens and 
noxious substances (40). At the apical surface is the glycocalyx; membrane-bound mucins (MUC) 
entangle and cross-link with other molecules, such as glycolipids and glycoproteins, to form an 
adherent  ~500 µm thick coating layer between the cells and loosely held mucus (33). Specifically, 
MUC 3 is expressed in the apical membrane of enterocytes and goblet cells as part of this process 
to produce extended rod-like structures, that form a component (200 – 1500 nm) of the glycocalyx 
(41). Frey et al. (1996) showed the glycocalyx is a size-selective barrier with a functional pore 
size of 7.4 – 28.8 nm (42). There is constant turnover of the adherent layer and the glycocalyx to 
remove the potentially damaging compounds on the lumen surface (43).  
 
Low permeability across the epithelium  
A greater challenge than these two hurdles of harsh environment and mucus layer is the low 
permeability of crossing the intestinal epithelium. The size of most therapeutic proteins ranges 
from ~3.5 kDa (calcitonin) to ~150 kDa (monoclonal antibodies), all being too large and too 
hydrophilic to readily diffuse across enterocytes driven by the concentration gradient in a manner 
similar to many small molecule drugs; this transcellular pathway is size-dependent (< 700 Da) 
(44, 45) and a minimum level of lipophilicity is needed for molecules to partition into the cell 
membrane, and to be transported across the cell (46). Molecules with a lower degree of 
lipophilicity can travel across the epithelium via the paracellular pathway, meaning via the 
intercellular spaces between two adjacent cells. Unfortunately, this pathway is restricted to 
relatively small compounds (< 3.5 kDa), which is not applicable for most therapeutic proteins (9).   
The low permeability of therapeutic proteins has direct impact on their bioavailability and thus 
limits their pharmacological effects (20). That is to say, even when the biopharmaceutical is 
extensively protected from the harsh environment in the GI tract, less than 1 % of therapeutic 








1.4  Overcoming these barriers 
 
Based on the anatomy of the GI tract and challenges of transporting therapeutic proteins via 
the oral route, various attempts have been made to improve the bioavailability of therapeutic 
proteins over the years. These approaches have attempted to overcome one or more of the barriers 
to oral protein delivery listed above. 
 
Enzyme inhibitors 
Co-administration of protein drugs with protease inhibitors, such as aprotinin (an inhibitor of 
trypsin and chymotrypsin), soybean trypsin inhibitor, and FK-448 (a chymotrypsin inhibitor), has 
shown increased permeability of proteins (47). The choice of protease inhibitor depends on the 
structure of delivered protein and its specificity towards the enzyme. For example, Yamamoto et 
al. (1994) showed significant hypoglycaemic effect following large intestinal co-administration 
of insulin with Na-glycocholate, camostat mesilate and bacitracin, while marginally enhanced 
insulin absorption was observed following co-administration with soybean trypsin inhibitor and 
to a moderate degree for aprotinin (48). In addition, the cocktail of enzymes present in different 
segments of the GI tract is different, which would make the choice of enzyme inhibitors more 
difficult. Furthermore, due to the potential denaturation of enzyme inhibitor itself in the gut, 
excessive amount of inhibitor is required. If a long-term treatment is considered, normal protein 
digestion might be affected (18). 
Some mucoadhesive polymers are promising candidates as enzyme inhibitors. Hutton et al. 
(1990) firstly reported the inhibitor properties of polyacrylate on intestinal proteases (49). Lueßen 
et al. (1995) proposed that the inhibitor effect of polyacrylate derivatives is due to the formation 
of complexation with divalent cation ions (calcium ions), so that the ion-dependent enzymatic 
effects are prevented (50). Although these polymers are generally regarded as safe, protective 
effects on the polymer-embedded proteins might not be sufficient (47). 
 
Absorption enhancers 
Absorption enhancers are substances that can promote the absorption of a poorly absorbed 
drug across the intestinal epithelium. Various mechanism(s) of absorption enhancers have been 
proposed: 1) disrupting the structural integrity of the cell membrane temporarily to make it more 
permeable for drug transport (51); 2) increasing the retention time on the mucus layer; 3) opening 





tight junctions to utilise the paracellular pathway (this will be discussed in detail at section 1.5.1) 
(52).  
Some absorption enhancers result in enhanced permeability not only by one mechanism. For 
example, the cationic polymer chitosan has the combined effects of mucoadhesion and reversibly 
opening tight junction structures; and carbopol and polyacrylate derivatives can inhibit enzymatic 
activities as well as opening tight junctions through the removal of extracellular calcium ions (53, 
54). Recently, bile acid/salt derivatives have attracted considerable interest as absorption 
enhancers.  Mournir et al. (2002) demonstrated that co-administration of insulin with bile acid/salt 
derivatives (such as deoxycholate and cholate) led to a hypoglycaemic effect in rabbits. Perhaps, 
bile salts were masking the hydrophilic protein surface via micelle formation (55, 56). It has been 
suggested that the apical sodium-dependent bile salt transporter in the ileum can be targeted for 
enhancing oral absorption of macromolecules physically complexed with bile acid/salt derivatives 
(56). It is important to note that this pathway is used for the reabsorption of bile acid from the 
proximal and distal ileum back to the liver.   
Since absorption enhancers have the potential to reduce the barrier function of the intestinal 
epithelium, toxicological effects clearly need to be evaluated. Taking into consideration the 
physiological environment in the small intestine, it appears difficult to control and maintain the 
enhancer concentration sufficiently well to use this strategy; these enhancers would be dispersed 
and diluted in varied volumes of intestinal fluid (57).  
 
Chemical modification of proteins  
Some absorption enhancers described above can also be conjugated to proteins, for example, 
DOCA (deoxycholic acid) was conjugated with heparin to target ASBT (58). Attempts have been 
made to chemically conjugate proteins with functional groups in order to improve their 
lipophilicity, and thereby to enhance their uptake. Hashizume et al. (1992) demonstrated that 
conjugation of insulin with fatty acids (palmitic acid) not only increased the lipophilicity of 
insulin but also reduced its degradation (59). The oral insulin product hexyl-insulin 
monoconjugate 2 (HIM2) has demonstrated efficacy in both type I and type II diabetics, HIM2 
contains recombinant human insulin covalently modified with a single amphiphilic oligomer (60, 
61). However, this strategy has not resulted in any marketed product to date.  
Ideally, functional groups (conjugation groups) would detach or cleave from the delivered 
protein before its arrival in the systemic circulation, so that the structure and efficacy of protein 
would remain the same. Otherwise, the conjugated protein would be considered to be a new drug, 






on pharmacokinetics and other pharmacological activities of such delivered proteins must be 
considered carefully (9).  
 
Novel carrier systems 
Numerous carriers have been exploited for oral protein delivery, such as microspheres, 
liposomes, emulsions, and nanoparticles (NPs). All of these systems have the potential to increase 
the bioavailability of a protein loaded into them, but each also has unique challenges to overcome 
before being developed into an efficient delivery system. For example, the physiochemical 
stability of emulsions is one critical drawback for this strategy (21).  
 
Advantages of nanoparticles 
The formulation strategy discussed herein involves using nano-carriers. The concept of 
pharmaceutical NPs was first introduced by Peter Speiser (1960s) (62). Mohanraj and Chen 
(2006) listed several advantages of developing NPs as a drug delivery system in general for oral, 
nasal, and parenteral administrations: 1) they have relatively high drug loading, 2) normally no 
chemical reaction is required for the encapsulation of drugs, this is important for preserving the 
bioactivity of fragile drugs; 3) they can achieve site-specific targeting so as to increase therapeutic 
effects of the drugs and reduce the unintended side effects; 4) the release properties of an 
entrapped drug can theoretically be controlled during the transportation or at the site of 
localisation; and 5) their size, charge and other characteristics can be manipulated to achieve both 
active or passive drug targeting after various routes of administrations (63).  
Another potential advantage, specific to the oral route, is that NPs have a high surface area per 
mass, allowing increased contact with the epithelia and therefore more chance of uptake, and 
studies have shown the increased bioavailability of NPs (64). In addition, the architecture of the 
NPs can protect the loaded proteins from the enzymatic or acid environment (65).  
  
Biodegradable polymeric nanoparticles 
 Biodegradable polymers are materials that can break down naturally either by inherent 
instability or through the action of enzymes (66). The first record of biodegradable polymer in 
medicine is the catgut suture (made from sheep intestine), dating back to at least 100 AD (67).  
Although the first industrialisation of a synthetic polymer was started in the 1910s by Baekeland, 
the concept of synthetic biodegradable polymer was not introduced until the 1980s (68). Since 





then, biodegradable polymers have innumerable uses in the biomedical field, particularly in tissue 
engineering and drug delivery (69).  
Various biodegradable polymers have been emerging for the preparation of NPs, such as PLA 
(polylactic acid), PLG (polyglycolic acid), PLGA (poly (lactic-co-glycolic acid)), PEG 
(polyethylene glycol), and PCL (polycaprolactone). Four methods are commonly used for the 
preparation of NPs from these polymers, their advantages and disadvantages are listed in Table 
1-1 (70).   





















































1.5 Epithelial transport of biodegradable polymeric nanoparticles  
     
Biopharmaceuticals can be protected from the harsh environment in the GI tract, by using 
enteric coating (71). Therefore, the low permeability across the intestinal epithelium remains as 
the main challenge for efficient delivery via the oral route. Three theoretical pathways have been 
utilised for transporting NPs across the epithelium.   
 
1.5.1 The paracellular pathway 
 
The paracellular space is the intercellular space between two adjacent enterocytes, this channel 
is mainly controlled by the tight junctions that only allow the passage of compounds < 3.5 kDa 













Some absorption enhancers (anionic polymers and bile acids) mentioned earlier have been 
used to open tight junction structures by removal of extracellular calcium ions, which are 
important in the maintenance of tight junction integrity. For example, Chuang et al. (2013) 
demonstrated a reversible tight junction opening in the Caco-2 cell line after treatment with EGTA 
(ethylene glycol tetraacetic acid)-conjugated NPs (73). Chitosan-based NPs are another widely 
studied system, which have shown the ability to reversibly open tight junction structures. Lin et 




Figure 1-5: Diagram of different transport routes across the intestinal epithelium. (a) 
Transcellular pathway: small molecules (<700Da) can transport passively or actively through this 
route; (b) paracellular pathway: extracellular transport between two adjacent enterocytes under 
the regulation of tight junctions; (c) transcytosis across the enterocytes: travel across the 
enterocyte involving forming transport vesicles; (d) vesicle-based transcytosis across the M cell: 
being taken up by M cell and transport into the immune cells under the epithelium. Image was 
modified from (9) with permission from Nature Publish Group. 





al. (2007) showed that insulin-loaded NPs, prepared by chitosan and poly (γ-glutamic acid), 
reduced the blood glucose level more effectively compared to an oral insulin solution (74). This 
group (2011) also demonstrated that chitosan-induced tight junction opening is linked to changes 
in claudin-4, an important protein for tight junction integrity of polarised epithelial cells. The 
interaction between claudin-4 and chitosan leads to the redistribution of claudin-4 from the cell 
membrane to lysosomal degradation and an increased paracellular permeability (75).   
It is important to note that the paracellular space regulated by tight junctions comprises only 
~0.01 % of the total absorptive surface area of the GI tract (76). Opening tight junctions also 
carries the risk of introducing unintended substances into the body (77). Thus, altering tight 
junctions to enhance the uptake of a biopharmaceutical is not without difficulty.  
 
1.5.2 Transcytosis across M cells 
 
Transcytosis involves particles being taken up into the cell via endocytosis from the apical 
membrane, being transported through the cell in endosomal vesicles and released from the 
basolateral side (77). 
M cells present in Peyer’s patches have less organised microvilli, and are also less protected 
by the mucus layer compared to the rest of the intestinal epithelium (33). Optimal NP 
characteristics for targeting the Peyer’s patches, in terms of size, hydrophobicity and surface 
charge, have been studied. It is generally agreed that particles less than 1 µm in diameter can be 
taken up by M cells. Besides size, Eldridge et al. (1990) showed that hydrophobic NPs were taken 
up by Peyer’s patch more efficiently than less hydrophobic ones (78).  
M cells can take up NPs mainly via phagocytosis and pinocytosis (79). Recent studies by Yin 
et al. (2009) and Camile et al. (2011) demonstrated enhanced drug (loaded into NPs) absorption 
was mainly due to uptake by M cells (80, 81). Nevertheless, the importance of M cells might have 
been over-emphasised as Hussain et al. (1997) pointed out, considering they only make up ~1 % 
of the total intestine surface (77, 82). Fievez et al. (2009) suggested that M cells might be a target 
for oral vaccination, as they are specialised cells for transporting antigens from the lumen to 










1.5.3 Transcytosis across enterocytes  
 
Transcytosis across enterocytes appears to provide a route for NPs transporting across the 
epithelium, since they are the most abundant cells in the epithelium and have an extensive surface 
area available for absorption. A specific transport route is required for an efficient delivery of 
NPs, as passive diffusion only applies to small molecules. In this regard, several studies have 
attached NPs to transport ligands, such as Vitamin B12 (VitB12), lectin, IgG (immunoglobulin), 
and transferrin (Tf), with the intention of using these ligands to facilitate the trans-epithelial 
transport of NPs. 
 
Vitamin B12  
VitB12 is a hydrophilic molecule that cannot be absorbed via simple or facilitated diffusion like 
other small molecules. After VitB12 is released from food, it forms a complex with haptocorrin 
(HC) (Figure 1-6), which protects VitB12 from degradation in the acidic environment of the 
stomach. The VitB12-HC complex travels to the small intestine, where the HC is degraded by the 
action of trypsin and chymotrypsin. Intrinsic factor (IF), produced in the stomach, then forms a 
complex with VitB12, and this complex is recognised by the intrinsic factor receptor (IFR) at the 
apical surface of enterocytes. This VitB12-IF-IFR complex is then internalised via a receptor-
mediated endocytosis, with VitB12 being transported across the enterocyte through a process that 
involves transcobalamin II (TCII) binding to VitB12 once IF is released (84).  
 
 





 VitB12 has been used as a ligand to facilitate the 
transport of NPs across the epithelium. Chalasani et 
al. (2007) showed a reduction of blood glucose 
levels in rats when insulin was loaded in VitB12 
conjugated-NPs that was much greater than 
comparing to NPs without the conjugation with 
VitB12 (85). More recently, Fowler et al. (2013) 
investigated the mechanism of uptake and transport 
of NPs mediated by VitB12 in airway epithelial cells. 
NP uptake was reduced when filipin and 
chlorpromazine were added, suggesting that 
caveolae-mediated and clathrin-mediated 
endocytosis might be involved in the uptake (86). 
Using the VitB12-mediated pathway is not without 
disadvantage, since VitB12 has a minimal oral uptake 
capacity (1-2 µg), which might limit its applications 
(87).    
 
Lectin 
Lectins are plant proteins that can recognise glycosylated protein and lipid on most of the cell 
surface. The concept of using lectins for GI target delivery was first proposed by Woodley in 
1988, bioadhesion of tomato lectin was shown to slow down the intestinal transit of oral drugs 
and increase their bioavailability (88). The bioadhesion of lectin-conjugated NPs was also tested 
in gastric pig mucin, an ex vivo model based on rat intestinal mucosa, and also in a Caco-2 cell 
line (89-91). Hussain et al. (1997) demonstrated the total systemic circulation of lectin-conjugated 
NPs reached 23 % compared to < 0.5 % uptake of the same NPs with a lectin inhibitor (N-
acetylchiototraose), and the majority of them were considered to be taken up via non-lymphoid 
tissue. Tissue analysis revealed that 12 % of the NPs were associated with the intestine 
(enterocytes) as compared to < 1 % associated with the Peyer’s patches (82).  
Wheat germ agglutinin (WGA) is another commonly studied lectin, which binds to N-acetyl-
D-glucosamine and sialic acid found at the luminal surface of both M cells and intestinal epithelial 
cells (92). Russell-Jones et al. (1999) showed significant uptake and transport of WGA-
conjugated NPs (80 %) compared to unmodified NPs (10 %) when tested in Caco-2 cell 
monolayers (91). The uptake of WGA-conjugated NPs was reduced when other lectins were used, 
but not with the addition of bovine serum albumin; the uptake and transport mechanisms, 
 








Figure 1-6: Diagram of VitB12 transcytosis 
across the enterocyte. VitB12 is complexed to 
HC, which is believed to protect VitB12 from 
degradation in the acidic environment of the 
stomach. The VitB12-HC travels to the small 
intestine where IF binds to VitB12 after the 
degradation of HC. VitB12-IF is internalised 
by the enterocyte and VitB12 is transported to 
the basolateral membrane after binding with 






however, are unknown. Yin et al. (2006, 2007) encapsulated an immunomodulating peptide 
(thymopentin) into WGA-conjugated NPs, and reported a ~2-fold increase in the ratio of 
CD4+/CD8+ T cell populations in immunosuppressed rats as compared to unconjugated NPs (93). 
Interestingly, orally administered WGA-conjugated NPs had similar effects as thymopentin 
solution administered by intravenous injection in these studies. In a subsequent study, systemic 
uptake of these NPs was reported to be as high as 6 – 13% of dose at 1 day and 7 – 15 % at 7 
days, comparing to ~4.8 % at 1 day and ~4.9 % at 7 days for the unconjugated ones (94). Ensign 
et al. (2013) suggested that the high overall systemic uptake of both conjugated and unconjugated 
NPs could have been due to large gavage volumes in these two studies, but the specific volume 
was not stated (33). Overall, lectin-mediated NPs have advantages for delivering vaccines, as they 
could elicit an immune response (95).   
 
IgG  
Another pathway that transports a macromolecule is the transcytosis of IgG, which is a process 
that involves the specific binding of this class of antibodies to a specific membrane receptor 
known as the neonatal Fc receptor (FcRn). 
As suggested from the name, FcRn binds 
IgG antibodies via their faction crystallisable 
(Fc) domain at the apical enterocyte surface. 
Human FcRn was initially discovered in the 
placenta where it transports IgG from mother 
to foetus, and later on, it was detected in the 
epithelial cells present in the lung and the 
intestine of an adult (96). Dickinson et al. 
(1999) showed in vitro that FcRn is the 
receptor for transporting IgG across human 
intestinal epithelial cells (97). As shown in 
Figure 1-7, IgG can be internalised by 
binding to FcRn at the apical surface of 
epithelial cell, undertaking transcytosis 
involving vesicles that are trafficked to the 
basolateral side of the enterocyte where the IgG molecule is released (98). 
The concept of using Fc as a transport ligand was tested by Low et al. (2005) using the oral 
administration of FSH (follicle-stimulating hormone) fused with Fc in rats; ~2-fold greater 




Figure 1-7: Diagram of the transcytosis of IgG across 
the enterocyte. IgG firstly binds to FcRn on the 
apical membrane of the enterocyte, and then IgG 
travels across the enterocyte via a transport vesicle 
involving FcRn. The image was modified and reused 
with the permission from Nature Publish Group (5). 





addition, Fc-mediated NP transcytosis was tested using polarised monolayers of an airway 
epithelial cell line, Calu-3, by Vllasaliu et al. (2012). Comparing Fc-coated NPs to unmodified 
NPs showed increased uptake and transport that was reduced with the presence of additional Fc 
(99). Pridgen et al. (2013) encapsulated insulin into Fc-conjugated PLGA NPs, and demonstrated 
~13.7 % absorption of IgG-conjugated NPs, compared to ~1.2 % for unmodified NPs. 
Furthermore, IgG-decorated NPs showed distinct effects on blood glucose compared to 
unmodified NPs, and this effect was reduced with the extra addition of IgG, suggesting the 
transport of these Fc-NPs involved interactions with the FcRn (100).  
 
Transferrin 
Transferrin (Tf), is an iron-transporting glycoprotein that has been used to facilitate nano-
carrier transport across the blood brain barrier and the 
GI epithelium, since the Tf receptors (TfR) are highly 
expressed on both of these two barriers (101). Tf binds 
two ferric (Fe3+) ions to form the holo-Tf, resulting in 
a conformational change favourable for binding to 
TfR at the cell membrane. In non-polarised cells, 
holo-Tf is internalised and, once reaching an acidic 
vesicular compartment Fe3+ ions are discharged from 
the Tf protein to help supply cells with this essential 
ion.  
However, for polarised cells, holo-Tf is believed to 
transport Fe3+ in vesicles that traffic across the cell to 
reach the basolateral membrane; the exact transport 
mechanism is not elucidated (102). TfR is expressed 
in both apical and basolateral sides of the polarised 
epithelial cells, while the majority of these receptors 
are localised at the basolateral membrane of the 
intestinal epithelial cells (103).  
Xia el al. (2000) demonstrated that a Tf-insulin conjugate exhibited a slow but prolonged 
hypoglycaemic effect in streptozotocin-induced diabetic rats (104). The same group (2005) 
showed that an oligomeric Tf-conjugate had ~2-fold higher intracellular retention in Caco-2 cells 
than a monomeric Tf-conjugate; an in vivo study in rats showed the same trend (105). A full 
understanding of the Tf-mediated transport mechanism, however, is required for the safe use of 
this approach for chronic application. 
 Lumen 
Lamina propria 
Figure 1-8: Presumed transport route of ions 
across the enterocyte. Tf binds to two ions 
(Fe3+) to form holo-Tf, which is internalised 
into the cell via a receptor-mediated 
endocytosis and translocated to the 
basolateral membrane. This image is 
modified and reused with the permission of 







Bacterial toxins have been examined for their ability to transport across intestinal epithelia. 
Several of these proteins secreted from a variety of bacteria are able to travel across the mucus 
epithelial barrier and target underlying immune cells. Examples of these toxins and the bacteria 
they are derived from include, shiga toxin from Shigella sp., cholera toxin from Vibrio cholera, 
and cytolethal distending toxins from Salmonella typhi. These toxins exist as A-Bn subunit 
molecules, where the subunit A is the active/toxic component to kill the cell by various means, 
while the subunit(s) B appears responsible for internalisation and translocation of subunit A (106).  
Cholera toxin B (CTB) has been used to form a fusion protein with lumbrokinase (LK), which 
is used for the treatment of vascular thrombus. According to in vivo studies in rats and mice, the 
fusion protein CTB-LK exhibited distinct anti-thrombotic effects compared to the oral 
administration of LK alone (107). Salman et al. (2005) decorated NPs with flagella-enriched 
Salmonella extract, in order to increase the adhesion of these NPs to rat GI epithelium. NPs were 
found in enterocytes and Peyer’s patches 2 h after oral administration, and the coated NPs 
exhibited competitive binding to Peyer’s patches with Salmonella. More studies are needed to 
determine the uptake and transport process of Salmonella flagella prior to using this ligand in an 
oral delivery strategy (108). In terms of the systemic effect of NPs coated by bacterial toxins, 
Hussain et al. (1998) demonstrated that 13 % of NPs conjugated with invasin C192 (from Yersina 
pseudotuberculosis)  were detected in the systemic circulation, compared to 2 % of the 
















1.6  Bacterial toxin-mediated transcytosis 
 
     Toxin-conjugated NPs may be useful for delivery of biopharmaceuticals across the intestinal 
epithelium where the NPs can be loaded with biopharmaceuticals. To achieve this goal, 
characteristics of NPs capable of loading a biopharmaceutical must be optimised in favour of 
uptake and transcytosis.  
 
1.6.1 Transport ligand 
 
Pseudomonas exotoxin A (PE) is a virulence factor secreted by Pseudomonas aeruginosa, 
belonging to the family of A-B toxins as mentioned earlier in the section 1.5.3. Subunit A is 
composed of domain I and II, and subunit B consists of domain III (Figure 1-9) with diphtheria 
toxin being the first and best known protein of this toxin family. Most studies for this A-B family 
of proteins have focused on their intoxication of non-polarised cells. For PE, domain Ia (residues 
1-252) binds to LRP-1 (low-density lipoprotein receptor-related protein, also known as CD91) on 
the surface of the host cell. Once bound, a PE molecule is internalised via a clathrin-mediated 
endocytosis. After cleavage by the protease furin, domain II (amino acids 253-364) participates 
in translocation of domains Ib (amino acids 365-404) and III (amino acids 405-613) of the protein 






Figure 1-9: Diagram for the structure of PE. The protein is composed of domain Ia (1-252) 
responsible for cell recognition and receptor binding (blue); domain II (253-364) functions for 
protein translocation and contains furin-cleavage site for toxin activation (green); domain Ib (364-






the cytoplasm, domain III functions enzymatically to kill the cell by inhibiting protein synthesis 
through ADP ribosylation of elongation factor 2 (110).  
The trafficking pathway used by PE in non-polarised cells is well characterised. Following the 
internalisation by a receptor-mediated endocytosis, PE travels to the early endosome (EE), where 
the protein undergoes a conformational change in the decreased pH, so that a furin cleavage site 
can be cut for toxin activation (111, 112). Once in the EE, PE has been reported to utilise several 
pathways to reach the cytosol. One pathway is mediated by the KDEL-receptor, where the toxin 
is driven to the late endosomes (LE) in a Rab9/Arf1-dependent pathway and transported to the 
trans Golgi network (TGN) where a C-terminal REDL motif binds to the KDEL receptor, which 
facilitates its transport to the endoplasmic reticulum (ER) in a retrograde manner (113). An 
alternative pathway involves PE trafficking directly from the EE to the TGN and ER via a Rab-6 
controlled lipid-dependent sorting pathway (114). The intracellular pathways of PE appear to be 
cell-dependent, as Chaudhary et al. (1990) demonstrated PE trafficking in Swiss mouse 3T3 cells 
is fully dependent on the Rab-9-mediated pathway and the presence of the REDL sequence, while 
Smith et al.(2006) reported that PE can use either pathway to reach the ER in HeLa cells (114, 
115). 
 
          
 
Figure 1-10: Potential cellular pathways of PE in the non-polarised cell. PE is internalised into 
clathrin-coated vesicle following recognition by its receptor (CD91) on the cell surface. PE is then 
cleaved by furin at a site in domain II while the two fragments are still linked via a disulphide bond 
in the EE. Once in the EE, PE has the potential to utilise two possible pathways to reach the cytosol: 
(a) lipid-dependent sorting pathway, where PE travels directly from the EE to the TGN and ER 
or (b) PE transports to the TGN network, where it interacts with KDEL-receptor and travels to 
the ER in a retrograde manner. In the cytosol, domain III of PE inhibits protein synthesis through 
ADP ribosylation of elongation factor 2. Image is modified and reused with the permission from 
Frontiers Media SA (10).  
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 Based on this understanding of the PE intoxication pathway, this protein has been constructed 
as recombinant immunotoxin (Figure 1-11), in which the receptor-binding domain of the toxin 
(domain I) has been replaced by a cell-specific ligand to enhance its targeting for more directed 
cell killing (110). Recombinant immunotoxins based on PE have been widely studied as an 
approach for cancer treatment. For example, the domain I of PE has been replaced by a Fv 
fragment which targets CD22 on B cell malignancies, and monoclonal antibody K1 has also been 
fused to truncated PE for targeting mesothelin, which is overexpressed on mesothelioma and 
ovarian cancer cells (116, 117); both of these two immunotoxins have reached clinical trial. 
  
The rationale of using PE as a trans-epithelial ligand is based on the fact that for this exotoxin 
to reach the non-polarised, antigen-presenting cells in the submucosa, it must first translocate 
across the polarised epithelium such as that present in the airway and intestinal epithelium (118). 
Importantly, the cytotoxicity can be completely lost by the deletion of a glutamic acid at the 
position 553; this non-toxic version of PE (ntPE) becomes applicable to facilitate the transport of 
NPs (119).  
Mohammed et al. (2012) replaced the catalytic domain of PE (domain III) with a therapeutic 
protein and fused a cell-penetrating peptide onto the N-terminus of domain II to facilitate the 
cytosolic delivery of cargo protein (120). Recently, Carter (2014) showed that PE can deliver 
siRNA across polarised intestinal epithelial cells and also delivered the cargo to elicit knockdown 
effect in the macrophages present in the basolateral compartment below the cell monolayer (121). 
The strategy utilised in this work conjugated ntPE to NPs to enhance their trans-epithelial 
transport. The conjugation strategy to connect ntPE to NPs was achieved by inserting a tobacco 
etch virus (TEV) protease-specific sequence into the plasmid, which allows for introduction of a 





Figure 1-11: The diagram of immunotoxin based on PE. Immunotoxin is a 
recombinant protein, in which domain I has been replaced by another cell-







1.6.2 Methods for the preparation of mucoadhesive nanoparticles 
 
The concept of mucoadhesion as an approach to improve drug targeting and absorption was 
first introduced in the early 1980s (122). These mucoadhesive materials/polymers can interact 
with mucus by means of electrostatic interaction and hydrogen bonds (123). There are many 
widely used mucoadhesive polymers, such as cellulose derivatives, polyacrylates, chitosan, 
pectin, alginate, and starch.  
Alginate is a water-soluble anionic polysaccharide produced by brown algae and bacteria. It 
has been widely used in food and pharmaceutical areas, due to its biodegradability and high 
biocompatibility. Structurally, it consists of α-L-guluronic acid (G) and β-D-mannuronic acid (M) 
residues, linearly linked by 1, 4-glycosidic linkages. Alginate gelation is mainly achieved by 
exchanging Na+ in the guluronic acid with Ca2+, which results in stacking the guluronic groups to 
form the characteristic “egg-box” structure (Figure 1-12). The ease of gelation has broadened 
applications of alginate in tissue engineering, wound healing, and drug delivery. The first report 
of alginate-based NPs was from Rajaonarivony et al. (1993), the prepared NPs were in the size 
range of 250 – 850 nm in diameter (124). In addition, from a manufacturing perspective, alginate 
has an abundant supply and is relatively inexpensive.  
 
Chitosan shares similar advantages attributed to alginate, also being relatively inexpensive, 
biodegradable, and having abundant supply from natural sources. This cationic polymer is 
produced by deacetylation of chitin, which results in randomly distributed β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). The positively 
charged amine groups in chitosan are believed to interact with the negatively charged proteins in 
             
 Figure 1-12: Diagram for the alginate-Ca2+ complex. Ca2+ ionically cross-links 
with the guluronic acid of alginate and form an “egg-box” structure. Image is 
reused with the permission from Elsevier (3).  





the mucus layer (125). Chitosan-based NPs have been widely investigated using in vitro and in 
vivo models, and some chemical modifications on chitosan have been also carried out, with the 
intention of increasing its retention time with mucus and enhancing its capability to affect tight 
junction function (126-128).  
These two biopolymers, alginate and chitosan, are generally regarded as safe, mucoadhesive, 
abundantly available, and relatively inexpensive, providing the rationale for their selection in NP 
preparation in the present studies. Preparation methods based on these two biopolymers are 
different from methods used for synthetic and hydrophobic polymers listed in Table 1-1. Instead, 
these preparation methods are mainly performed in aqueous solution with a mild process, which 
is favoured for the encapsulation of labile biopharmaceuticals.    
 
Chitosan-based nanoparticles  
 
Preparation methods of chitosan-based NPs can be classified into ionic gelation, 
polyelectrolyte complexation, chemical cross-linking, and emulsification solvent diffusion. 
Ionic gelation: Gelation can be achieved through ionic interactions between protonated amine 
groups of chitosan and small negatively charged molecules, such as triphosphate (TPP), citrate, 
or sulphate. This preparation process is relatively simple, mild, and without the involvement of 
organic solvent. In addition, this preparation method allows the encapsulated labile molecules in 














Figure 1-13: Schematic diagram for the ionic gelation method. NPs 
are formed with the addition of TPP into chitosan solution dropwise, 
the negatively charged molecules cross-link with the positively 
charged amine groups of chitosan. The image is reused with the 







Chemical cross-linking in water in oil (w/o) emulsion system: A w/o emulsion can be 
prepared by emulsifying a chitosan aqueous solution in an oil phase (e.g. toluene), with the 
suitable surfactant as a stabiliser (e.g. Span 80®). Chemical cross-linking is between the reactive 
amine groups of chitosan with the aldehyde groups of a cross-linking agent such as glutaraldehyde 
(131). This method can produce a narrow particle size distribution, but it suffers from the negative 
effects of residual solvent and/or cross-linking agent on the cell viability, and the integrity of the 
entrapped biopharmaceutical (132).   










Chemical modification: By simple covalent modification of chitosan, its physicochemical 
properties can be changed, and it becomes more suitable for oral protein delivery. For example, 
addition of thiol groups into the chitosan chain would enhance its interactions with mucus; this is 
mainly due to the potential covalent bonds between the thiolated polymers and cysteine-rich 
subdomains of glycoproteins in the mucus layer (80).   
 Emulsion solvent diffusion: An organic phase, containing dichloromethane and acetone, is 
added to an aqueous solution containing chitosan and stabiliser with constant stirring. This leads 
to the formation of an oil in water (o/w) emulsion which is then subjected to high pressure 
homogenisation. Subsequent evaporation of dichloromethane from the organic phase leads to the 
diffusion of acetone (water miscible) into the aqueous phase. This solvent diffusion decreases the 
solubility of chitosan, and results in the formation of NPs (133). However, these preparation 
conditions are harsh, with high shear forces and the presence of organic solvent, which might not 
be suitable for labile biopharmaceuticals. In addition, hydrophobic drugs are more suitable for 
encapsulation using this method (4).  
 
 
Figure 1-14: Schematic diagram of the method of emulsification and 
cross-linking. A w/o emulsion is formed by chitosan (in aqueous 
solution) and oil phase (e.g. toluene) with a surfactant (Span 80®), NPs 
are formed with the addition of cross-linking agent such as 
glutaraldehyde. The image is reused with the permission from Taylor & 
Francis (4).  
Glutaraldehyde addition 







Polyelectrolyte complexes (PECs): These associated complexes are formed due to the 
electrostatic interactions between oppositely charged polyions, such as between chitosan and 
alginate. The preparation process avoids the use of a chemical cross-linking agent, and the 
preparation conditions are mild, which should help preserve the structure of an entrapped 
biopharmaceutical as well as reducing possible toxic effects at targeted sites (4). A protein or 
DNA/RNA biopharmaceutical can be loaded into PECs by polyion coacervation between charged 
groups, and other molecular forces are involved at the same time, such as hydrogen bonds and  
hydrophobic interactions (134). 
In contrast to chitosan, the study of alginate-based NPs is relatively scarce (135). Besides 
modification of alginate with thiol groups, forming polyelectrolyte complexes, w/o nanoemulsion 







Figure 1-15: Schematic diagram of the emulsion solvent diffusion 
method of NP production. An o/w emulsion is formed with acetone 
and dichloromethane in the oil phase and with chitosan in the aqueous 
phase. After homogenisation, NPs are formed when acetone diffuses 
into the aqueous phase followed by the evaporation of 
dichloromethane. The image is modified and reused with the 










1.6.3 Importance of specific nanoparticle characteristics 
 
Size: Particle size and size distribution are the most important characteristics, as they 
determine the pharmacokinetics, biodistribution, toxicity, and target ability of NPs. In addition, 
size can influence drug loading and release, as well as the stability of NPs. It is well known that 
NP size plays a key role in their cellular uptake and transcytosis, and the impact of size is also 
cell-dependent (137). Desai et al. (1997) suggested that NP uptake by polarised Caco-2 
monolayers is size-dependent, and Win et al. (2005) showed that 100 – 200 nm is the optimal size 
range (137, 138).   
Surface properties: The nature of NP surface properties determine their interactions with the 
surroundings, thus influencing their fate in vivo. NP hydrophobicity determines the extent of 
adsorption of blood components, mainly proteins. Coating the surface of NPs with a hydrophilic 
polymer/surfactant, like polyethylene glycol, polysorbate 80, and polyoxamer, can reduce the 
adsorption of serum proteins, known as opsonisation, which acts as bridge between NPs and 
phagocytes (63).  
NP surface charge can also affect their fate and behaviour at specific sites in the body or within 
a tissue. In turn, their uptake behaviour is also influenced by the cell type (139). For example, 
charged polystyrene NPs are taken up better than their uncharged counterparts (140) and 
positively charged NPs are better taken up than negatively charged NPs (128). Although it is 
generally agreed that positively charged NPs result in higher uptake rate, Bannunah et al. (2014) 
showed that a larger number of negatively charged NPs are able to transport across intestinal 
epithelial cells (141).  
Based on current understandings of the importance of the physicochemical properties of NPs 
to their behaviours, one can summarise an optimal size characteristic for intestinal transcytosis of 
100 – 200 nm diameter. Since there is still uncertainty with respect to the impact of surface charge, 












1.7  Thesis Outline 
 
The overall goal of this work was to design and prepare nano-carriers for transporting a protein 
cargo across the intestinal epithelium. The hypothesis is that a bacterial toxin, specifically ntPE, 
can facilitate transcytosis of polymeric NPs across the intestinal epithelium. By testing the 
feasibility of this hypothesis, we hope to identify a strategy for the oral delivery of 
biopharmaceuticals. Specific objectives to address this hypothesis were:  
1) develop and characterise biodegradable NPs;  
2) conjugate ntPE onto the surface of these NPs; 
3) evaluate ntPE-coupled NP transcytosis in vitro using Caco-2 cell monolayers;  
4) assess ntPE-coupled NP transcytosis in vivo, and test their ability to deliver biopharmaceuticals 
across the intestinal epithelium.  
Chapter 2 explores different methods of making biodegradable NPs using alginate and 
chitosan. The physicochemical properties of NPs were optimised and the preparation method was 
selected for the chemical conjugation with ntPE.   
     Chapter 3 describes a method for the chemical conjugation between ntPE and NPs. The 
feasibility of the conjugation was first tested on polystyrene NPs before applying the strategy to 
alginate-chitosan NPs. The physicochemical properties of these NPs were characterised by a 
variety of methods, to better understand NP behaviours in the later in vitro and in vivo tests.  
     Chapter 4 evaluates the transcytosis of polystyrene and alginate-chitosan NPs in an in vitro 
model using Caco-2 cell monolayers. Secondary structural studies of ntPE after coupling to the 
surface of NPs were performed. The expression of LRP-1 on Caco-2 cells was evaluated and the 
effect of serum on LRP-1 expression was studied.  
     Finally, in Chapter 5 the transcytosis of both polystyrene and alginate-chitosan NPs was 
assessed in living rat small intestine. The feasibility of this nano-carrier strategy for delivering a 
cargo protein was tested by loading green fluorescent protein into alginate-chitosan NPs.   









Chapter 2    Preparation of polymeric nanoparticles 
Overview:  
Aim: The aim of this chapter was to prepare biodegradable nano-carriers in the size range of ~100 
–200 nm, and to test the ability of these nanoparticles to encapsulate biopharmaceuticals.   
Methods: Chitosan-triphosphate nanoparticles were prepared using an ionic gelation method. 
Calcium phosphate nanoparticles were prepared by the co-precipitation of calcium nitrate and 
ammonium hydrogen phosphate. These two types of nanoparticles were characterised in terms of 
size, charge and morphology using dynamic light scattering and scanning electron microscopy. 
Chitosan was coupled onto the surface of calcium phosphate nanoparticles using carbodiimide as 
a cross-linking agent. This conjugation was characterised using Fourier transform infrared 
spectroscopy and 31P nuclear magnetic resonance spectroscopy. In addition, alginate and chitosan 
nanoparticles were prepared by ionic pre-gelation of alginate cores followed by chitosan 
polyelectrolyte complexation. The resulting nanoparticles were characterised in size, charge, and 
shape by dynamic light scattering and transmission electron microscopy. The influence of pH, 
polymer concentration, stirring speed, and polymer ratios were studied. Finally, green fluorescent 
protein was used to represent a potential biopharmaceutical to be encapsulated into alginate-
chitosan nanoparticles.   
Results: Chitosan triphosphate nanoparticles had an average diameter of 93 ± 2 nm, 98 ± 18 nm, 
and 171 ± 25 nm when ratios of chitosan to TPP of 1:20, 1:10, and 1:5 were used, respectively; 
zeta potential values were determined to be 7 ± 5 mV, 17 ± 11 mV, and 16 ± 9 mV, respectively. 
Calcium phosphate nanoparticles had an average diameter of 181 ± 13 nm with zeta potential of 
-42 ± 5 mV. Their size and zeta potential changed to 173 ± 63 nm and 11 ± 1 mv, respectively, 
after coating with chitosan. Infrared spectra of chitosan-conjugated calcium phosphate 
nanoparticles were not consistent with the spectra anticipated for 31P nuclear magnetic resonance, 
suggesting that additional studies will be required to confirm conjugation outcomes. After 
optimising preparation parameters, such as pH, polymer concentrations, and polymer ratios, 
alginate-chitosan nanoparticles had a diameter of 179 ± 3 nm, and a zeta potential of 17 ± 5 mV. 
When green fluorescent protein was loaded into alginate-chitosan nanoparticles (92 % 
encapsulation efficiency), these nanoparticles had a diameter of 196 ± 13 nm, and a zeta potential 
of 14 ± 7 mV. 
 
 
   





2.1  Introduction  
      
As mentioned in Chapter 1, the overall goal of this thesis is to test the hypothesis that ligand-
conjugated nanoparticles (NPs) could be used to carry biopharmaceuticals across the intestinal 
epithelium. In this chapter, studies are described that had the goal of preparing biodegradable NPs 
in the size range of 100 – 200 nm that were capable of encapsulating a model protein, green 
fluorescent protein (GFP). This chapter also discusses the ability of these NPs for surface 
conjugation with a ligand.  
Several aspects of ligand-conjugated NPs for the oral delivery of a biopharmaceutical must be 
considered to make this approach pharmaceutically acceptable. These NPs must 1) have the 
capacity to readily release the biopharmaceutical following the process of transcytosis, 2) be  
biodegradable, and 3) have no potential toxicity as these systems are likely to be used in chronic 
dosing strategies. Chitosan and alginate fit these criteria and were selected for this study; both are 
generally regarded as safe and are also cost-effective since they have abundant sources of 
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Figure 2-1: Chemical structure of alginate and chitosan. (a) Alginate, a linear copolymer with α-L-
guluronic acid (G block) and β-D-mannuronic acid (M block); (b) Chitosan is a linear cationic polymer 
composed of randomly distributed D-glucosamine and N-acetyl-D-glucosamine.  




Alginate is a water-soluble anionic linear polysaccharide, which consists of α-L-guluronic acid 
(G) and β-D-mannuronic acid residues (M), linearly joined by 1, 4-glycosidic linkages (Figure 
2-1a) (142). On the other hand, chitosan is a cationic polymer and the second most abundant 
biopolymer after cellulose. It is produced by deacetylation of chitin, which is a long-chain 
polymer of an N-acetylglucosamine, resulting in randomly distributed β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (Figure 2-1b). The 
amine groups on chitosan provide a potential site for chemical conjugation with a ligand; alginate 
carboxyl groups provide a similar potential site for chemical conjugation with a ligand or easy 
modification for the purpose of conjugation. Both of these polymers have demonstrated 
mucoadhesive properties, which can increase their residence time at the epithelial surface of the 
small intestine (143).  
It has been suggested that the physicochemical properties of NPs have great impact on their 
uptake and transcytosis behaviour. Based on these understandings, desirable characteristics of 
NPs to enhance the oral delivery of a biopharmaceutical could be proposed. Firstly, the uptake of 
NPs by small intestinal enterocytes occurs in a size-dependent manner. In this regard, spherical 
NPs between 20 and 50 nm have the highest uptake rate by non-phagocytic cells (144, 145); while 
enterocytes have shown preferential uptake particles in the range of 100 – 200 nm (137). Surface 
charge is another important parameter to be considered. In general, charged NPs are internalised 
more readily than their uncharged counterparts (140). Positively charged NPs, prepared from 
chitosan have demonstrated better uptake compared to negatively NPs composed of poly 
(ethylene glycol)-D, L-polylactide (PEG-PLA) and polystyrene NPs (128, 146, 147). However, 
Bannunah et al. (2014) showed that although positively charged NPs seemed to be internalised 
by Caco-2 cells to a greater extent than the negatively charged ones, a larger number of negatively 
charged NPs was transported across the Caco-2 cells (141). Thus, it is still unclear how NP surface 
charge may affect transcytosis. Furthermore, NPs uptake and transport behaviours are shown to 
be cell-specific (147). 
A robust and consistent method of NP preparation would be required to assess their 
transcytosis across the intestinal epithelium. Additionally, efficient entrapment and stability of a 
biopharmaceutical in NPs would be essential. For commonly used preparation methods, such as 
emulsification-solvent evaporation, solvent displacement, and solvent diffusion, the use of an 
organic solvent (acetone, ethyl acetate) is unavoidable. The presence of organic solvent trace 
results in a potential toxicological issue as well as increasing the potential to cause damage to the 
entrapped biopharmaceutical (148). Recently, polyelectrolyte complexes have become recognised 
as an attractive delivery system, due to their ease of preparation, and organic solvent-free 
preparation process (149). These complexes are formed due to electrostatic interaction between 
oppositely charged polyions; a process that avoids the use of covalent cross-linkers and organic 




solvents (134). Additionally, the mild preparation conditions favour encapsulating fragile 
biopharmaceuticals.   
 Chitosan and alginate can form a polyelectrolyte complex due to their opposite charges. The 
protonated amine groups of chitosan can also cross-link with small molecules, like phosphate, 
citrate, and sulphate to form NPs through a process known as ionic gelation (150). Another 
biodegradable type of NP, prepared using calcium phosphate (CaP), was also studied. Because of 
its biocompatibility and biodegradation, CaP NPs have been used for cell transfection since the 
1970s and more recently have shown potential as an oral delivery carrier for insulin (151, 152). 
Furthermore, the process of preparing CaP NPs is easy to perform and cost-effective. The 
conjugation of ligands on CaP NPs can be achieved by coating CaP NPs with a polymer on the 
surface.   
 
2.2 Methods  
2.2.1 Preparation of chitosan-triphosphate nanoparticles (Chitosan-TPP NPs)  
    
20 mL of 0.25 mg/mL sodium triphosphate (TPP, MW=367.86 g/mol, T5883, Sigma-Aldrich) 
solution was added dropwise into 10 mL of 2.5 mg/mL chitosan solution (pH 4.5 – 5.0, chitosan 
deacetylation at 83 %, 448869-50G, Sigma-Aldrich) under magnetic stirring. The resulting 
suspension was allowed to stabilise for 30 min at room temperature (RT). Different ratios of 
chitosan to TPP (w/w) were performed: 20:1, 10:1, 5:1, and 2:1. The concentration of chitosan 
was kept the same during these preparations. 9 batches of each ratio were prepared (3 batches per 
day, over 3 days). Each batch was characterised 3 times using the following equipment (see in 
2.2.5). This approach was used throughout this chapter.  
 
2.2.2 Preparation of calcium phosphate nanoparticles (CaP NPs)  
 
100 mL of a 20 mM calcium nitrate solution (27607, BDH chemicals Ltd.) and 100 mL of a 
12 mM ammonium hydrogen phosphate solution, pH 10 (Fisons Scientific Apparatus LTD) were 
prepared in Milli-Q water. 10 mL of both solutions were warmed independently to 80 °C and then 
mixed in a beaker (50 mL) with magnetic stirring at 80 °C for 7 min. Afterwards, 20 mL of a 10 
mM sodium citrate solution (S1804-500G, Sigma-Aldrich) was slowly added over 5 min with 
constant stirring. The resulting suspension was sonicated using a probe sonicator for 10 min 
(Model 2501450, Sonifier, Branson, discontinuous mode: pulse on for 4 s and pulse off for 2 s). 
Following sonication, NPs were washed and suspended in Milli-Q water, with the NPs being 




pelleted by ultracentrifugation at 80640 × g (Rotor type: 70.1 Ti, L8-M Ultracentrifuge, Beckman) 
for 20 min at 20 °C (153).  
Conjugation between chitosan and CaP NPs was carried out using carbodiimide as a cross-
linker (154). Washed CaP NPs were suspended in 10 mL of MES buffer (2-ethanesulfonic acid, 
10 mM, pH 6.0, M3671-50G, Sigma-Aldrich). While shaking at 100 rpm, 100 mg of EDC (N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, E1769-1G, Sigma-Aldrich) were 
added and the mixture was shaken for 1 h at RT. NPs were then washed twice using PBS 
(phosphate-buffered saline, 10 mM of phosphate buffer in 137 mM sodium chloride, pH 7.4, 
Dulbecco “A” Tablets, BR0014G, Oxoid Ltd), pelleted by ultracentrifugation, and suspended in 
10 mL of PBS. Finally, 200 µL of 1 % (w/w) chitosan, dissolved in acetic acid solution (1 %, v/v; 
537020, Sigma-Aldrich) was diluted in 1 mL PBS before adding dropwise into a CaP NPs 
suspension, and the reaction was allowed to proceed overnight at RT.  
The linkage between CaP NPs and chitosan was analysed using a Perkin Elmer Frontier Optica 
FTIR spectrometer equipped with a mercury cadmium telluride (MCT) detector. Suspensions of 
CaP NPs and chitosan conjugated-CaP NPs were applied onto the crystal of the spectrometer for 
analysis. Spectra were collected at RT over wavenumber range of 5000-600 cm-1 in the 
transmission mode, and at the resolution of 1 cm-1. Conjugation between chitosan and CaP NPs 
was also characterised using 31P nuclear magnetic resonance (NMR) spectroscopy, with NMR 
spectra of CaP NPs and chitosan-conjugated CaP NPs being obtained at 25°C on a Bruker 
Advance 500 spectrometer (Bruker, UK).  
 
2.2.3 Preparation of alginate-chitosan nanoparticles (AC NPs) 
 
 The method used to prepare AC NPs was adapted from that described by De and Robinson 
(2013) (155).  Specifically, 2 mL of a 0.51 mg/mL calcium chloride (C3881-500G, Sigma-
Aldrich) solution was added dropwise into 10 mL of a 0.6 mg/mL sodium alginate (W201502-
sample, Sigma-Aldrich) solution under a micro-tip probe ultra-sonicator (Figure 2-2) at 4 °C. The 
resulting pre-gel was stirred for 30 min before the addition of 2 mL of 0.3 mg/mL chitosan 
solution (dissolved in 0.01 % (v/v) acetic acid) at RT. The suspension was then equilibrated 
overnight to allow the formation of NPs at RT. All materials were filtered through 0.45 µm 
membranes (MF-MilliporeTM Membrane, 0459, Merck Millipore Ltd.) prior to use. 
Characteristics of the alginate-chitosan complexes formed at different ratios of calcium chloride 
to alginate (0, 0.08, 0.17, and 0.25, w/w) and different ratios of chitosan to alginate (0, 0.05, 0.1, 
and 0.2, w/w) were studied using a Malvern ZetaSizer Nano ZS instrument (Malvern Instruments 
Limited, Malvern, UK) (details in section 2.2.5). AC NPs formation was also performed at 
different pH (3.8, 4.5, 5.0 and 5.5) and characterised using the ZetaSizer.  





2.2.4 Preparation of green fluorescent protein-loaded AC NPs 
 
After the formation of alginate and calcium complex as described in 2.2.3, 0.3 mg of green 
fluorescent protein (GFP, MW=26 kDa, pKa=5.7) was mixed with 2 mL of 0.3 mg/mL chitosan 
solution which was added dropwise into the alginate-calcium complex. The suspension was then 
equilibrated at RT for 2 h. Unloaded GFP was separated from NPs by ultracentrifugation at 61740 
× g for 30 min at 4 °C. Supernatant from the NP’s suspension was assayed on a 96 well microplate 
in triplicate (655086, Cell culture microplate, 96 well, F-bottom, black, Cellstar®, Greiner bio-
one) and measured using a fluorescence microplate reader (FLUOstar Omega, BMG Labtech). 
The amounts of unloaded GFP were quantified according to a standard curve. The encapsulation 
efficiency of GFP was calculated by the following equation: 
 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐺𝐹𝑃−𝑡ℎ𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐺𝐹𝑃 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐺𝐹𝑃
× 100 
Different ratios of GFP to polymer (1:5, 1:3, 1:2 and 2:1) were prepared and characterised in 
triplicate while the ratio of chitosan to alginate was kept 1:1.  
 
2.2.5 NPs characterisation 
 
    Size and zeta potential measurements of NPs were performed in triplicate using a ZetaSizer at 
25 °C. 












Figure 2-2: Schematic diagram of method used to prepare alginate-
chitosan nanoparticles. Calcium chloride solution was added into alginate 
solution during sonication, and polyelectrolyte complexes were formed by 
the addition of chitosan.  




    Chitosan-TPP NPs and CaP NPs morphology was observed by scanning electron microscopy 
(SEM; JEOL FESEM6301F, JEOL Ltd.). Both sets of samples were freeze-dried using a Micro 
Modulyo 230 lyophilizer (Thermo Scientific) and the freeze-dried samples were placed on Leit 
Adhesive Carbon Tabs (AGG3357N, Agar scientific) adhered to SEM stubs. Samples were stored 
in a desiccator prior to SEM analysis. 
Morphological analysis of AC NPs was performed using a transmission electron microscope 
(TEM; JEOL JEM1200EXII). NP suspensions were diluted 10-fold in PBS (pH 7.4) and dropped 
onto carbon-coated copper grids (FC300Cu, EM Resolutions) with the liquid being quickly 
removed by touching the edge of the grid with filter paper. Negative staining was performed by 
exposing samples to 2 % uranyl acetate for 30 seconds, which was also removed by filter paper 
absorption. Samples were stored in a desiccator after air drying until being viewed in the TEM.   
A preliminary stability test of NPs was performed. 1 mL of AC NPs was dispersed in 10 mL 
of simulated intestinal fluid (SIF, pH 6.8) for 15, 30 and 60 min. At each time interval, 1 mL of 
sample was withdrawn and used to prepare TEM samples using the protocol described above. AC 
NPs were kept at RT for over 7 days, and the size of AC NPs was measured using ZetaSizer at 
day 1, day 2, day 3 and day 7.   
 
2.2.6 Data Analysis 
 
Data reported as mean ± standard deviation of the mean throughout.  
 
 
2.3 Results and discussion  
2.3.1 Chitosan-triphosphate nanoparticles (Chitosan-TPP NPs) 
 
Chitosan-TPP NPs were prepared by ionic gelation by dropwise addition of TPP to a chitosan 
solution at RT. This preparation method is relatively simple and inexpensive; it also avoids the 
use of an organic solvent and harsh conditions, such as high temperature or high speed 
homogenisation. Nano-scale chitosan-TPP complexes prepared for the encapsulation of 5-
fluorouracil were first published by Ohya et al. (1994). This cross-link complex was not a new 
delivery system, and an earlier study can be found in 1989 by Bodmeier (156). Later on, thanks 
to the mild preparation conditions, chitosan-TPP NPs have been used to deliver fragile molecules, 
like protein and genetic materials (DNA/RNA), through establishment of ionic interactions 
between negatively charged biomolecules with positively charged chitosan (130, 157, 158). 





    When preparing NPs with different ratios of chitosan and TPP, the concentration of chitosan 
was kept constant. NP size and zeta potential appeared to be influenced by the ratio of TPP to 
chitosan (w/w). Chitosan-TPP NPs are believed to be formed by ionic interactions between the 
phosphate groups and the protonated amine groups of chitosan (159). In this study, the ratio of 
chitosan to TPP was changed from 20:1 to 10:1 and to 5:1, resulting in NPs with a diameter 
average of 92 ± 1 nm, 119 ± 10 nm, and 149 ± 14 nm, and zeta potential of 7 ± 5 mV, 17 ± 11 
mV and 16 ± 9 mV. The higher TPP concentration appeared to result in larger NPs, and the 
suspension visibly turned from opalescent to turbid, consistent with observations made by others 
(158).  At a ratio of chitosan to TPP at 2:1, the suspension could not be measured by ZetaSizer, 
so this preparation was not depicted in the data sets. Rampino et al. (2013) reported the same 
phenomenon that increasing amounts of TPP resulted in greater particle aggregations (157). 
Overall, these observations were consistent with the mechanism proposed by Koukaras et al. 
(2012) where the addition of TPP reduces the solubility of chitosan, and when the amount of TPP 
exceeds the amount of amine groups on chitosan, aggregated particles are produced (158).  
    The measured polydispersity by ZetaSizer for NPs was 0.610 ± 0.02, 0.457 ± 0.01, and 0.425 
± 0.06, respectively, for the ratio of chitosan: TPP, 20:1, 10:1 and 5:1, respectively. Chitosan-
TPP NPs appeared to have a low polydispersity under SEM analysis (Figure 2-4). No significant 
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Figure 2-3: The effects of polymer ratios on NPs size and zeta potential. The size of NPs, by DLS was 
92 ± 1 nm, 119 ± 10 nm, and 149 ± 14 nm for the ratios of chitosan to TPP, of 20:1, 10:1, and 5:1, 
respectively; and corresponding zeta potential values were 7 ± 5 mV, 17 ± 11 mV and 16 ± 9 mV. The 
size of NPs increased with the increasing amount of chitosan in the suspension. The zeta potential also 
increased with the addition of chitosan, but kept steady from the ratio of 10:1 (n=3). 




prepared at these three different polymer ratios were in the size range of 100 – 200 nm, which 
would be desired for protein delivery across the intestinal epithelium. However, conjugation of 
chitosan-TPP NPs with ligands at the same time as conjugation with a fluorescent tag for in vitro 
or in vivo visualisation, is challenging. Therefore, further studies with chitosan-TPP NPs were not 
carried out.  



































Figure 2-4: Representative SEM images of chitosan-TPP NPs. 
(a) The ratio of chitosan: TPP was 20:1; (b) the ratio of chitosan: 
TPP was 10:1; and (c) the ratio of chitosan: TPP was 5:1. 
Chitosan-TPP NPs appeared to have low polydispersity, and no 
significant changes were observed in the morphology of NPs at 
the different chitosan-TPP ratios.  




2.3.2 Calcium phosphate nanoparticles (CaP NPs) 
 
     Calcium phosphate was used for fracture treatment in the 1920s, and since then it has been 
applied broadly in orthopaedics, dentistry, and as a carrier for protein and gene delivery (160-
162). Its wide application is attributed to a simple and cheap preparation process (163).   
 
Table 2-1: Characterisation of CaP NPs before and after coating with chitosan (n=3). 
 Before coating with chitosan After coating with chitosan 
Particle size (nm) 181 ± 13 173 ± 63 
Zeta potential (mV) -42 ± 5 11 ± 1 
Polydispersity index 0.287 ± 0.018 0.410 ± 0.167 
 
CaP NPs in this study were prepared using a co-precipitation method: calcium nitrate and 
ammonium hydrogen phosphate were the reactants, and sodium citrate served as the stabilising 
agent. This method is a simple and quick process, as other methods either require a reactor or are 
time-consuming (164).  
Using DLS, CaP NPs were determined to have a diameter of  ~181 ± 13 nm, and their zeta 
potential averaged -42 ± 5 mV (Table 2-1) (153). CaP NPs showed a larger size in SEM (Figure 
2-5, 438 ± 107 nm, n=50) compared to these DLS measurements. The larger size in SEM could 
have been due to the freeze-drying process that was carried out without lyoprotectant, which 
might have allowed aggregation of NPs (165). Chitosan was chosen to link with CaP NPs, since 
it could be readily used for conjugation with ligands. Additionally, a surface layer of this polymer 
was also anticipated to improve the colloidal stability of CaP NPs (166). Phosphate groups present 
in the CaP NPs were conjugated to chitosan amine groups by using carbodiimide cross-link 
chemistry. Carbodiimide activates the phosphate group to an intermediate phosphate ester similar 
to its reaction mechanism demonstrated for carboxylates. Then, in the presence of an amine, the 
ester reacts to form a stable phosphoramidate bond (167).  
 




After coating CaP NPs with chitosan, their size was determined to be 173 ± 63 nm in diameter, 
and their zeta potential changed from -42 ± 5 mV to 11 ± 1 mV (Table 2-1). The positive zeta 
potential values suggested that chitosan was presumably on the surface of CaP NPs. 
Consequently, the presence of chitosan also increased the polydispersity of NPs (Table 2-1), as 
could be seen by SEM and from the polydispersity values by DLS. This higher polydispersity 
could be due to the unreacted chitosan forming complexes with phosphate in the suspension 
(Figure 2-5).  
One potential problem with these NPs was their propensity to aggregate, as noted by the high 
polydispersity. This might result in a reproducibility issue, resulting in inaccurate dosing when 
therapeutic agents are loaded. Also, large CaP NPs agglomerates would limit the efficiency of 
receptor-mediated endocytosis, and the extended extracellular exposure to these materials could 












Figure 2-5: Representative SEM images of CaP NPs. (a) CaP NPs were spherical and oval 
in shape, some NPs were aggregated; (b) CaP NPs were coated with chitosan, and 
appeared not uniform in size and shape.    





The ability of chitosan-coated CaP NPs to be conjugated with proteins was assessed using 
FTIR and 31P NMR. The FTIR spectrum acquired from CaP NPs demonstrated a characteristic 
band of PO4 at 1042 cm-1 (Figure 2-6). The band at 1410 cm−1 was considered to describe the 
alkaline C–H bond present in citrate (169). The FTIR spectrum from chitosan showed a band at 
1413 cm-1 that probably represented an alkaline C-H bond and the band at 1547 cm-1 was assigned 
to –NH2 scissoring (170). In the spectrum acquired from chitosan coated-CaP NPs, the absorption 
bands at 1643 cm-1 and at 1563 cm-1 were attributed to the presence of chitosan (170).  
     In summary, these studies confirmed that chitosan was present on the CaP NPs. Whether this 
was due to covalent bonds between phosphate groups of CaP NPs with amine groups of chitosan 
was not verified. To know if chemical conjugation between chitosan and phosphate had occurred, 
these NPs were characterised using 31P  NMR (171). As shown in Figure 2-7, peaks at δ=0.913 
and 0.396 ppm were both considered to be the phosphate groups from CaP NPs, while the 







Figure 2-6: FTIR spectra of CaP NPs, chitosan-coated CaP NPs and chitosan. Characteristic bands of 
PO4 at 1042 cm-1 were found in the spectrum of CaP NPs. The appearance of bands at 1643 cm-1 and at 
1563 cm-1 in the spectrum of the chitosan-coated CaP NPs were attributed to the presence of chitosan 
in the NPs suspension.  





    More studies are required to confirm the conjugation between chitosan and CaP NPs, in order 
to ensure the possibility of linking NPs with ligands in the next step. Considering the additional 
complication of particle aggregation and the limited chance of conjugation with ligands, further 
studies on CaP NPs were not carried out.   
 
2.3.3 Alginate and chitosan nanoparticles (AC NPs) 
2.3.3.1 Preparation and characterisation of AC NPs  
 
    Alginate is a linear polysaccharide composed of repeating units of glucuronate (G) and 
mannuronate (M). Gelation of alginate occurs when sodium ions in the glucuronate residues are 
exchanged with multivalent cations, like calcium ions, and stacking of these G blocks form an 
“egg-box” like structure. In general, alginate hydrogels are considered to be biologically inert and 
are commonly used since the 1980s for biomedical purposes, especially in wound dressing, 
controlled release systems and in tissue engineering (173). More recently, NPs in the size range 
of 250 – 850 nm prepared from alginate were published by Rajaonarivony et al. (1993), and their 
formation required lower concentrations of sodium alginate and calcium compared to 
conventional methods of alginate gelation (124).   
 
 
Figure 2-7:  31P NMR spectra of CaP NPs and chitosan coated-CaP NPs. Peaks at 
δ=0.913 and 0.396 ppm were both considered to be phosphate groups from CaP NPs. 
The expected phosphoarimidate group was not found at δ =3.3 and 3.1 ppm. This 
outcome suggested that chitosan was not covalently bonded to CaP NPs. 




     Different particle sizes caused by reagent concentrations were also observed in the present 
studies; lower concentrations of alginate formed NPs, while higher concentrations resulted in the 
formation of gels. As shown in Figure 2-8, a relatively higher concentration of alginate (6 mg/mL) 
led to gelation, while at lower concentrations (0.06 mg/mL and 0.6 mg/mL), NPs were obtained. 
For example, NPs prepared using 0.06 mg/mL of alginate had a diameter of 192 ± 15 nm, and 
when the alginate concentration was increased to 0.6 mg/mL, the diameter of NPs increased to 
255 ± 38 nm (Figure 2-9).  
 
     Surface charge of AC NPs was also influenced by alginate concentration (174); measured zeta 
potential values were -34 ± 1 mV when the concentration of alginate was 0.6 mg/mL, and 
increased to -21 ± 1 mV when the alginate concentration was 0.06 mg/mL, which is related to 
more chitosan (cationic polymer) remaining unreacted.  
 
 
Figure 2-8: Appearance of AC NP preparations using different alginate 
concentrations (from left to right, 0.06 mg/mL, 0.6 mg/mL, and 6 mg/mL). 6 
mg/mL of alginate formed a gel when calcium was added, while NPs were 
formed at lower concentrations of alginate (0.6 mg/mL and 0.06 mg/mL).   





AC NPs were formed by first adding calcium chloride into an alginate solution, which was 
followed by adding chitosan solution to form polyelectrolyte complexes. It is known that calcium 
ions and guluronate (G) residues in alginate interact to form a gel, thereby greater amounts of G 
blocks in alginate lead to greater interactions and stronger gels. Calcium ions have shown to be 
important for the formation of AC NPs (175). Different calcium to alginate ratios (0, 0.08, 0.17, 
0.25, w/w) were used to prepare AC NPs, with optimal complexes being obtained at a ratio of 
0.17 (w/w, data not shown) (176). Thus, it is necessary to have a calcium ions/alginate ratio < 0.2 
for the formation of NPs, as De and Robinson (2003) concluded (155). 
 Alginate and chitosan are both pH-sensitive polymers, thus their charges at different pH values 
would have considerable impacts on the formation and characteristics of AC NPs. Alginate has 
low aqueous solubility in an acidic environment, and chitosan is poorly water soluble at neutral 
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Figure 2-9: Characterisation of AC NPs prepared using different alginate concentrations. 
The size of AC NPs prepared using 0.06 mg/mL and 0.6 mg/mL of alginate was 192 ± 15 
nm, and 255 ± 38 nm, respectively, and zeta potential was measured to be -21 ± 1 mV and 
-34 ± 1 mV, respectively (n=3).  
  




Different pH conditions were evaluated to assess the influence of this parameter on AC NPs 
characteristics. When pH was higher than 5.5, most of the amine groups of chitosan were 
considered to be un-protonated (chitosan pKa = 5.5 – 6.5), and therefore, unable to have ionic 
interactions with alginate (178). The insolubility of chitosan at pH 5.5 caused flocculation and the 
particle size was above the detection limit of the ZetaSizer. Interestingly, lower pH conditions did 
not necessarily mean smaller AC NPs; the size of NPs prepared at pH 3.8 was 265 ± 30 nm, while 
the size of AC NPs prepared at pH 4.5 was 179 ± 5 nm (Figure 2-10) (176). This outcome was 
consistent with other studies where smaller NPs were obtained when chitosan amine groups and 
carboxyl groups of alginate were ionised, which indicates ionisation state is important for the 
formation of polyelectrolyte complex (179, 180). When the NP formation was performed at pH 
3.8, alginate started to precipitate due to decreased solubility (alginate pKa ~3.5), providing a 





Figure 2-10: Characterisation of AC NPs prepared at different pH. The particle size was 266 ± 18 nm, 
179 ± 3 nm, and 194 ± 16 nm when prepared at pH 3.8, 4.5, and 5.0, respectively. Measured zeta potential 
values of the corresponding NPs were 18 ± 5 mV, 17 ± 5 mV and 19 ± 1 mV. The smallest NPs were 
obtained when the pH was 4.5, consistent with the possibility that maximising the ionisation of the 
alginate carboxyl groups and the chitosan amine groups optimises the formation of polyelectrolyte 
complexes (n=3). 




Characteristics of nano-complexes formed by ionic interactions are dependent on the relative 
concentrations of soluble, charged forms of the two polymers involved. So, the influence of 
different ratios of alginate: chitosan (w/w) to generate NPs were also investigated.  
     AC NP sizes were larger for conditions with increasing amounts of chitosan in the suspension. 
Interestingly, the smallest NPs were formed when the ratio of alginate: chitosan was 1:1 (Figure 
2-11). This observations were consistent with the study by Douglas and Tabrizian (2005) where 
the smallest NPs were obtained when the alginate: chitosan ratio was between 1:1.5 and 1.5:1 
(176). Data presented herein does not contradict the idea that smaller NPs are formed when the 
availability of the functional groups of two polymers are in stoichiometric proportion (176). It is 
also important to note that the zeta potential of AC NPs changed from negative to positive when 
the ratio changed from 5:1 to 1:1 (Figure 2-11), it is thought that when a higher amount of alginate 
was used (5:1 ratio) the chitosan was unable to “cover” the total amount of carboxyl groups 
(negative charge) in the alginate.  
Stirring speed seemed to have less of an impact on AC NP characteristics in terms of particle 
size and zeta potential. All AC NPs prepared using stirring speeds of 500 rpm, 1000 rpm, and 
1500 rpm were in the size range of 175 –180 nm (Figure 2-12), with 1000 rpm being considered 
to be the optimal stirring speed due to relatively smaller particle size outcomes. When the stirring 
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Figure 2-11: Characterisation of AC NPs at different polymer ratios (w/w). Chitosan to alginate ratios (20:1, 
10:1, 5:1, 1:1, 1:2, and 1:5) resulted in NPs having average diameters of 193 ± 8 nm, 192 ± 18 nm, 205 ± 32 
nm, 179 ± 3 nm, 267 ± 11 nm, and 305 ± 13 nm, respectively. The smallest NPs size occurred at the ratio of 
1:1. Zeta potential values measured for these different ratios were -22 ± 1 mV, -21 ± 1 mV, -21 ± 2 mV, 17 ± 
5 mV, 32 ± 2 mV, and 37 ± 4 mV, respectively. Zeta potential was observed to change from negative to positive 
as the amount of chitosan was increased (n=3).  
 




to 26 mV (Figure 2-12). This increase might indicate that extensive stirring facilitated the 
interactions between alginate and chitosan. No increase of zeta potential at the speed of 1500 rpm 
was measured, suggesting that 1000 rpm was sufficient to adequately mix these two polymers. 
  
In addition to the parameters studied herein, such as alginate concentrations, pH, ratio of 
polymers, and stirring speeds, others parameters might also influences the formation of AC NPs. 
In this regard, Douglas and Tabrizian (2005) investigated the influence of polymer molecular 
weight, demonstrating that the molecular weight of chitosan has much more of an impact than the 
molecular weight of alginate on NP size. In general, NPs prepared using low molecular weight 
chitosan were smaller than those prepared with high or medium molecular weight chitosan (176). 
Nevertheless, chitosan molecular weight does not significantly influence surface charge, as 
different molecular weights of chitosan may have a similar degree of deacetylation, which means 
they have a similar proportion of functional groups to interact with alginate (181).  
Deacetylation degree of chitosan is another important parameter which determines 
physicochemical and biological properties of chitosan (182). Lavertu et al. (2006) observed a 
slight increase of NP zeta potential as deacetylation degree (72 %, 80 %, 92 %, and 98 %) of 
chitosan was increased (183). It is important to point out that the influence of deacetylation degree 
 
Figure 2-12: Characterisation of AC NPs prepared at different stirring speeds. Stirring speeds of 500 
rpm, 1000 rpm, and 1500 rpm resulted in NPs with mean diameters of 179 ± 5 nm, 177 ± 7 nm, and 180 
± 4 nm, respectively; measured zeta potential values were 17 ± 8 mV, 26 ± 2 mV, and 28 ± 2 mV, 
respectively. The stirring speed seemed to have less impact on the size and zeta potential of AC NPs. 
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is also pH-dependent, as the ionisation state of polymer is sensitive to the pH of the suspension 
(184).  
    The morphology of AC NPs was evaluated using TEM (Figure 2-13). AC NPs appeared to be 
individual spherical NPs, although a tendency for these particles to agglomerate was observed. 
The measured average diameter of these particles was 48 ± 14 nm (n=100).  Particle size measured 
by TEM was smaller than the measurement from DLS, which has been reported previously (185). 
This discrepancy is perceived to be due to the fact that DLS measurements give the hydrodynamic 
diameter of NPs in hydrated conditions, while TEM images are obtained from samples following 
dehydration. In addition, particle size differences can also be a result of the multiple scattering 
effect in the DLS technique; multiple scattering refers to the process when light scattered by the 
diffusing particle is re-scattered by one or more particles before reaching the detector (186). 
    
 
     The aim of this study was to develop a nano-carrier that could be loaded with 
biopharmaceuticals. As the pH in the small intestine is between pH 6 to pH 7.4, the morphology 
of these AC NPs in simulated intestinal fluid (SIF, pH 6.8) after 60 min was examined using TEM 
(187). While a considerable number of AC NPs was observed in TEM after the exposure to SIF 
for 15 min (Figure 2-14a), fewer AC NPs were observed after longer times of incubation in SIF 
(Figure 2-14b and c). It should be pointed out that SIF at pH 6.8 is close to the pKa of chitosan (~ 
6.5) (180). Thus, ionic interactions between alginate and calcium ions may reduce dramatically 











Figure 2-13: Representative TEM images of AC NPs. Particles were generally spherical in shape and 
had an average diameter measured by using Image J of 48 ± 14 nm (n=100).  




amine groups of chitosan, as well as alginate carboxyl groups, so that the electrostatic interactions 
between them are no longer the dominant force involved in maintaining AC NP integrity (189).  
Particle size stability over a short time frame is important and relevant for subsequent in vitro 
and in vivo studies. AC NP particle size was determined to be constant during 7 days of storage 
at RT (Table 2-2).  
Table 2-2: Change of NPs size and polydispersity over 7 days at RT 
 Day 1 Day 2 Day 3 Day 7 
Particle size (nm) 174 ± 3 170 ± 1 174 ± 3 165 ± 2 
Polydispersity index 0.245 ± 0.01 0.224 ± 0.01 0.233 ± 0.01 0.244 ± 0.01 
 






























Figure 2-14: Representative TEM images of AC NPs incubated 
in SIF at pH 6.8. The numbers of detected AC NPs were 



































2.3.3.2 Encapsulation of green fluorescent protein (GFP) into AC NPs  
 
     Once the size (179 ± 3 nm) and zeta potential (16 ± 5 mV) of AC NPs were optimised, the 
ability of AC NPs for encapsulating biopharmaceutical was tested using green fluorescent protein 
(GFP) as a model. This protein has a molecular weight of 26.9 kDa and an isoelectric point (pI) 
of 5.7.  
     Different ratios of GFP to alginate (1:5, 1:3, 1:2 and 2:1, w/w) were tested using a constant 
ratio of alginate: chitosan (1:1). Encapsulation efficiency of each ratio was calculated and 
compared, as well as the particle size and zeta potential (Figure 2-15 and Figure 2-16). AC NPs 
prepared using the ratio of 1:2 appeared to have the highest encapsulation efficiency of 91.7 %, 
while AC NPs prepared at the ratio of 2:1 had an encapsulation efficiency of only 61.6 %, the 
lowest amongst the ratios tested (Figure 2-15). For AC NPs prepared at ratio of 1:2, the average 
diameter measured by DLS was 196 ± 13 nm and measured zeta potential was 14 ± 7 mV (Figure 
2-16). When the ratio of GFP: polymer was adjusted to 2:1, the measured size increased to 207 ± 
4 nm and zeta potential changed to 23 ± 5 mV (Figure 2-16).   
These changes in encapsulation efficiency and physicochemical properties of AC NPs 
suggested that the excess GFP molecules, which are positively charged, were on the surface of 
NPs after reaching the ratio of 1:2. This ratio is believed to have the highest level of interactions 
possible between polymers. Comparing with AC NPs without loading GFP, which had a diameter 
of 179 ± 5 nm and a zeta potential of 16 ± 5 mV, the size of AC NPs loaded with GFP was 
increased, but no significant changes were observed in zeta potential. 
 Protein encapsulation in AC NPs are likely dependent upon electrostatic interactions between 
the protein molecule and the alginate and chitosan polymer (184). Under the conditions used to 
form AC NPs (pH 4.5), GFP (pI=5.7) was positively charged, which means it should 
preferentially interact with the negative charges provided by the alginate. This electrostatic 
interaction normally exhibits a saturation kinetic which reaches a peak value at high concentration 
of loaded material. Gan et al. (2007) found an almost linear increase of protein encapsulation in 
relation to protein concentration. A direct relationship between encapsulation efficiency and the 
concentration of loaded material (GFP) was not observed in this study (184). This might have 
suggested that other interactions were involved in the encapsulation of GFP, as there is no 
consensus in the literature for the relation between the protein concentration and the encapsulation 
efficiency. Akbuga and Bergisadi (1999) suggested that the concentration of the loaded material 
(cisplatin) had no effect on the encapsulation efficiency, but the small molecule nature of the 
encapsulated drug should be taken into consideration (190). In addition, Xu and Du (2003) 




showed that lower concentrations of loaded proteins (BSA) resulted in higher encapsulation 
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Figure 2-16: Characterisation of GFP-loaded AC NPs prepared using different ratios of GFP to 
polymer (w/w). NPs prepared at GFP: polymer ratios of 1:5, 1:3, 1:2, and 2:1, had hydrodynamic 
diameters of 196 ± 16 nm, 205 ± 20 nm, 196 ± 13 nm, and 207 ± 4 nm, respectively; zeta potential 
values for these preparations were measured to be 17 ± 6 mV, 17 ± 8 mV, 14 ± 7 mV, and 23 ± 5 mV, 
respectively (n=3).  
Figure 2-15: Encapsulation efficiency of GFP in AC NPs at different ratios of GFP to polymer (w/w). 
GFP encapsulation efficiency was 85 ± 6 %, 74 ± 5 %, 91 ± 3 %, and 61 ± 3 % when NPs were prepared 
at ratios of 1:5, 1:3, 1:2, and 2:1, respectively (n=3).  
 
 




     It is also important to note that electrostatic interactions could occur between negative groups 
of GFP and chitosan amine groups, as well as between the positive charges of GFP with alginate 
carboxyl groups. Furthermore, GFP can also interact with alginate and chitosan via hydrogen 
bonds. As chitosan molecules would be fully extended at pH 4.5, protein accessibility to amine 
groups would be without serious steric hindrance (184).  
     At the GFP: polymer ratio of 1:2 most of the positive groups of GFP were interacting with 
alginate negative groups, which led to a high encapsulation efficiency (Figure 2-15) that was 
consistent with a low measured zeta potential (Figure 2-16). When the GFP: polymer ratio was 
increased to 2:1, the excess amount of GFP molecules resulted in higher zeta potential. It is 
important to note that besides the electrostatic interaction, other interactions, like Van der Waals 
forces might be involved.  
     Apart from the GFP: polymer ratio, other parameters that could influence cargo protein 
encapsulation, including polymer concentration, polymer molecular weight, and degree of 
chitosan deacetylation would be relevant for the current studies. Xu and Du (2003) showed that 
increasing chitosan concentration decreases BSA encapsulation efficiency (191). Vanerberg et al. 
(2001) showed that the highly viscous nature of a gelation medium hinders the encapsulation of 
BSA (192). On the other hand, polymer molecular weight influences both NP size and the 
encapsulation efficiency, with higher chitosan molecular weight resulting in a higher 
encapsulation efficiency (191). This outcome could be explained by the idea that longer polymer 
chains can entrap greater amounts of protein during loading.  
     In contrast, Vila et al.(2004) showed that encapsulation of tetanus toxoid was irrespective of 
chitosan molecular weight, indicating that the entanglement of the protein within the chitosan 
chains was not affected by their molecular weight (193). This disagreement in literature about the 
effects of molecular weight on the encapsulation efficiency, may have resulted from the use of 
chitosan forms with different degrees of deacetylation. Lavertu et al. (2006) also showed that 
chitosan with a low degree of deacetylation results in physically unstable complexes with DNA. 
According to Köping-Höggård et al. (2001), the degree of deacetylation must exceed 65 % in 
order to obtain stable complexes with BSA for the purpose of cell transfection (194). As 
mentioned earlier, the ionised state of chitosan is also dependent on pH (184). That is to say, the 
behaviour of chitosan polymers with different molecular weight is partially dependent on their 
deacetylation degree, and the behaviour of the deacetylated chitosan is affected by the pH. 
The present studies using AC NPs have shown their ability of encapsulating a model 
biopharmaceutical (GFP), resulting in particles with size and surface charge in the desirable range. 
In terms of chemical linkage with ligands, alginate and chitosan provide flexibility for the direct 
conjugation of protein ligands via their functional groups at the surface of these particles. 
Specifically, the carboxyl groups on alginate can be used to cross-link with the amine groups from 




ligand to enhance transcytosis, whilst the amine groups from chitosan can also be used to cross-
link to carboxyl groups of a ligand (195). In addition, a cysteine residue could be integrated into 
either chitosan or alginate to facilitate site-directed chemical linkage with potential ligand to 
enhance transcytosis. A covalent attachment of cysteine onto alginate can be achieved by 
carbodiimide cross-link chemistry, and this thiolated alginate may also interact with cysteine-rich 
subdomains of mucus glycoproteins, improving its mucoadhesive properties (177). On the other 





Different preparation methods have been explored to generate biodegradable NPs in a 
desirable size range of 100 – 200 nm. These NPs had the capacity of encapsulating GFP 
representing a model biopharmaceutical. Importantly, these NPs should have surface accessible 
moieties that could be used to chemically cross-link a ligand to facilitate epithelial transcytosis of 
an NP loaded with a biopharmaceutical.  
Chitosan TPP NPs could be prepared with a diameter of 92 ± 1 nm, and a zeta potential of 7 ± 
5 mV when the ratio of chitosan: TPP was 20:1. While these characteristics would be considered 
promising for epithelial transcytosis, there may be limited applications for these NPs if one cannot 
identify ways to functionalise their surfaces for the chemical coupling of a transport ligand.  
Another biodegradable nano-carrier, based on CaP NP was prepared and characterised. These 
NPs were 181 ± 13 nm in diameter and had a zeta potential of -42 ± 5 mV. In order to facilitate 
their conjugation with ligands and increase their bioadhesion in the intestine, chitosan was used 
to coat them. However, it was not possible to confirm the chitosan coating was on the surface. 
For this reason, no further study was carried out with this type of NP.  
Finally, AC NPs were prepared by the ionic interactions between two oppositely charged 
polymers. The formation of this nano-carrier was influenced by pH, polymer concentrations and 
polymer ratios. We identified an optimised method involving an alginate concentration of 0.06 
mg/mL, a polymer ratio of 1:1 for alginate to chitosan, pH 4.5, and stirring speed of 1000 rpm 
when preparations are performed at room temperature. The obtained NPs were 179 ± 5 nm in 
diameter, with a zeta potential of 16 ± 5 mV. Both alginate and chitosan have the ability to 
conjugate ligands and/or to be chemically modified for conjugation. The ability of AC NPs to 
encapsulate biopharmaceuticals was tested using GFP as a model. The best encapsulation 
efficiency of GFP (92 %) was reached at a GFP: polymer ratio of 1:2. GFP-loaded AC NPs were 
196 ± 13 nm in diameter and with a zeta potential of 14 ± 7 mV. These AC NPs had the desired 




size, the ability to encapsulate a biopharmaceutical, and the ability to conjugate a transport ligand 
on the surface.  
Therefore, a nano-carrier using alginate and chitosan was developed and characterised 
sufficiently to warrant subsequent studies involving surface conjugation with ligands to mediate 













Chapter 3   Chemical linking of proteins with nanoparticles 
Overview: 
Aim: To chemically link non-toxic Pseudomonas exotoxin (ntPE) with stable fluorescent 
polystyrene nanoparticles (fPS NPs) and biodegradable alginate chitosan nanoparticles (AC NPs).   
Methods: The gene sequence for expressing ntPE with a C-terminal extension composed of a 
cleavable, constrained loop followed by a hexa-histidine (H6) tag was expressed in Escherichia 
coli K12 bacteria. This protein was then purified using immobilised metal ion affinity 
chromatography (IMAC) and size exclusion chromatography (SEC). Following cleavage of the 
constrained loop, a free thiol group was exposed and was used to link ntPE with fPS NPs or AC 
NPs via a heterobifunctional cross-linking reagent (EMCH; N-ε-maleimidocaproic acid 
hydrazide). Bovine serum albumin (BSA) was similarly coupled to fPS NPs or AC NPs to serve 
as a negative control in subsequent studies. Protein-modified NPs were characterised by dynamic 
light scattering (DLS), transmission electron microscopy (TEM) and ZetaSizer to determine the 
particle size and zeta potential. For the purpose of validating proteins on the surface of fPS NPs, 
the change in fluorescence intensity of fPS NPs after the conjugation with BSA or ntPE was 
recorded using the fluorescence intensity detector in a microplate reader. To check the presence 
of proteins in the BSA- or ntPE-coupled AC NPs, each NP preparation was characterised by using 
Fourier transform infrared spectroscopy (FTIR). Fluorescein-5-thiosemicarbazide (FTSC) was 
used to detect and compare the extent of residual functional sites on AC NPs before and after the 
linkage with proteins, with the intention of revealing molecular level information about the 
conjugation.  
Results: The diameter of blank fPS NPs, fPS NPs-BSA and fPS NPs-ntPE was 134 ± 22 nm, 151 
± 26 nm, and 111 ± 10 nm, respectively. After conjugation with BSA or ntPE on the surface of 
fPS NPs, the zeta potential of these particles changed from -30 ± 2 mV to -20 ± 5 mV and to -20 
± 0.4 mV, respectively. Observed fluorescence quenching on fPS NPs-BSA and fPS NPs-ntPE 
suggested that proteins might be located on the surface of fPS NPs. The conjugation of BSA or 
ntPE onto AC NPs altered the particle sizes from 215 ± 8 nm to 280 ± 9 nm for AC NPs-BSA and 
to 202 ± 20 nm for AC NPs-ntPE. The zeta potential of the AC NPs changed from 20 ± 8 mV to 
-19 ± 11 mV for AC NPs-BSA and to -6 ± 5 mV for AC NPs-ntPE. FTIR spectral analysis of AC 
NPs-BSA and AC NPs-ntPE supported the possibility of the chemical linkage between BSA and 
ntPE with AC NPs.   
Conclusion: BSA and ntPE appear to have been successfully linked to fPS NPs and AC NPs, this 
was sufficient to warrant biological studies that would assess the role of these proteins to facilitate 
trans-epithelial transport of these NPs.  





3.1 Introduction  
Chapter 2 explored NP preparation methods to achieve desired physicochemical properties 
that could facilitate their uptake and transport in the gastrointestinal tract (GI tract). It has been 
generally accepted that NPs in the size range of 100 – 200 nm are favoured for cell uptake (138). 
Although NPs can be internalised into the enterocytes of the GI tract, the fate of NPs after 
endocytosis into these cells is presumed to be degradation in lysosomes or non-specific exocytosis 
(197). Consequently, very small amounts of NPs are able to travel across the epithelium: from the 
apical to the basolateral side (transcytosis). It has been hypothesised that specific ligands on NPs 
might lead to receptor-mediated transport, which could possibly evade digestion and facilitate 
efficient transcytosis (34).  
     Pseudomonas aeruginosa secrete a virulence 
factor, exotoxin A that can efficiently cross an 
epithelial barrier. Pseudomonas exotoxin A (PE) 
consists of three domains: domain I binds to the 
low-density lipoprotein receptor-related protein 
(LRP-1) at the apical surface of simple polarised 
epithelial cells such as those in the intestine and 
airway (by inhibiting protein synthesis through 
ADP ribosylation (110). In non-polarised cells, 
domain II is responsible for inducing PE access 
into the cell cytoplasm, and domain III functions 
as a cytotoxic enzyme that results in cell death by 
inhibiting protein synthesis through ADP  
ribosylation (110).  
 
Remarkably, PE is able to travel across polarised epithelial cells without changing the 
toxicological properties determined by its structure (118). Deletion of a glutamic acid at position 
533 of PE removes its cytotoxic effect, a mutant that has been widely used in immunotoxin 
development (198). In this present study, we hypothesised that attachment of ntPE at the surface 
of NPs would facilitate permeability of NPs across intact, simple, polarised epithelium. In order 
to achieve a controlled coupling to NPs, a unique construction was prepared that would generate 
a single available thiol group on ntPE. 
Chitosan and alginate were selected to prepare biodegradable and biocompatible polymeric 
NPs. Both chitosan and alginate have shown great flexibility for conjugation with protein and for 
 
 
Figure 3-1: Schematic diagram of the 
structure of PE. It consists of three domains, 
domain I is responsible for the recognition on 
the cell membrane, the function of domain II 
is to translocate the protein after 
internalisation, and domain III leads to the 
cytotoxic effect.   




chemical modification for conjugation (177). A mild chemical linking strategy was selected 
because of the fragile nature of proteins. It is critical to ensure that properly folded, biologically 
active proteins are coupled onto NPs so that these NPs could be tested in vitro and in vivo. 
Conjugation of ntPE onto the surface of preformed NPs was carried out in water using the cross-
linking agent EMCH (N-ε-maleimidocaproic acid hydrazide). Using the maleimide group of 
EMCH, the free thiol groups on a C-terminal modified form of ntPE could be selectively linked, 
while the hydrazide group at the other end of EMCH was anticipated to link with carboxyl groups 
present at the surface of NPs (Figure 3-2). This linking strategy would allow unwanted byproducts 
to be easily removed by nonchromatographic methods (199). 
 The chemical linking protocol was first developed using stable PS NPs before moving to the 
more labile NPs prepared from chitosan and alginate. Additionally, BSA was used to optimise 
chemical coupling conditions that could then be used with ntPE; BSA and ntPE have a similar 
isoelectric point (pI) and molecular weights (200, 201). 
It is widely acknowledged that physicochemical properties of NPs, such as size and surface 
chemistry, dramatically affect their behaviours in biological systems (202). Therefore, the 
physicochemical characterisation of NPs and protein-conjugated NPs was performed in this study, 
anticipating they would provide important information for understanding the in vitro and in vivo 
behaviours of NPs surface-coupled with ntPE.   
  
 
Figure 3-2: Illustration of the chemical linkage between NPs and ntPE or BSA. The carboxyl groups on NPs 
were linked with thiol-BSA or thiol-ntPE using the cross-linker EMCH (the particles and molecules depicted 
do not represent the actual size and location). 
 




3.2        Methods 
3.2.1 Production of ntPE used for selective coupling 
 
A non-toxic mutant of Pseudomonas exotoxin A (ntPE) was used; deletion of the glutamic 
acid at position 553 (E553) resulted in detoxification of the enzyme activity of domain III (119). 
A plasmid containing nt-PE (pVC 45D) was kindly donated by Dr David FitzGerald (NCI/NIH, 
Bethesda, MD, USA). A tobacco etch virus (TEV) protease-specific sequence followed by a hexa-
histidine sequence (CENLYFQSGTCHHHHHH) was inserted into the plasmid at the C-terminus 
of the ntPE open reading frame (ntPE-TEV-H6). 
 
3.2.1.1 Protein expression in the periplasm 
 
The bacterial strain used to express ntPE-TEV-H6 was Escherichia coli K12. A single colony 
of SHuffle® T7 (C3026H, New England Biolabs) transformed with the ntPE-TEV-H6 expression 
vector was used to inoculate 50 mL of Lysogeny Broth (LB) medium containing 50 µg/mL 
ampicillin (BP1760-25, Fisher Scientific) and grown overnight at 37 °C with shaking at 250 RPM. 
The protocol for making LB medium was: 10 g of tryptone (1279-7099, Fisher Scientific), 5 g of 
yeast extract (BPE9727-2, Fisher Scientific), and 10 g of sodium chloride (S9625-5KG, Sigma-
Aldrich) in 1 L of water. The next day, 1 L of LB medium supplemented with 50 μg/mL ampicillin 
was inoculated with 25 mL overnight culture and cells were grown at 37 °C with shaking at 250 
RPM until the OD600 reached 0.6 – 0.8. At this point, cell cultures were induced using 0.5 mM 
IPTG (isopropyl β-D-1-thiogalactopyranoside, C9H1805S, Fisher Scientific) and grown 
overnight at 18 °C. Cells were harvested by centrifugation at 1530 × g (calculated by rmin, refers 
to the distance between the centre of rotor to the top of the tube) at 4 °C for 20 min (JA-10 fixed 
angle rotor on Beckman J2-MC centrifuge), and the cell pellets were suspended in 30 mM Tris-
HCl (T6066-1KG, Sigma-Aldrich), 20% sucrose (S7903-250G, Sigma-Aldrich), pH 8.0 at 80 mL 
per gram wet weight. 200 mM EDTA (Ethylenediaminetetra-acetic acid, E9884-100G, Sigma-
Aldrich) was added dropwise to the cell suspension while on ice until a final concentration of 1 
mM EDTA was reached. Following 10 min of gentle shaking, cell suspensions were centrifuged 
at 3225 ×g (HeraeusTM PrimoTM/ Primo R Centrifuge, Thermo Scientific) for 20 min at 4 °C, with 
the pellets suspended in ice-cold water and incubated on ice with gentle shaking for 10 min. Cell 
debris following this osmotic shock step was pelleted by centrifugation at 3225 ×g for 20 min at 
4 °C. The supernatant, containing proteins from the periplasm, was collected and processed for 
the purification of ntPE-TEV-H6 protein.  
 




3.2.1.2 Protein purification 
 
Purification of ntPE-TEV-H6 was a two-step process. Firstly, immobilised nickel ion affinity 
chromatography (IMAC) was used to capture the full-length protein, then size exclusion 
chromatography (SEC) was used to capture monomeric protein. The H6 tag at the C-terminus of 
ntPE-TEV was designed for high affinity capture using a His Trap column prepacked with nickel 
ion-Sepharose (5mL, HisTrapTM HP, 17-5248-02, GE Healthcare Life Sciences). A linear gradient 
of imidazole (20 mM to 500 mM, 301870010, Acros Organics) in a solution containing 50 mM 
Tris pH 8.0, and 300 mM sodium chloride at a flow rate of 4 mL/min was used to elute ntPE-
TEV-H6 captured by the His Trap column. Fractions with proteins were collected at every 5 mL 
(referred to as fractions A1-A12). These fractions were then concentrated by reducing the volume 
to 1 mL using a 10 kDa MWCO spin filter (Amicon® Ultra-4 Centrifugal Filter Unit with Ultracel-
10 membrane, UFC801024, Merck Millipore Ltd.).    
SEC was used to separate aggregated forms and other unwanted substances from monomeric 
ntPE-TEV-H6. A concentrated protein solution obtained following the IMAC purification step 
was loaded onto a Superdex® 200 HR10/30 column (17517501, GE Healthcare Life Sciences) 
and eluted with PBS (10 mM of phosphate buffer in 137 mM sodium chloride, pH 7.4, Phosphate-
buffered saline, Dulbecco “A” Tablets, BR0014G, Oxoid Ltd) at a flow rate of 0.5 mL/min. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; the full protocol can 
be found in Appendix 1) was used to identify column fractions containing ntPE-TEV-H6. Protein 
concentrations were determined using a NanoDropTM 2000c spectrophotometer (Thermo 
Scientific) at the wavelength of 280 nm. 
 
3.2.2 Preparation of EMCH-ntPE and EMCH-BSA for conjugation with NPs 
3.2.2.1 Cleavage of ntPE-TEV-H6 protein and preparation of EMCH-ntPE  
 
The ntPE-TEV-H6 protein sequence contains a TEV cleavage sequence (CENLYFQ√ 
SGTCHHHHHH) at its C-terminus where √ refers to a TEV-specific cleavage site. Mild reaction 
allows opening the disulphide bond present and exposes a linear form of the amino acid sequence 
identified and cleaved by the tobacco etch virus (TEV) protease. Removal of the C-terminal amino 
acids (SGTCHHHHHH) using a second IMAC step allowed for the preparation of ntPE-
CENLYFQ that contained an unpaired cysteine residue, which could be used for selective 
conjugation. This was achieved by the following steps. 2 mg ntPE-TEV-H6 protein was mixed 
with the TEV cleavage reaction buffer containing 50 mM Tris-HCL pH 8.0, 0.5 mM EDTA and 
0.5 mM DTT (Dithiothreitol, 1452675, Novex® by Life Technology)  and was incubated for 4 h 




at room temperature (RT) after the addition of TEV enzyme (1351394, Novex® by Life 
Technology). A 1 mL HisTrap HP column (prepacked with nickel- Sepharose, 29-0510-21, GE 
Healthcare Life Sciences) was used to separate cleaved protein (ntPE-CENLYFQ) from the 
SGTCHHHHHH peptide. A PD-10 column (17-0851-01, GE Healthcare) was used to perform 
buffer exchange into PBS solution.  
Chemical coupling between the free thiol group of the cysteine residue in ntPE-CENLYFQ 
and carboxyl groups present on the surface of NPs was achieved by using the heterobifunctional 
chemical linker EMCH (N-ε-maleimidocaproic acid hydrazide, 22106, Thermo Fisher Scientific). 
The maleimide moiety of EMCH was used to conjugate with thiol groups of ntPE-CENLYFQ, 
whilst the hydrazide moiety of EMCH was used to conjugate to the free carboxyl groups on NPs. 
The thiol-maleimide reaction was allowed to occur at RT for 2 h. Unreacted EMCH was removed 
by dialysis (SnakeSkinTM Dialysis tubing, 10K MWCO, 68100, Thermo Fisher Scientific) against 
water overnight at 4 °C.  
 
3.2.2.2   Introduction of free thiol groups into BSA and the preparation of EMCH-BSA  
 
BSA (A7906-100G, Sigma-Aldrich) was chosen as a control for ntPE due to its similarities in 
physicochemical properties (molecular weight, isoelectric point). In order to use a similar 
coupling approach for both molecules, free thiol groups were introduced into BSA to allow for 
the EMCH-based conjugation. Traut’s reagent (2-iminothiolane, 26101, Thermo Fisher 
Scientific) was used to achieve a one-step conversion of free amines to free thiols. A 3-fold molar 
excess of Traut’s reagent was added to BSA (12mM in PBS containing 3 mM EDTA) in a 
dropwise manner and the reaction solution was incubated at RT for 1 h. Afterwards, the number 
of thiol groups was determined to be ~1 per BSA molecule using Ellman’s reagent (5,5’-
Dithiobis(2-nitrobenzoic acid), S39637, Sigma-Aldrich). This reagent can react quantitatively 
with thiol groups to yield detectable reaction products, which can be quantitated 
spectrophotometrically (λmax= 412nm; the full protocol can be found in Appendix 2). The thiol 
groups induced to BSA were reacted with EMCH in a manner identical to that used for ntPE-








3.2.3 Conjugation of EMCH-ntPE and EMCH-BSA onto fPS NPs 
 
fPS NPs ~100 nm in diameter and with carboxylate groups on the surface were used (Ex/Em: 
580/605 nm, 50 mg/mL, F8801, Thermo Fisher Scientific). 0.5 mL of fPS NPs were rinsed twice 
by ultrafiltration at 5000 × g for 10 min using Amicon Ultra-15 Centrifugal Filter Units (10kDa 
MWCO, UFC901024, Merck Millipore) in MES buffer (2-ethanesulfonic acid, 50 mM, pH 6.0, 
M3671-50G, Sigma-Aldrich). Rinsed NPs were suspended in 10 mL MES buffer to the final 
concentration of 2.5 mg/mL. 
2 mL of fPS NPs were reacted with 0.5 mg of EMCH-BSA or EMCH-ntPE prepared earlier, 
the reaction being allowed to occur in 3 mL of 50 mM phosphate buffer (50 mM of Na2PO4 
71636-250G, Sigma-Aldrich) containing 0.9 % sodium chloride. After 15 min of incubation at 
RT, 4 mg of EDC (1-Ethyl-3-(3-dimethylaminopropyl), carbodiimide, E1769, Sigma-Aldrich) 
and 5 mg of NHS (N-hydroxysuccinimide, 24500, Thermo Fisher Scientific) was added to the 
reaction solution (203). After the addition of EDC and NHS, the pH was adjusted to 6.5 and the 
reaction was allowed to proceed overnight at RT. Unreacted proteins and reagents were excluded 
from the suspension through ultrafiltration (Amicon Ultra-4 Centrifugal Filter Units, 652000, 
100K MWCO, Merck Millipore) at 2500 × g for 10 min; un-coupled proteins were collected and 
quantified by Bradford assay (described in section 3.3.2.5).  
 
3.2.4 Alginate-chitosan nanoparticles coupling to EMCH-BSA or EMCH-ntPE 
3.2.4.1 Oxidation of sodium alginate  
 
Carboxyl groups on AC NPs were produced by the oxidisation of alginate. A 1 % (w/v) sodium 
alginate (W201502, Sigma-Aldrich) solution was mixed with sodium periodate (50 mM, 311448-
5G, Sigma-Aldrich) and incubated at RT for 24 h with the reaction being quenched by the addition 
of an equimolar amount of ethylene glycol (102466-500ML,Sigma-Aldrich). Sodium chloride 
(2.5 g) was then added to the solution, followed by precipitation with 2 excess volumes of ethyl 
alcohol (200 mL). The precipitates were collected by centrifugation and dissolved in distilled 
water (100 mL) prior to a second precipitation using ethyl alcohol (200 mL). The resulting 
oxidised alginate was freeze-dried (MicroModulyo 230, Thermo Scientific) under reduced 
pressure to yield a white solid (0.8 g, 80 % yield).  
 
 




3.2.4.2 Preparation of oxidised AC NPs 
 
2 mL of 0.51 mg/mL calcium chloride (C3881-500G, Sigma-Aldrich) solution was added into 
10 mL of 0.06 mg/mL oxidised alginate solution dropwise under micro-tip probe ultra-sonication 
(Model 2501450, Sonifier, Branson). The resultant material was stirred for another 30 min before 
the addition of 2 mL 0.3 mg/mL chitosan solution (448869-50G, Sigma-Aldrich). The suspension 
was equilibrated overnight at RT to allow the formation of NPs. All materials were filtered 
through 0.45 µm membranes (MF-MilliporeTM Membrane, 0459, Merck Millipore Ltd) prior to 
use. 
 
3.2.4.3 Conjugation of EMCH-ntPE and EMCH-BSA onto AC NPs 
 
The carboxyl groups on oxidised alginate were reacted with the hydrazide groups on EMCH-
BSA and EMCH-ntPE. 2 mL of oxidised AC NPs were mixed with 0.5 mg of EMCH-BSA or 
EMCH-ntPE in a 10 times diluted PBS buffer (1 mM for phosphate, 13 mM for sodium chloride, 
pH 7.4). After 2 h reaction at RT, the un-coupled EMCH-BSA or EMCH-ntPE was excluded by 
overnight dialysis against water at RT (Spectra/Por® Biotech membranes, 100K MWCO, 
SpectrumLabs). The extent of protein coupled onto AC NPs was quantified by Bradford assay.  
 
3.2.5 Standard curve for Bradford assay and protein quantification 
 
Bradford assay is a simple, fast and sensitive method to determine protein concentration. It 
relies on absorbance shift of the dye Coomassie blue after its binding to protein. In the acidic 
assay reagent solution, the dye is in the cationic form and has a λmax of 470 nm. In contrast, the 
anionic form of the dye, which binds to protein, has a λmax of 595 nm. Thus, the amount of protein 
can be quantified by the measurement of the absorbance of the solution at 595 nm.  
A standard curve from 2.5 to 50 µg of BSA was used for protein quantitation, with 50 µL of a 
protein solution being mixed with 150 µL of Coomassie blue solution (1856209, Thermo 
Scientific) in a 96 well microplate (3370, 96 Well Flat Bottom, Costar®, Corning Incorporated). 
Coomassie blue-protein complexes were left for 10 min at RT before spectroscopic measurement. 
The standard curve of ntPE from 2.5 to 100 µg was generated the same way as the BSA standard 
curve. To quantify the amount of proteins on NPs, the values from blank NPs were subtracted for 
each reading.  




3.2.6 Physicochemical characterisation of NPs 
3.2.6.1 Measurement of size and zeta potential  
 
The hydrodynamic size of NPs was measured using a NanoSight NS 500 instrument 
(NanoSight Ltd, Amesbury, UK), equipped with a sample chamber and syringe pump. All 
samples were diluted 10-fold in PBS (1 mM for phosphate, 13 mM for sodium chloride, pH 7.4) 
prior to measurement. Nanoparticle Tracking Analysis (NTA) 2.2 software was used to control 
the measurement process, to capture, and analyse data. The injection tube was immersed in 1 mL 
of sample solution, and the machine automatically loaded a sample into the viewing unit. Three 
recordings were obtained for each sample. The instrument settings were standardised for 
measuring each type of NP. Particle concentration was acquired from the NanoSight report. 
Protein density on each NP preparation was calculated as follows:  
 
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 𝑝𝑒𝑟 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒) =
𝑐 × 106 × 𝑁
𝑀 × 𝑐𝑝
 
c: the concentration of protein on NPs in 1 mL  
M: molecular weight of protein  
cp: number of nanoparticles in 1 mL  
N: Avogadro's number, 6.022×1023 mol-1 
 
Zeta potential measurements were performed in triplicate in a Malvern ZetaSizer Nano 
instrument (Malvern Instruments Limited, Malvern, UK) at 25 °C. 
 
3.2.6.2 Transmission Electron Microscopy 
 
The morphological analyses of fPS NPs and AC NPs were performed using TEM (JEOL 
JEM1200EXII). Samples were diluted 10-fold in PBS (pH 7.4). A suspension of NPs was then 
dropped onto carbon-coated copper grids (FC300Cu, EM Resolutions) with the liquid being 
quickly removed by touching the edge of the grid to filter paper. Negative staining was performed 
using uranyl acetate to treat samples for 30 seconds, which was also removed by filter paper 
absorption. Samples were stored desiccated after air drying (179).  
 




3.2.6.3 Fluorescence excitation/emission spectra of fPS NPs 
 
Fluorescence intensity is related to the concentration of a fluorescent molecule but also to its 
environment; under certain circumstances the intensity of a fluorescent molecule can be quenched 
(204). The change in fluorescence intensity of fPS NPs is probably one way of showing the 
presence of proteins on NPs surface. 100 µL volumes of fPS NPs, fPS NPs-BSA and fPS NPs-
ntPE solutions were displayed in a 96 well microplate (655086, Cell culture microplate, 96 well, 
F-bottom, black, Cellstar®, Greiner bio-one), and the fluorescence spectra of these fPS NPs were 
performed using a microplate reader (FLUOstar Omega Microplate Reader, BMG LABTCH), 
with an excitation and emission wavelength range of 475 – 576 nm and 545 – 660 nm, 
respectively. Excitation and emission spectra of each fPS NPs were performed in triplicate.  
 
3.2.6.4 Attenuated Total Reflection Fourier Transform Infrared Spectroscopy 
 
FTIR is a well-established technique for providing information on molecular structure and 
interactions. ATR FTIR is able to measure a wide variety of solid and liquid samples without the 
need for complex preparations. FTIR spectra were obtained by using a Perkin Elmer Frontier 
Optica FTIR spectrometer equipped with a mercury cadmium telluride (MCT) detector (Perkin 
Elmer). Correction of the buffer was carried out before each measurement. A drop of AC NPs, 
AC NPs-BSA and AC NPs-ntPE solution was placed on the ATR crystal and the signals were 
obtained under the wavenumber from 4000 to 600 cm-1 at a resolution of 4 cm-1.  
 
3.2.6.5 Fluorescent labelling of AC NPs  
 
In order to understand the chemical linkage of protein with AC NPs at a molecular level, a 
fluorescent label was used to detect the free aldehyde groups on the surface of AC NPs before 
and after the linkage with proteins. FTSC (fluorescein-5-thiosemicarbazide, MW=421.3 g/mole, 
46985, Sigma-Aldrich, λex= 492 nm; λem=516 nm) was used to react with aldehyde groups on 
oxidised AC NPs prior to reaction with proteins. 150 µg of FTSC was added into 2 mL of oxidised 
AC NPs solution and incubated for 4 h at 37 °C. Unreacted FTSC was removed by overnight 
dialysis (SnakeSkinTM Dialysis tubing, 10K MWCO, 68100, Thermo Fisher Scientific) against 
water at RT. The amount of FTSC on AC NPs was used to determine the total amount of aldehyde 
groups on AC NPs (labelled as AT). The same batch of AC NPs were reacted with EMCH-BSA 
or EMCH-ntPE as described in section 3.2.4.3, and then 2 mL of AC NPs coupled to EMCH-




BSA or EMCH-ntPE were reacted with 150 µg of FTSC. The extent of FTSC reacted with free 
aldehyde groups on AC NPs coupled to EMCH-BSA or EMCH-ntPE was quantified and defined 
as AN. Reacted aldehyde groups were calculated by the difference between the total amount of 
aldehydes on NPs and the free aldehyde groups (AR= AT- AN) after the conjugation with proteins. 
The amount of FTSC was measured in a microplate reader (205). All experiments were performed 
in triplicate.  
   
3.3   Results and discussion 
3.3.1 Expression and purification of ntPE-TEV-H6 protein 
 
ntPE secretion into the bacterial periplasm was facilitated by the OmpA signal sequence in the 
plasmid. It is believed that the oxidising environment in the periplasm facilitates the formation of 
disulphide bonds in ntPE, promotes protein folding and preserves protein stability (206). A hexa-
histidine sequence (CENLYFQSGTCHHHHHH) was inserted into the plasmid at the C-terminus 
of the ntPE open reading frame (ntPE-TEV-H6), which facilitated capture purification methods. 
This C-terminus location of H6 instead of an N-terminus ensures that only full-length protein, not 
partially expressed or truncated form of ntPE, would be captured by the initial purification step 
that involved immobilised nickel ion affinity chromatography (IMAC). Followed by the hexa-
histidine sequence, a tobacco etch virus (TEV) protease-specific sequence was inserted into the 
plasmid which allowed the introduction of a single free thiol for the subsequent chemical 
coupling.  
A representative IMAC purification step for ntPE-TEV-H6 showed extensive amounts of UV-
absorbing materials (280 nm) obtained from the bacterial periplasm that are present in the column 
flow through, as shown in Figure 3-3a and indicted by the blue arrow. Elution of the desired ntPE-
TEV-H6 was achieved by switching to the imidazole buffer (Figure 3-3a, red arrow). Eluted ntPE-
TEV-H6 material, captured in fractions A3-A4, was separated by SDS-PAGE (Figure 3-3b). 
Comparing proteins from E.coli before and after IPTG induction (shown in Figure 3-3b at lane 1 
and lane 2 respectively), there was one band appearing around 70 kDa in lane 2, suggesting 
proteins were induced to express after the addition of IPTG. Following the initial purification 
using IMAC, the eluted proteins were collected, analysed and shown in Figure 3-3b at lane 4 and 
lane 5 around 70 kDa; their molecular weight  corresponds to the molecular weight of ntPE-TEV-
H6 which is 68 kDa (207) . 




    
 
Following IMAC purification, SEC was used to further purify monomeric ntPE-TEV-H6. As 
IMAC is an affinity purification process which would enrich aggregated or fragmented forms of 
this protein, as well as unrelated materials produced by E. coli that might interact with nickel ions 
within the histidine column.  
Proteins eluted from the SEC column were collected corresponding to fractions A6–A12 
(Figure 3-4, red arrow), and were analysed in SDS-PAGE (Figure 3-4b). It appeared that there 
were some aggregated forms of ntPE (as circled in Figure 3-4b, lane 1) and some fragments (as 
circled in Figure 3-4b, lane 6). Considering they were in low quantity, most of the protein shown 





Figure 3-3: ntPE purification by IMAC. (a) Chromatogram obtained by IMAC. Extensive amounts of 
UV-absorbing materials passed through the column first (blue arrow) and then ntPE-TEV-H6 were 
released from the column and collected in tubes A3–A4 (red arrow) with the elution of the imidazole 
buffer.  (b) Coomassie blue-stained SDS-PAGE analysis shows how the IMAC step was used to isolate 
ntPE-TEV-H6. Lane 1, protein from E. coli before the IPTG induction; lane 2, proteins from E.coli after 
IPTC induction; lane 3, protein extracted in osmotic shock solution; lane 4 and lane 5 protein fractions 
corresponding to the UV peaks in (a), A3–A4.     




    
3.3.2 Preparation of protein for chemical linkage with NPs 
3.3.2.1 TEV cleavage of ntPE-TEV-H6 and the preparation of EMCH-ntPE for chemical 
linkage with NPs 
 
The C-terminal TEV cleavage sequence (CENLYFQ√SGTCHHHHHH) in ntPE-TEV-H6 
exposed an unpaired cysteine residue for selective conjugation; the cleavage reaction and 
purification process is illustrated in Figure 3-5. The H6 tag was separated from ntPE-CENLFQ 
using a HisTrap column, which would allow ntPE-CENLFQ to go through the column and to be 
collected, whilst the H6 tag was trapped inside the column. The conjugation of ntPE and NPs was 
achieved by a heterobifunctional chemical cross-linker, EMCH, the maleimide end of which 
reacted with thiol groups on ntPE-TEV-H6; while its hydrazide groups reacted with carboxyl 





Figure 3-4: Purification of nt-PE by SEC. (a) Chromatogram obtained by SEC. Large amounts of UV-absorbing 
materials passed through the SE column and collected in the tube from A6 to A12 (red arrow). (b) Coomassie 
blue-stained SDS-PAGE analysis of nt-PE fractions corresponding to the UV peaks in (a), lane 1-lane 6, 
corresponding to A6–A12.There were some aggregated forms of ntPE-TEV-H6 in lane 1, and some fragments in 
lane 6. The rest of the protein collected in A7–A11 corresponding to lane 2 – lane 5 was considered to be the 
monomeric form of ntPE-TEV-H6. 
 
 
Figure 3-5: Illustration of the preparation process of EMCH-ntPE. TEV protease opened an unpaired 
cysteine residue of ntPE-TEV-H6 for thiol-maleimide reaction with EMCH, and the H6 tag was removed 
using a HisTrap column.  
 




3.3.2.2 Preparation of EMCH-BSA for chemical linkage with NPs  
 
BSA served as a negative control due to its similarity in structure and physicochemical 
properties to ntPE (200, 201). Calculated by Ellman’s reagent, there were 5 mM of thiol groups 
in a 12 mM BSA solution, suggesting that ~42 % of BSA molecules have free thiol groups on 
average. In order to mimic the organisation of thiol-ntPE (Figure 3-6), each BSA was allowed to 
carry one thiol group after different amounts of Traut’s reagent had reacted with BSA (209). One 
thiol group for each BSA molecule was kept consistently with a 3-fold mole excess of Traut’s 
reagent over BSA. EMCH was coupled to thiol-BSA using the same protocol as for thiol-ntPE.  
                                  
3.3.3 Preparation of fPS NPs-BSA conjugate and fPS NPs-ntPE conjugate   
 
    A commercial and stable nano-system, fPS NPs, was used to verify the chemical linking 
process. The carboxylate groups on the surface of the fPS NPs were linked with EMCH-BSA or 






Traut’s reagent  
BSA BSA SH 
EMCH 
BSA SH EMCH 
Figure 3-6: Illustration of the preparation process for EMCH-BSA. Amine groups on BSA were 
converted into thiol groups and linked with maleimide groups from EMCH 
 
 
 Figure 3-7: Illustration of EDC and NHS coupling. EDC and NHS form a more stable intermediate, 
amine-reactive NHS ester for improving the amine and carboxylate reaction efficiency between 
EMCH-BSA and fPS NPs.  
 




Using EDC and NHS in the chemical reaction between fPS NPs and EMCH-BSA (or EMCH-
ntPE) is believed to increase the amine-carboxylate reaction efficiency. It has been proposed that 
EDC reacts with carboxyl groups from fPS NPs and forms an active O-acylisourea intermediate. 
The intermediate is not stable and can hydrolyse easily in aqueous solutions (in Figure 3-7). NHS 
was added into the reaction mixture to improve the reaction efficiency by forming a more stable 
intermediate with EDC and allowing more efficient conjugation with hydrazine groups from 
EMCH (203). This conjugation reaction was carried out in a mild environment which favours 
preserving protein structures, and the by-products generated were excluded from the solution via 
ultra-centrifugation in this study.  
 
3.3.4 Physicochemical characterisation of fPS NPs-BSA and fPS NPs-ntPE 
 
Following the conjugation of proteins onto NPs, different techniques were used to verify the 
linkage and explore their physicochemical properties.  
Particle size measurement was performed using a NanoSight instrument, which is based on 
the mechanism of DLS. Blank fPS NPs (fPS NPs without protein) had a diameter of ~134 ± 22 
nm, the addition of BSA altered the size to ~151 ± 26 nm (see Table 3-1). It was anticipated from 
a previous study that adding BSA onto the surface of NPs would increase particle size (210). 
Based on the particle size measured in this study, the surface area for each particle was 
approximately ~5.6 × 104 nm2, according to the calculated protein density (shown in Table 3-1), 
there were ~1.26 × 104 BSA molecules on each NP. It is known that the ellipsoid dimensions of 
BSA is 3.8 × 3.8× 14.0 nm (211), assuming the diameter of BSA was 4 nm when it was coupled 
onto a NP, BSA would occupy ~5.0 × 104 nm2 on each particle, and thus, it is reasonable to 
propose that BSA molecules were distributed on NP with different orientations, considering there 
was 17 nm measured increase in thickness. It is also important to note that all these calculations 
were based on the assumption that NP and BSA molecules are spherical, however, that may not 
always represent the real situation.   
The particle size of fPS NPs-ntPE was ~111 ± 10 nm in diameter, no size increase was 
observed comparing to blank fPS NPs. Particle size measured by DLS reflects the hydrodynamic 
size, i.e., NP size plus a hydration layer on the surface. Therefore, the observed small particle size 
of fPS NPs-ntPE might be due to the hydrophilic carboxylate groups on fPS NPs being replaced 
by less hydrophilic ntPE; or the hydrophilic carboxylate groups on the surface being blocked by 
the protein. Overall this may suggested a thinner hydration layer around fPS NPs, resulting in 
smaller measured size. The surface area of each fPS NP was calculated to be 5.6 × 104 nm2, if 




ntPE diameter was assumed to be 4 nm as BSA, then ntPE would occupy 3.76 × 104 nm2, thus 
suggesting ntPE were presumably located on NP with different orientations.  
  
 
 Blank fPS NPs fPS NPs-BSA fPS NPs-ntPE 
Particle size (nm) 
from Nanosight 
134 ± 22 151 ± 26 111 ± 10 
Particle size (nm) 
from TEM 
32 ± 10 44 ± 13 38 ± 14 
Zeta potential (mV) -30 ± 2 -20 ± 5 -20 ± 0.4 
Protein density  
(protein molecule per 
particle) 
--- 1.26 ± 0.37×10
4 9.38 ± 3.3×103 
 
 
Zeta potential is an indication of the NP surface charge, thereby, the observed changes in zeta 
potential can be considered as evidence of proteins conjugation on NPs. For blank fPS NPs, zeta 
potential was -30 ± 2 mV measured using ΖetaSizer, while after conjugation zeta potential 
changed to -20 ± 5 mV for fPS NPs-BSA and -20 ± 0.4 mV for fPS NPs-ntPE. The changes in 
zeta potential might be related to the additional proteins on NPs surface. Since blank fPS NPs 
were prepared and measured using the same protocol as fPS NPs-BSA and fPS NPs-ntPE, it 
excluded potential changes brought from chemical reagents or experimental processes. 
Originally, fPS NPs were negatively charged due to carboxylate groups on the surface, which 
were ionised at the pH where the measurement was carried out (pH 6.5). It can be understood that 
the replacement of these carboxylate groups with less acidic molecules, for instance, ntPE 
(pI=5.53, calculated by using ExPASy ProtParam) and BSA (pI=4.7) (207, 212), resulted in the 
increase of zeta potential values, as shown in Table 3-1. In addition, some positively charged 
residues of proteins would compensate the negatively charged surface on NPs.   
It was difficult to compare the protein density calculated in this study to other similar reports, 
since every report used different ways of interpreting protein density, for instance, µg/m2 and 
protein per particle (213, 214). The lack of standard units and interpretation of protein density is 
due to the inaccurate and unstandardised NP counting methods. So far, each of the reported 
methods for determining the number of NPs has the potential of biased counting or misleading 
information. Some mathematical calculations were based on the assumption that an individual NP 
is an atom or a single sphere. These different underlying assumptions might lead to considerable 
errors when it comes to protein density (215). Besides, there is also discrepancy between 
Table 3-1: Characterisation of polystyrene nanoparticles (n=3) 




mathematical calculation of the numbers of NPs and the experimental data, therefore, the number 
of NPs in 1 mL was directly obtained from NTA measurements reported in this study. 
The morphology of the NPs was observed using TEM. fPS NPs were spherical in shape and 
had a diameter of ~32 ± 10 nm (n=100, in Figure 3-8). Particle size measured by TEM was smaller 
than the measurement from NanoSight, this has been also reported by other researchers (185). 
Perhaps this discrepancy is because NanoSight measures the hydrodynamic diameter of NPs, 
which refers to NPs along with the solvent layer, while TEM images were taken on dried samples. 
In addition, the difference in particle size is probably a result of the multiple scattering effect in 
DLS; which occurs when the light scattered by the diffusing particle is re-scattered by one or 
more particles before reaching the detector (186).  
     After the conjugation with proteins, fPS NPs were still in a similar shape, with fPS NPs-BSA 
having a diameter of 44 ± 13 nm and fPS NPs-ntPE having a diameter of 38 ± 13 nm (in Figure 
3-8 and Table 3-1). The contrast seemed to be stronger for fPS NPs-BSA and fPS NPs-ntPE than 
for blank fPS NPs. Perhaps the proteins on the surface of fPS NPs made the binding with uranyl 
ions stronger, which resulted in higher contrast in the TEM images (216).      
 
 
Blank fPS NPs    fPS NPs-BSA fPS NPs-ntPE 
Figure 3-8: TEM images of fPS NPs. NPs were in the size range of ~40 nm; after the addition of BSA or 
ntPE onto NPs, they appeared to be a similar size and shape (scale bar = 100 nm). 
 




The fluorescent properties of fPS NPs also provide a perspective for physicochemical 
characterisation. Complex-formation is believed to be one of the causes of fluorescence 
quenching; it is reasonable to hypothesise that the fluorescence intensity of fPS NPs would change 
accordingly if proteins were on the surface of the NPs (204). The fluorescence excitation/emission 
spectra of fPS NPs were obtained before and after the conjugation with proteins. The excitation 
spectrum was determined by monitoring fluorescence emission at the wavelength of maximum 
intensity while the fluorophore is excited through consecutive wavelengths. Regarding the 
absorbed energy that molecules needed to be promoted to the excited electronic singlet state S1, 
for fPS NPs-BSA and fPS NPs-ntPE (in Figure 3-9a), it seemed lower energy was needed. A 
reduced fluorescence intensity was also observed in the emission spectrum of fPS NPs-BSA and 
fPS NPs-ntPE compared to blank fPS NPs (Figure 3-9b). The observed fluorescence quenching 
in both excitation and emission spectra were considered and clarified as static quenching, which 
occurs when a ground state complex forms before excitation occurs (217). The ground state 
complex was understood to be the fPS NPs-protein conjugation in this study.  
 
3.3.5 Conjugation of AC NPs-BSA and AC NPs-ntPE 
3.3.5.1 Preparation of oxidised AC NPs  
 
As discussed in chapter 2, AC NPs offer more chance for modification, since both alginate 
and chitosan can be directly coupled with proteins or chemically modified to be coupled. 
Aldehyde groups were introduced by the oxidation of alginate before particles were formed, for 
the purpose of conjugation with the hydrazide groups of EMCH.   
 
 
Figure 3-9: Fluorescence excitation and emission spectra of fPS NPs. The fluorescence quenching was observed in 
fPS NPs-BSA and fPS NPs-ntPE in both excitation and emission spectra compared to blank fPS NPs.   
 




 The oxidised alginate was used to prepare AC NPs in the same way as un-oxidised alginate 
(details are in Chapter 2.2.3). Both oxidised and un-oxidised AC NPs were characterised by 
particle size and surface charge. By DLS, the diameter of the oxidised AC NPs was ~185 ± 5 nm, 
while the un-oxidised AC NPs was ~266 ± 18 nm (in Table 3-2), suggesting that AC NPs became 
smaller when oxidised materials were used. The size of the NPs was reported to be influenced by 
polymer concentrations and molecular weight (155). During the oxidation process, the reduction 
in molecular weight of alginate is not inevitable, therefore, the reduced NPs size might be due to 
the reduced molecular weight of alginate (188).  
 
 Un-oxidised AC NPs Oxidised AC NPs 
Size from DLS (nm) 266±18 185±5 
Polydispersity index 0.30±0.01 0.24±0.02 
Zeta potential (mV) 18±5 28±4 
      
Oxidised-AC NPs had a higher zeta potential compared to un-oxidised AC NPs. AC NPs were 
formed mainly due to the electrostatic interactions between oppositely charged alginate and 
chitosan (7). In the oxidisation process of alginate, sodium periodate broke down the guluronate 
ring at the position of C-2 and C-3 of alginate and induced two aldehyde groups (illustrated in 
Figure 3-10). The induced aldehyde groups were believed to give alginate polymer more 
negatively charged groups, with the result that more chitosan molecules were attracted on the 
surface and leading to a higher surface charge measurement (218).  
 
                     
 
Table 3-2: Characterisation of oxidised AC NPs and un-oxidised AC NPs (n=3) 




3.3.5.2 Physicochemical characterisation of AC NPs-BSA and AC NPs-ntPE 
 
By DLS measurement, the size of AC NPs had increased from 215 ± 8 nm to 280 ± 9 nm after 
the addition of BSA onto the surface (in Table 3-3), while it had reduced to 202 ± 20 nm after the 
conjugation with ntPE. Particle size increase in AC NPs-BSA and size decrease in AC NPs-ntPE 
was consistent with the findings for fPS NPs in section 3.3.4. The zeta potential of blank AC NPs 
was 20 ± 8 mV and it was attributed to the presence of chitosan on the surface; after the addition 
of BSA and ntPE, zeta potential dropped to -19 ± 11 and -6 ± 5 mV for AC NPs-BSA and AC 
NPs-ntPE respectively. The pIs of BSA and ntPE are both below the measurement condition, pH 
7.4, thus these proteins were negatively charged in the solution. It seemed that the addition of 
negatively charged BSA and ntPE onto positively charged AC NPs resulted in a negatively 
charged surface as indicated in Table 3-3.  
 
 Blank AC NPs AC NPs-BSA AC NPs-PE 
Size (nm) from NanoSight 215 ± 8 280 ± 9 202 ± 20 
Size (nm) from TEM 48 ± 14 48 ± 15 46 ± 24 
Zeta potential (mV) 20 ± 8 -19 ± 11 -6 ± 5 




                    
 Figure 3-10: The oxidisation of alginate. The oxidation process induced two aldehyde 
groups on the guluronate ring of alginate.  
 
Table 3-3: Physicochemical Characterisations of AC NPs (n=3) 




Protein density on AC NPs surface was calculated by the same equation used for fPS NPs (in 
3.2.6.1). On average, there were 3.30 ± 0.90×105 BSA molecules on each AC NP and 3.41 ± 
0.82×105 ntPE molecules on each AC NP. Comparing with fPS NPs, it seemed that AC NPs had 
more proteins on the surface. A possible explanation is that their different NP structures resulted 
in different organisations with protein. fPS NPs are solid NPs in the suspension and have a rigid 
spherical structure as shown in Figure 3-11. While, in contrast, AC NPs are polyelectrolyte 
complexes formed by polymeric interactions (7). In terms of structure, AC NPs were similar to a 
polymeric matrix, and might have some polymer extending out from the complex (142), as 
illustrated in Figure 3-11. These extended groups from AC NPs possibly linked with protein and 
left some distance between the NP and the protein. Therefore, perhaps the numbers of protein 
molecules were not restricted by the available functional sites on NP surface or by steric 
hindrance. In addition, proteins have shown a tendency to interact with the AC NPs via non-
covalent bonds, such as hydrogen bonds or electrostatic interactions (219).  
 
Blank AC NPs were observed using TEM, and compared with AC NPs conjugated to BSA 
and ntPE. Blank AC NPs were ~48 ± 14 nm in size (n=100, see Figure 3-12), and some of them 
appeared to be aggregated forms. After the conjugation with proteins, AC NPs-BSA were ~48 ± 
15 nm (n=100) in diameter and AC NPs-ntPE were ~46 ± 24 nm (n=100) in diameter. Although 
this may not represent all particles morphologies and sizes, TEM observation can at least provide 
a glimpse of NPs. Under TEM it appeared that the protein-coupled AC NPs have less aggregation. 
The presence of proteins on the surface can shield the NP from agglomeration, which could 
increase the colloidal stability and result in less aggregation (166). 








Figure 3-11: Illustration of AC NP and fPS NP. AC NP was formed by electrostatic 
interactions in a flexible structure, while fPS NP were solid and spherical. 
 






3.3.5.3 FTIR spectra of AC NPs 
    AC NPs were characterised by FTIR and the spectra were compared before and after 
conjugation with BSA and ntPE.  
 
Blank AC NPs  AC NPs-BSA  AC NPs-ntPE 
Figure 3-12: TEM images of AC NPs. Particles were ~48±14 nm in size, blank AC NPs tended to aggregate, 
while less aggregation was observed for AC NPs-BSA and AC NPs-ntPE. 
 
 
Figure 3-13: FTIR spectra of AC NPs and AC NPs-BSA. The broad peak at 3700-3000 cm-1 in AC 
NPs spectrum suggested the intermolecular hydrogen bonds between alginate and chitosan. The 
appearance of amine bonds (1538 cm-1) in AC NPs-BSA suggested the presence of BSA. 
 




The spectrum obtained from AC NPs showed strong intermolecular hydrogen bonds between 
alginate and chitosan at the broad peak of 3700-3000 cm-1 (in Figure 3-13), which is consistent 
with a previous study (220). The bands at 1590 cm-1 and 1412 cm-1 were identified as the 
antisymmetric stretch and symmetric stretch of alginate, respectively. Moreover, the band at 1564 
cm-1 was assigned to bending vibrations of the N-H (N-acetylated residues, amide bond) from 
chitosan (170).  
Proteins have characteristic absorption bonds in infrared spectra owing to the stretching 
vibrations of the C=O bond and the bending vibration of the N-H bond of the amine bond. The 
bands at 1644 cm-1 and 1528 cm-1 in the BSA spectrum was attributed to these two vibrations of 
amine bonds (221). In the spectrum generated from the AC NPs-BSA, the appearance of the peak 
at 1538 cm-1 was presumably due to the N-H bond of BSA. It suggested that there were BSA 
molecules associated with AC NPs, considering that the uncoupled BSA molecules were excluded 
from the system via dialysis. 
In the spectrum of ntPE, the bands at 1644 cm-1 and 1534 cm-1 were considered to have resulted 
from the amine bonds (as shown in Figure 3-14). The appearance of the amine bonds in the AC 
NPs-ntPE spectrum suggested that ntPE was associated with AC NPs. In both cases, for BSA and 
ntPE, the detected protein bands in AC NPs system provided evidence that proteins were 
associated with AC NPs, however, further investigation is needed to establish whether they were 
covalently bonded or whether other types of bonding were involved.  
 
 
Figure 3-14: FTIR spectra of ntPE and AC NPs-ntPE. The appearance of the amine bonds 
(1631 cm-1, 1537cm-1) in AC NPs-ntPE spectrum confirmed the chemical conjugation of ntPE 
onto AC NPs. 
 





3.3.5.4 Fluorescent labelling of AC NPs 
A quantitative method was exploited in this study to understand the AC NP-protein conjugates. 
FTSC is a fluorescent label that can link with aldehyde groups on the AC NPs. Molecular level 
information about NP-protein conjugates may be revealed by comparing the FTSC on the surface 
of AC NPs before and after modifying the surface with proteins (illustrated in Figure 3-15). 
Before the conjugation of proteins onto AC NPs, there were ~1.31 ± 0.15×10-9 moles of 
aldehyde groups on the surface of NPs per mL of suspension, suggested by the amount of FTSC 
which reacted with aldehyde groups on NPs (as shown in Table 3-4). After the conjugation with 
BSA, there were 1.01 ± 0.07×10-9 moles of free aldehyde groups on NPs accessible for FTSC to 
react with. This suggested that 2.98 ± 1.0×10-10 moles of aldehyde groups had reacted with BSA, 
and were therefore no longer accessible for FTSC. The same experiment was performed on AC 
NPs-ntPE. There were 1.19 ± 0.27×10-9 moles of aldehyde groups available on the surface of AC 
NPs before the protein-NP conjugation and 0.66 ± 0.24×10-9 moles of these aldehyde groups were 
occupied by proteins after the conjugation. The measurement and calculation of FTSC gave 






              
 Figure 3-15: Illustration of labelling AC NP with FTSC. Before the conjugation of proteins 
onto NP, the amount of FTSC shows the amount of aldehyde groups on the surface of AC 
NP; after the conjugation with proteins, the amount of FTSC reflects the amount of 
functional groups that did not react with proteins. 
 





                                 
 AC NPs-BSA AC NPs-PE 
Total amount of aldehyde groups (mole) per 
mL of suspension 
1.31 ± 0.15×10-9 1.19 ± 0.27×10-9 
Amount of aldehyde groups which did not react 
with protein (mole) per mL of suspension 
1.01 ± 0.07×10-9 0.66 ± 0.24×10-9 
Amount of aldehyde groups which reacted with 
protein (mole) per mL of suspension 
2.98 ± 1.0×10-10 5.26 ± 2.32×10-10 
 
3.4 Conclusion 
ntPE was expressed and purified for the purpose of conjugating with NPs. BSA was also 
prepared in a similar organisation, with one thiol group on each BSA molecule on average (as 
illustrated in Figure 3-16). These proteins were linked with NPs via a heterobifunctional cross-
linker using EMCH.  
Commercial and stable fPS NPs were firstly used to test the conjugation method. With the 
conjugation of BSA and ntPE with NPs, the diameter of NPs changed from 134 ± 22 nm to 151 
± 26 nm for fPS NPs-BSA, and to 111 ± 10 nm for fPS NPs-ntPE. The increased size measurement 
in BSA-coupled fPS NPs was considered due to the conjugation of BSA on the surface of NPs. 
The relatively larger particle size of fPS NPs-BSA is consistent with the protein density values, 
of which 1.26 ± 0.37×104 BSA molecules were measured on the surface of fPS NPs, while for 




Figure 3-16: Diagram for preparing NPs-BSA and NPs-ntPE conjugate. TEV protease-specific sequence was 
used to induce a single free thiol group on ntPE for subsequent chemical coupling with EMCH, which served 
as a “bridge” between ntPE and NPs. BSA was prepared by converting amine groups into thiol groups using 
Traut’s reagent, and linked with NPs involving EMCH in a similar manner as ntPE.  
 




ntPE the value was 9.38 ± 3.3×103. The conjugation of proteins might have altered the 
hydrophobicity of NPs, which explains the reduced particle size for ntPE-coupled fPS NPs. The 
zeta potential of NPs also changed with the conjugation with BSA and ntPE, the zeta potential for 
blank fPS NPs, fPS NPs-BSA, and fPS NPs-ntPE was -30 ± 2 mV, -20 ± 5 mV and -20 ± 0.4 mV, 
respectively. Negative carboxylate groups on fPS NPs appeared to be covered by proteins on the 
surface. The reduced fluorescence intensity in the Ex/Em spectra suggested a static quenching, 
which involves the formation of a complex. These changes were attributed to the addition of BSA 
or ntPE on the NP’s surface.  
AC NPs were also conjugated with BSA and ntPE; changes in the physicochemical properties 
suggested the presence of proteins on AC NPs surface. The diameter of NPs changed from 215 ± 
8 nm for blank AC NPs to 280 ± 9 nm for AC NPs-BSA, and to 202 ± 20 nm for AC NPs-ntPE. 
The zeta potential of blank AC NPs, AC NPs-BSA and AC NPs-ntPE was 20 ± 8 mV, -19 ± 11 
mV, and -6 ± 5 mV respectively. On average, more protein molecules were present on the AC 
NPs than on the fPS NPs. This was considered due to their different NP structure, which leads to 
different arrangement of proteins on its surface. FTIR spectra suggested the presence of BSA and 
ntPE in the AC NPs suspension, and fluorescence labelling showed that certain amount of 
aldehyde groups on AC NPs (coupled with proteins) were no longer available for chemical 
coupling, which suggested these functional sites might have been occupied by proteins.  
BSA and ntPE-coupled NPs were prepared and characterised in this chapter, enabling testing 
the hypothesis that ntPE would facilitate the transport of NPs in vitro, in the next Chapter.
   




Chapter 4    In vitro study of ntPE-coupled nanoparticles  
Overview:  
Aim: To study the transcytosis of NPs mediated by ntPE in an in vitro model using Caco-2 cell 
monolayers. 
Methods: The trans-epithelial transport of fPS NPs (fluorescent polystyrene nanoparticles) and 
AC NPs (alginate-chitosan nanoparticles) mediated by ntPE (non-toxic Pseudomonas exotoxin) 
was tested in an in vitro model of human intestine using Caco-2 cell monolayers. Trans-epithelial 
electrical resistance was monitored during a 60-minute time course of transcytosis. Confocal 
microscopy was used to follow the fate of NPs with cell landmarks of Caco-2 cell nuclei and tight 
junction structures, being labelled with DAPI and an antibody to the tight junction-specific protein 
zonula occludens 1, respectively. Secondary structure of ntPE before and after its conjugation to 
AC NPs was examined using circular dichroism (CD). The effect of serum in the growth culture 
on the expression of the cell receptor for ntPE, LRP-1 (low density lipoprotein receptor-related 
protein 1), was analysed in the Caco-2 cell line by western blot. 
Results and Discussion:  Transcytosis rates across Caco-2 cell monolayers was 0.20 ± 0.13 %, 
2.60 ± 1.1 %, and 0.21 ± 0.01 % for blank fPS NPs, fPS NPs-BSA, and fPS NPs-ntPE, 
respectively. A low transcytosis rate was also observed for all the AC NPs: for blank AC NPs it 
was 2.83 ± 1.29 %, for AC NPs-BSA it was 4.18 ± 2.05 %, and for AC NPs-ntPE it was 4.36 ± 
2.24 %. The unexpectedly low transcytosis rates of NPs mediated by ntPE could have been due 
to a change in ntPE structure after attachment onto NPs. CD-based studies assessed the secondary 
structure of ntPE after its coupling onto AC NPs, however, the data did not suggest such changes 
were occurring. An attempt was made to examine the expression of LRP-1, a binding receptor of 
ntPE on the cells. The presence of serum in the growth medium did not significantly alter LRP-1 
expression. Since ntPE has also been suggested to utilise the ganglioside GM1 as a cell receptor 
during intracellular trafficking (2), and a previous study demonstrated that GM1 has a 
considerable impact on the transport of ntPE (121), it is possible that the low expression of GM1 












4.1 Introduction  
 
Chapter 3 describes coupling ntPE onto fPS NPs and AC NPs. In this chapter, epithelial 
transcytosis of ntPE-coupled NPs across Caco-2 cell monolayers was examined.  
Transporting NPs across the intestinal epithelium is a tremendous challenge, since the 
epithelium functions to selectively absorb nutrients while preventing the uptake of potential 
pathogenic materials and particles. The intestinal epithelium is a single layer of cells mainly 
composed of nutrient-absorbing enterocytes and mucus-secreting goblet cells. Much less 
frequently present are a wide variety of specialised cell types, such as micro-fold (M), Paneth, 
enteroendocrine, cup, and tuft cells (23). All of these are polarised cells, with the apical side 
exposed to the lumen and the basolateral side linked with lamina propria of the epithelium. 
Three pathways are theoretically possible for NPs crossing the epithelium: 1) paracellular 
pathway; 2) transcytosis across the M cells involving mostly pinocytosis or phagocytosis; and 3) 






 Figure 4-1: Three potential pathways for NPs crossing the epithelium. (a) Paracellular pathway: 
substances go across the epithelium by directly or indirectly opening tight junctions between two 
adjacent enterocytes; (b) Transcytosis across the M cells: M cells take up macromolecules and 
transport them into the underlying immune cells; (c) Transcytosis across the enterocytes: 
molecules are internalised into the cell via endocytosis and move from the apical to the 




The intestinal epithelium is sealed by tight junctions, which contain transmembrane proteins 
that protrude into the intercellular space and regulate the paracellular movement of water, ions, 
and solutes (30). Opening tight junction is one strategy for overcoming the intestinal barrier for 
oral delivery of poorly-absorbed therapeutics. However, it carries the risk of introducing 
unintended substances into the body at the same time. In addition, the tightness of the junctions 
between the enterocytes (pore diameter between 3 and 10 Å)  and the very small surface area of 
the intercellular spaces limits transporting NPs via the paracellular pathway (57, 223).  
The second pathway for NPs to cross the epithelium is by transcytosis across M cells. 
Transcytosis involves particles being taken up into the cell via endocytosis on the apical 
membrane, and then being transported through the cells and released from the basolateral side 
(77). M cells are highly specialised microfold cells for the endocytosis and transport of antigens, 
i.e. macromolecules and bacteria, to immune cells residing under the epithelium (224). Although 
a certain amount of research has been conducted on attempting to deliver NPs via the M cells, 
Hussain et al. (1997) suggested that the pathway through M cells should not be over emphasised 
considering the numbers of M cells are limited in the intestine (82).  
Finally, transcytosis across the enterocytes appears to be an alternative means of transporting 
NPs into the blood circulation. It involves endocytosis into the enterocyte, intracellular 
translocation and release from the basolateral side. This transport has the advantage of large 
surface area, as enterocytes are the most abundant cells in the epithelium. However, the 
transcytosis of NPs across the enterocytes is prone to generate a low transport rate. This is because 
either the endocytosed NPs would undertake the lysosome pathway leading to degradation, or the 
apical protein-NP complex would be easily delivered back to the apical side by exocytosis (197). 
A receptor-mediated transcytosis is needed to efficiently deliver NPs across the enterocytes. 
Lessons from nature have taught us some macromolecules can be transported across the 
enterocytes intact via a specific transport pathway, for instance, Vitamin B12, lectins, Ig G, and 
bacterial toxins. Modifying NPs surface with these molecules has shown enhanced uptake and 
transport of NPs across the epithelium (87, 91, 95, 225). 
The transport strategy in this study is to conjugate NPs with a bacterial toxin, so that the 
bacterial toxin could facilitate the transport of NPs via the transcytosis pathway utilised by the 
toxin. Specifically, Pseudomonas exotoxin A (PE) was used to try and enhance the uptake and 
transport of NPs. PE is a major virulence factor extracted from Pseudomonas aeruginosa. It can 
go across the epithelium and target the antigen-presenting cells present in the submucosal space. 
PE consists of three prominent domains: domain Ia binds to the low density lipoprotein receptor-
related protein (LRP-1) on the cell membrane to allow entry into the cell (226); domain II 
facilitates the intracellular trafficking within the cell after internalisation in a clathrin-coated 
vesicle; and domain III is the catalytic domain which functions to enzymatically stop protein 
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synthesis and induce cell apoptosis (227, 228). The toxicity of PE can be removed by the deletion 
of the glutamic acid at position 553, referred to as ntPE (for non-toxic PE) (119). ntPE is able to 
transport across the polarised cells at equal rates to PE (229), therefore, it has been chosen as a 
transport ligand for NPs in this study.  
The Caco-2 cell line, which is derived from human colorectal carcinoma, is a standard in vitro 
model, used in this work to mimic human intestinal epithelium. Importantly, a good correlation 
has been found for drug absorption in human jejunum and Caco-2 cells, especially for passively 
absorbed drugs; various transporters, enzymes, and receptors present in human intestinal 
epithelial are also expressed by Caco-2 cells (230). In a typical Caco-2 cell experiment, a 
confluent monolayer of cells are grown on a permeable filter until they become polarised. These 
Caco-2 monolayers differentiate both structurally and functionally into cells resembling mature 
enterocytes; they express the majority of morphological and functional characteristics of 
enterocytes. By culturing Caco-2 cells in this way, the apical and basolateral compartments of the 
Transwell® (Figure 4-2) correspond to the intestinal lumen side and the lamina propria in vivo 
(231).   
 
In this chapter, the transport of stable fPS NPs and biodegradable AC NPs, which are both 
coupled with ntPE or BSA, were tested using Caco-2 cell monolayers, with BSA-coupled NPs 





                   
 
Figure 4-2 : Diagram for Caco-2 cell monolayers on Transwell®. Caco-2 cells are 
seated on the membrane of Tranwell® plate, as the apical side representing the 







4.2.1 Subculture of Caco-2 cell line  
 
Caco-2 cells were obtained from the American Type Culture Collection and grown in T75 
flasks (156499, Thermo Scientific) in Dulbecco Modified Eagle Medium (1813348, Life 
Technologies) containing 10 % heat-inactivated foetal bovine serum (10500, Life Technologies) 
and 50 IU each of penicillin and streptomycin (P/S, P4333-100ML, Sigma-Aldrich). Cells were 
sub-cultured after reaching 60 – 70 % confluency. After medium removal, cells were rinsed with 
PBS before adding 0.25 % trypsin (v/v, 15090-046, Life Technologies) containing 0.02 % of 
EDTA (w/v Ethylenediaminetetra-acetic acid, E9884-100G, Sigma-Aldrich). Trypsin was 
inactivated by adding growth medium in a 1:1 ratio after a period of time when most of the cells 
had detached from the flask. Suspended cells were centrifuged at 125 × g for 5 min (accuSpinTM 
400, Fisher Scientific). Pelleted cells were suspended in fresh growth medium, counted under a 
light microscope using a haemocytometer and diluted before being seeded at a desired cell density 
into a new T75 flask or onto Transwell® filters. 
 
4.2.2 Transcytosis of fPS NPs  
 
Sub-cultured Caco-2 cells were plated at a density of ~21,000 cells/well onto polycarbonate 
membrane Transwell® filters (6.5 mm, 0.4 µm pore size) from Corning Incorporated (Corning, 
NY, USA). Growth medium was changed every other day until cells differentiated into polarised 
epithelial cells (typically after 18 days). Cells were considered polarised when their trans-
epithelial electrical resistance (TEER) was > 350 Ω·cm2, as measured using an EVOM2 Epithelial 
Volt/Ohm Meter (World Precision Instruments).  
Once polarised, each Caco-2 monolayer was prepared for transcytosis studies by washing both 
apical (150 µL) and basolateral (500 µL) surfaces twice for 5 min with warm HBSS (Hank’s 
balanced salt solution, 14025-050, Invitrogen, Life Technologies) at 37°C. After equilibration in 
HBSS for 30 min at 37 °C, the basolateral compartment medium was collected to provide a 
baseline value for t=0. After replacing the basolateral compartment medium with fresh HBSS, 
test materials were applied onto the apical surface. Basolateral compartment medium was then 
collected with replacement after 30 and 60 min of incubation at 37 °C. These studies were used 
to assess the transcytosis of fPS-NPs conjugated with ntPE. Various control materials were tested, 
including fPS-NPs without any modification, and fPS NPs conjugated with BSA which was 
selected owing to its similar size and isoelectric point to ntPE.  
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Before performing a transcytosis study, the fluorescence intensity (termed Fb) of the materials 
being tested for transport was measured using a fluorescence microplate reader (FLUOstar 
Omega, BMG Labtech). 150 µL of fPS NPs, fPS NPs-BSA, or fPS NPs-ntPE (the concentration 
of protein in NPs suspension was kept at 66 µg/mL), were added to the apical compartment with 
transport studies being performed in triplicate. The fluorescence intensity of each sample (Fs) 
collected from the basolateral compartment was assayed in triplicate using a fluorescence 
microplate reader. Fluorescence values of the initial HBSS solutions collected at 0 min (F0) were 
subtracted to obtain the extent of fPS NP transcytosis. During the experiment, TEER was 
measured at each time interval to ensure cells were still polarised (>350 Ω∙cm-2). The transport 
efficiency of fPS NP preparations was calculated by the equation:  
𝐹𝑠−F0
𝐹𝑏
× 100%.  
 
4.2.3 Confocal microscopy sample preparation 
 
Following transcytosis, residual fPS NPs at the apical surface were removed by three washes 
with PBS before the cells were fixed in 4 % PFA (paraformaldehyde, P6148, Sigma-Aldrich) for 
20 min at RT (room temperature). After PFA removal, cells were washed three times with PBS. 
These cells were permeabilised using 0.5 % of Triton-X 100 (X100-500ML, Sigma-Aldrich) in 
PBS and washed with blocking buffer containing 20 % BSA (w/v) for 1 h. To demonstrate cell-
cell contacts at the plasma membrane, permeabilised samples were incubated overnight at 4 °C 
with a rabbit monoclonal antibody that recognised ZO-1 (diluted 1:50 in PBS, 8193S, Cell 
signalling Technology). Following three washes by PBS, ZO-1 distribution was visualised using 
a fluorescein-labelled goat anti-rabbit secondary antibody (diluted 1:100 in PBS, F1-1000, 
Vector) that was incubated with these cells for 30 min at RT prior to three washes with PBS. Cell 
nuclei were labelled with DAPI (4', 6-diamidino-2-phenylindole, Dihydrochloride, D1306, 
Thermo Fisher Scientific), by incubation for 30 min at RT. Following antibody and DAPI 
labelling, polycarbonate membranes were removed from the Transwell® filter and mounted onto 
microscope slides.  A drop (~15 µL) of Fluoroshield Mounting Medium (ab104135, Abcam) was 
placed between the glass slide and Transwell® filter. Another drop of Fluoroshield Mounting 
Medium was added onto a coverslip so that it formed the organisation of “slide-medium-







4.2.4 Western blot analysis of LRP-1 expression in non-polarised Caco-2 cells 
 
LRP-1 expression can be influenced by the presence of serum in the growth medium (232). 
Since the cell surface receptor for ntPE is LPR-1, expression levels of this protein were assessed 
in triplicate in Caco-2 cells by western blot analysis. Caco-2 cells were grown in a 12-well plate 
format (150628, NunclonTM Delta Surface, Thermo Scientific) and examined after reaching full 
confluence. Three different conditions were investigated: 1) no serum in the cell growth medium; 
2) with serum in the cell growth medium; and 3) serum removed from growth medium 12 h prior 
to analysis. Cells lysed using RIPA buffer (Radioimmunoprecipitation assay buffer, R0278-
50ML, Sigma-Aldrich) containing 5 % (v/v) of protease inhibitor (12841640, Fisher Scientific) 
and 5 % (v/v) phosphatase inhibitor (12841650, Fisher Scientific) were centrifuged at 9000 ×g 
(Heraeus Biofuge Primo R centrifuge, Thermo Scientific) for 10 min at 4 °C. Lysates were 
separated by 12 % polyacrylamide gels using sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 100 V for 3 h. After SDS-PAGE, polyacrylamide gel bands were 
transferred onto a PVDF transfer membrane (polyvinylidene difluoride, 0.45 m, 26.5 cm × 3.75 
m, pore size 0.45 µm, Immobilon®-FL, Merck-Millipore) at 30 V for 1.5 h. After blocking with 
0.04 % BSA in TBS (Tris-buffered saline containing 0.1 % of Tween 20 (P1379, Sigma-Aldrich)), 
the PVDF transfer membrane was incubated overnight at 4 °C with rabbit monoclonal to LRP-1 
antibody (ab92544, Abcam, diluted in 1:5000) and goat polyclonal IgG to β-actin (diluted in TBS 
1:10,000, SC-1615, Santa Cruz Biotechnology). The recipe for 1 L of TBS buffer is: 10 mL of 
Tris-HCl 1 M pH 8.0, 37.5 mL of 4 M sodium chloride, and 952.5 mL of distilled water. PVDF 
membranes were rinsed three times with TBS (containing 0.1 % of Tween 20) and then incubated 
in secondary antibody for 1 h at RT: donkey anti-rabbit (IRDye® 680 RD, 926-68073, LI-COR®, 
diluted in TBS 1:5000) for visualising of LRP-1 and donkey anti-goat (IRDye® 800 CW, 926-
32214, LI-COR®, diluted in 1:5000) to visualise β-actin. The PVDF membrane was washed in 
TBS buffer (containing 0.1 % of Tween 20) three times and imaged in Odyssey® CLx-0628 (LI-
COR®). 
 
4.2.5     Transcytosis of AC NPs  
 
Unlike fPS NPs that could be readily followed due to the fluorescent label incorporated into 
the PS polymer, AC NPs lacked a straightforward means of detection. To overcome this 
challenge, a fluorescent tag was chemically coupled onto the chitosan of AC NPs using 
fluorescein isothiocyanate (FITC).  
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4.2.5.1 Preparation of FITC labelled AC NPs 
4.2.5.1.1 Labelling chitosan with FITC  
 
FITC (20 mg, fluorescein isothiocyanate isomer I, F7250-500MG, Sigma Aldrich) was 
dissolved in 10 mL methanol (16K144019, VWR chemicals) and added to 20 mL 1 % w/v 
chitosan (200 mg) in 0.1 M acetic acid solution (pH 2.8, 27225-2.5L-R, Sigma-Aldrich). After 3 
h of reaction in the dark at RT, the FITC-labelled chitosan was precipitated by raising the pH to 
10 with the addition of 0.5 M sodium hydroxide (72064-500ML, Sigma-Aldrich). Unreacted 
FITC was removed using centrifugation until no fluorescence was detected in the supernatant. 
FITC-labelled chitosan was dissolved in 20 mL 0.1 M acetic acid and then dialysed (SnakeSkinTM 
dialysis tubing, 10K MWCO, 68100, Thermo Fisher Scientific) against 4 L of distilled water at 
RT for 3 days under darkness, with water being replaced every day (233).  
 
4.2.5.1.2 Formation of FITC-labelled AC NPs 
 
2 mL of 51 µg/mL calcium chloride solution was added into 10 mL of 60 µg/mL oxidized 
alginate solution dropwise during micro-tip probe ultra-sonication. The resultant pre-gel was 
stirred for another 30 min before the addition of 2 mL of 0.3 mg/mL FTIC-labelled chitosan 
solution. The suspension was equilibrated overnight to allow the formation of NPs. All materials 
were filtered through 0.45 µm membranes prior to use.  
 
4.2.5.2 Conjugation of BSA and ntPE onto FITC-labelled AC NPs 
 
FITC-labelled AC NPs were linked with proteins (BSA or ntPE) via a bifunctional cross-linker 
EMCH, details can be found in Chapter 3.2.4.3. The aldehyde groups from AC NPs linked with 
hydrazide groups of EMCH, which has previously attached to thiol-ntPE and thiol-BSA (details 
can be found in Chapter 3.2.2.1 and 3.2.2.2). 
 
4.2.5.3 Transcytosis of FITC-labelled AC NPs 
 
Transcytosis of FITC-labelled AC NPs was performed in triplicate using essentially the same 
protocol as that used for fPS NPs (details can be found in 4.2.2). The amounts of AC NPs to be 
tested were determined by the amounts of ntPE or BSA on the surface, which were kept at 10 µg, 




chemically labelling FITC onto NPs, therefore, the confocal microscopy sample preparation was 
performed in the same way as for fPS NPs, except that ZO-1 was visualised using Alexa Fluor® 
546 donkey anti-rabbit secondary antibody (diluted 1:100 in PBS, A10040, Thermo Fisher 
Scientific).  
 
4.2.6 Circular dichroism of ntPE and AC NPs-ntPE  
 
Retention of a protein’s native structure is essential for its biological function. Therefore, the 
secondary structure of ntPE following its coupling onto NPs was studied by circular dichroism 
(CD; ChirascanTM, AppliedPhotophysics). CD spectra were acquired under the following 
conditions: temperature 20 °C, bandwidth 1 nm, time per point 0.5s, wavelength from 190 – 350 
nm. A 5-mm path length quartz cuvette was used. Concentration of ntPE was 200 µg/mL and the 
concentration of AC NPs-ntPE was 17 µg/mL. Each sample was analysed in triplicate. 
Performance indices of each sample were calculated by the Selcon method available in 
DichroWeb (234, 235).  
 
4.2.7 Transcytosis of ntPE-Alexa Fluor® 546 and FITC-BSA  
     
Alexa Fluor® 546 C5 maleimide (A10258, Life Technologies) was chemically linked to thiol 
groups of ntPE via the maleimide-thiol coupling. The procedure for exposing thiol groups of ntPE 
was described in Chapter 3.2.2.1. After 2 h of the maleimide-thiol coupling reaction, ntPE-A546 
(ntPE coupled to Alexa Fluor® 546) was separated from reactants using size exclusion 
chromatography.  
Confluent Caco-2 cell monolayers on Transwell® plates as described in 4.2.2 were used; 10 
µg of ntPE-A546 and FITC-BSA (A23015, Thermo Fisher Scientific) were applied onto the apical 
compartment, and the transcytosis study was performed in triplicate for 120 min. The fluorescent 
secondary antibody to visualise ZO-1 was selected so as to not conflict with the fluorophore 
attached to BSA and ntPE. For cells treated with FITC-BSA, Alexa Fluor® 546 donkey anti-rabbit 
IgG was used to visualise ZO-1, while fluorescein goat anti-rabbit IgG was used accordingly for 
cells being treated with ntPE-A546.   
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4.2.8 Statistical analysis  
 
     Obtained data were analysed by using unpaired t-test (for comparing two groups of data). P 
values < 0.05 were considered to be statistically significant.  
 
4.3 Results and discussion 
4.3.1 In vitro transcytosis of fPS NPs 
 
 The transport percentage of fPS NPs across the Caco-2 cell monolayers was 0.20 ± 0.13 %, 
2.60 ± 1.1 % and 0.21 ± 0.01 %, for blank fPS NPs, fPS NPs-BSA and fPS NPs-PE respectively 
(Figure 4-3).   
For blank fPS NPs, the transport percentage was consistent with the value reported by Fowler 
et al. (2013), which 0.825 % of NPs were detected in the basolateral side after 3 h incubation 
(236). Surprisingly, no increase in the transport was observed when fPS NPs were conjugated to 
ntPE, and a higher transport efficiency of fPS NPs-BSA compared to fPS NPs and fPS NPs-ntPE 
was detected. In this regard, it has been described that albumin-mediated transport can occur in 
alveolar epithelial cells by binding to gp-60 albumin-binding proteins on the cell membrane (237).  
This might also occur in the intestinal epithelial cells, as Howard et al. (2014) suggested that 
albumin has the potential to be a delivery system for oral delivery (237, 238). As described above, 




Figure 4-3: Transport percentage of fPS NPs across Caco-2 cell monolayers. The transport rate for 
blank fPS NPs, fPS NPs-BSA and fPS NPs-PE was 0.20 ± 0.13 %, 2.60 ± 1.1 %  and 0.21 ± 0.01  %, 
respectively (n=3), *p=0.92 (>0.05), fPS NPs-ntPE compared to blank fPS NPs; **p=0.16 (>0.05), fPS 





the observed receptor-mediated uptake may contribute to or be the main cause of fPS NPs-BSA 
transport observed in the current studies.  
 Characteristics of NPs are known to have great impacts on their behaviours in vitro and in 
vivo (141, 239). Therefore, fPS NPs-ntPE and fPS NPs-BSA were prepared in the same protocol, 
so that they have similar characteristics (in Chapter 3), and would be more comparable for 
subsequent in vitro and in vivo study. Hydrodynamic size measured for fPS NPs-BSA was ~150 
nm, and for fPS NPs-ntPE was ~110 nm, the zeta potential of both fPS NPs was ~ -20 mV. As 
reported in Chapter 3, on average, ~1.26 ± 0.37×104 BSA molecules were present on each fPS 
NP-BSA, while ~9.38 ± 3.3×103 ntPE molecules were present on each fPS NP-ntPE; the extent 
of surface attachment for these two proteins were similar. The extent of cell surface receptors on 
polarised Caco-2 cell monolayers for BSA and ntPE to bind to is unknown.  
The arrangement of the ligands on NPs surface is another parameter which has impact on the 
cell uptake and transport (240). Carney et al. (2011) prepared gold NPs with surface coating with 
alternating hydrophobic and hydrophilic domains at different percentage ratios, as well as 
different shapes of the hydrophobic domains. Both the arrangement and shape of these ligands 
had an impact on the cellular internalisation, however the optimal NPs surface arrangement and 
structure was not concluded. In addition, for different ligands and NPs, the arrangement will be 
different too (240).    
ntPE enters the cell via LRP-1 associated endocytosis, undertakes intracellular trafficking 
avoiding lysosomal degradation and releases from the basolateral side of the epithelium (229). 
This receptor-mediated pathway of ntPE was anticipated to facilitate the transport of NPs across 
the Caco-2 cell monolayers. The lack of appreciable difference between the transport of fPS NPs 
and fPS NPs-ntPE (*p=0.92, >0.05), suggested that the transcytosis of fPS NPs-ntPE did not 
benefit from a specific transcytosis pathway. Studies were carried out with higher concentrations 
of fPS NPs-ntPE (up to 20 µg of proteins) and longer incubation times (up to 120 min). No 
increase in transport was observed (data not shown). Incubation beyond 120 min was not 
performed, as Desai et al (1997) reported that no significant increase of NPs uptake in Caco-2 
cell monolayers was measured after 120 min (138). During the transcytosis study, TEER values 
were measured as an indication of the integrity of Caco-2 cell monolayers. As shown in Figure 
4-4, Caco-2 cell monolayers used in these studies maintained TEER > 350 Ω∙cm-2, which was 
consistent with a polarised, differentiated state throughout the course of the experiment (241). 
Thus, none of fPS NPs tested appeared to induce significant changes in the functional properties 
of the Caco-2 cell monolayers used in this analysis. 




     To better understand the cellular fate of fPS NP preparations tested in vitro, confocal 
microscopy was used to examine fluorescence distributions and characteristics within the Caco-
2 cell monolayers. The extent and distribution of red channel fluorescence, representing fPS NPs, 
was evaluated at conditions comparable to green channel fluorescence used for the tight junction-
associated protein ZO-1 and blue channel fluorescence of DAPI-labelled nuclei (Figure 4-5). 
Results obtained for blank fPS NPs were consistent with the transcytosis data presented in Figure 
4-3; there were minimal associations between blank fPS NPs and the Caco-2 cell monolayers. It 






Figure 4-4: Measurement of TEER during the transcytosis of fPS NPs. TEER values remained above 






Figure 4-5: Representative confocal images of fPS NPs in Caco-2 cell monolayers. Few unmodified fPS NPs and fPS NPs-BSA were 
associated with Caco-2 cell monolayers; while considerable amounts of fPS NPs-ntPE were possibly located in the peri-nuclear compartment 
(red: fPS NPs, blue: nucleus, green: ZO-1, scale bar= 25 µm). 
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Few fPS NPs-BSA were demonstrated to associate with the Caco-2 monolayers by confocal 
microscopy, with the extent of those observed being comparable to blank fPS NPs (Figure 4-5d 
and Figure 4-5h). Interestingly, considerable amounts of ntPE-conjugated fPS NPs appeared in 
the peri-nuclear compartments (Figure 4-5l), which might be Golgi apparatus or endoplasmic 
reticulum (ER). This trend was consistent with other 16 images taken for Caco-2 cell monolayers 
treated with fPS NPs-ntPE at other independent experiments and at different locations on the 
membrane.  
Bacterial toxins, like ntPE and cholera toxins, can exploit the retrograde trafficking pathway 
and translocate to Golgi apparatus or endoplasmic reticulum (242). In terms of the transport of 
NPs, Cartiera et al. (2009) demonstrated that PLGA NPs (95 ± 20 nm) were observed to 
accumulate in the Golgi network of human bronchial epithelial and opossum kidney renal tubule 
cells in vitro (243). He et al. (2013) showed that unmodified PLGA NPs can also transport to the 
recycling endosome compartment (REC) and ER through apical early endosome (AEE)/REC and 
AEE/ER pathways in polarised Caco-2 cell monolayers (197).    
Research similar to that described herein has demonstrated the attachment of bacterial proteins 
onto microparticles can facilitate their uptake by Caco-2 cell monolayers. Rowland et al. (2005) 
coated 1 µm polystyrene particles with a fragment of internalin A, which the bacterium Listeria 
monocytogenes utilises to transport through the intestinal epithelium following an interaction with 
E-cadherin receptors; enhanced uptake by Caco-2 cell monolayers occurred for particles attached 
to internalin A, comparing with plain microparticles (244).  
 Cellular uptake and transport of NPs can be influenced by many factors. Not surprisingly, NPs 
size, surface charge, and surface coating have been identified to affect these events (245). Optimal 
NP size for uptake by Caco-2 cell is considered to be 100 – 200 nm in diameter (137); the size of 
the tested fPS NPs in this study was ~150 nm in diameter. In terms of surface charge, NPs 
decorated with negative materials have a higher uptake rate comparing with plain NPs, but the 
mechanism of the increased uptake has not yet been fully unravelled (137). Santos el at. (2011) 
tested the uptake of carboxylate PS NPs with sizes of 40 nm and 200 nm in HeLa and A549 cell 
lines (246). Uptake behaviours of these PS NPs appeared to be cell line-specific, and NPs showed 
to use multiple pathways to enter cells, which might include clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, as well as other uptake processes involving microtubules (246, 
247). It is also important to note that most of these studies were performed on non-polarised cells, 
for polarised cells, the effects of NPs characteristics on the uptake and transport are rarely studied. 
For polarised cells, such as Caco-2 cell monolayers herein, they have apical-basal polarity, and 
the apical and basolateral membranes are composed of different proteins and lipids. Accordingly, 
their uptake and transport of substances will probably be totally different from the non-polarised 




that more work is needed in order to have a comprehensive understanding of NPs uptake and 
transport, specifically the knowledge for polarised cells.  
The unexpectedly low transcytosis rate of ntPE-mediated fPS NPs might be due to absence of 
LRP-1, the cell receptor for ntPE. Data presented herein suggests that ntPE-mediated fPS NPs 
could enter polarised Caco-2 cells but may not be able to complete the transcytosis process to be 
detected in the basolateral compartment. Perhaps, AC NPs-ntPE entered the cell through a non-
LRP-1 mechanism, which limited their ability to complete the intracellular trafficking processes 
involved in ntPE transcytosis. Interestingly, others have noted that compounds which need a 
carrier-mediated transport process, showed a lower transport rate when they were tested in Caco-
2 cell monolayers compared to the test in vivo (248). If this is applicable to this study, the presence 
of the membrane-associated carrier proteins, in this case, LRP-1, needed to be verified.   
 
4.3.2 Identification of LRP-1 on Caco-2 cells 
 
Toquet et al. (2007) suggested that expression of LRP-1 is down-regulated by 48 % in 
adenocarcinoma cells; a lower LRP-1 expression in the Caco-2 cells used in these monolayers 
studies might explain why the transport levels of ntPE-mediated NPs were significantly lower 
than expected. Further, low expression of LRP-1 in adenocarcinoma cells can be a consequence 
of high albumin concentration in the culture medium (232, 249). Thus, the impact of albumin on 
LRP-1 expression in the Caco-2 cell model used in these studies was examined.   
Three different conditions were used to culture Caco-2 cells and the expression of LRP-1 was 
compared between these conditions: 1) culture medium has serum all the time, labelled as “S+”; 
2) “S-” stands for cells were in the absence of serum for 12 h before the analysis; 3) and culture 
medium has no serum all the time was labelled as “-”.  Western blot analysis suggested that LRP-























 Figure 4-6 : Western blot analysis of LRP-1 expression in Caco-2 cells (n=3). The 
expression of LRP-1 in Caco-2 cells which were cultured with serum all the time 
(“S+” ) did not show significant difference comparing to “S-” (cells in the absence 
of serum for 12h before the analysis), *p=0.73 > 0.05; nor comparing to “-” (cells 
were cultured without serum), ***p=0.64 > 0.05. There was so significant 
difference between the conditions of “S-” and “-” for the expression of LRP-1, 





4.3.3 In vitro transcytosis of AC NPs  
 
After a 60 min incubation the transport percentage for blank AC NPs was 2.83 ± 1.29 %, while 
for AC NPs-BSA and AC NPs-nPE was 4.18 ± 2.05 %, 4.36 ± 2.24 %, respectively (Figure 4-7).  
 
Compared to fPS NPs, more AC NPs appeared to have transported across the Caco-2 cell 
monolayers after 60 min of incubation, although an exact comparison of these two studies cannot 
be made without some way of calibrating transport properly. One reason for the possible transport 
increase observed with AC NPs may have been greater particle flexibility allowing better 
accommodation into forming apical endosomal structures. Unlike rigid and stable fPS NPs 
structures, AC NPs are comparatively soft, flexible and labile structures (Figure 3-11), which are 
formed by electrostatic interactions between chitosan and alginate (142). In addition, these 
polyelectrolyte complexes are sensitive to the change of environment, such as the change of pH 
and ionic strength (218, 250). The ionic strength of the cell culture medium is higher than the 
solution in which these AC NPs were suspended. This change in ionic strength might have altered 
the structure of these AC NPs, making them more likely to transport across Caco-2 monolayers 
in vitro. As demonstrated in Chapter 2, fewer NPs were found in simulated intestinal fluid (pH6.8) 
using a transmission electron microscope. Furthermore, chitosan is able to reversibly alter the 
functional properties of tight junctions without altering cell viability (251). Therefore, the 
 
Figure 4-7: Transport percentage of AC NPs across Caco-2 cells monolayers. The transcytosis rate 
for unmodified AC NPs, AC NPs-BSA and AC NPs-PE was 2.83 ± 1.29 %, 4.18 ± 2.05 % and 4.36 ± 
2.24  %, respectively  (n=3, *p=0.60 > 0.05, AC NPs-ntPE compared to blank AC NPs; **p=0.84 > 
0.05, AC NPs-ntPE compared to AC NPs-BSA). 
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chitosan component of these NPs might have additionally affected the paracellular pathway of 
these Caco-2 cells monolayers.  
AC NPs coupled with BSA and ntPE showed an increased percentage transport compared to 
unmodified AC NPs (in Figure 4-7). Proteins coupled onto the surface of AC NPs changed the 
zeta potential from 20 ± 8 mV to -19 ± 11 mV for AC NPs-BSA, and to -6 ± 5 mV for AC NPs-
ntPE, respectively (as described in Chapter 3). Although it is generally understood that positively 
charged NPs have higher cell internalisation rate compared to negatively charged NPs (146), 
Bannunah et al. (2014) demonstrated that the transport rate of negatively charged polystyrene 
NPs were two times higher than the positively charged ones in Caco-2 cell monolayers, even 
though the positive NPs were internalised more than the negative ones (141).  
     Chitosan and alginate are mucoadhesive polymers and generally regarded as safe. They have 
shown promise as nano-carriers for insulin, suggested by the observed pharmacological effects in 
rats compared to a solution of insulin alone (143). The physicochemical properties of AC NPs 
have been well characterised, as well as their in vitro release of the loaded drugs (insulin, 
nifedipin, and doxorubicin) in stimulated gastric and intestinal fluid (143, 252, 253). AC NPs 
have shown to be taken up by MCT-7 cells and HeLa cells with loading with doxorubicin and 
curcumin, respectively (253, 254). Katuwavila et al.(2016) proposed these AC NPs were non-
selectively internalised via endocytosis by MCT-7 cells (253). Ma et al. (2003) suggested that 
clathrin-mediated endocytosis might be involved in the uptake of these NPs in Caco-2 cell 
monolayer, as the uptake was considerably reduced with the co-administration with 
chlorpromazine, which is considered to be an inhibitor of clathrin-related endocytosis (255). In 
addition, they reported that a low level of AC NPs was detected in the basolateral side of this cell 
monolayer. In a more recent study, Chen et al. (2008) assessed the transport of N-trimethyl 
chitosan NPs loaded with FITC-BSA across Caco-2 cell monolayers, and showed increased 
permeation when the NP surface was modified with alginate compared to control FITC-BSA NPs, 
but the mechanism of the uptake and transport is unknown (127). 
Although NPs have demonstrated different levels of cell uptake, the fate after endocytosis and 
the potential transcytosis needs to be elucidated. In principle, three pathways could occur after 
NPs are internalised in the endosomal vesicle: 1) recycling back to the apical membrane; 2) 
transporting to the lysosomes for degradation; or 3) trafficking to the opposite membrane whereby 
NPs are released from the cell.  He et al. (2013) showed a low transcytosis of PLGA NPs across 
the polarised Caco-2 cell monolayers. This low rate is mainly due to: 1) the exocytosis to the 
apical side, which is significantly regulated by Golgi complex and ER, and 2) the lysosome 





Compared to AC NPs coupled with BSA, AC NPs-ntPE did not show a significant increase in 
transport across the Caco-2 cell monolayers (**p=0.84 > 0.05), suggesting these two types of NPs 
transported non-selectively across the cell monolayers. Considering the changes in the TEER 
values during the transcytosis study (Figure 4-8), the paracellular pathway might have been 
involved in the transport process due to the presence of chitosan in NPs composition. Chitosan 
has shown to induce a redistribution of tight junction-associated protein (Claudin-4) and it 
accompanies the increased paracellular permeability (75). It should be noted that the cell 
monolayers were cultured overnight in a fresh medium after the transcytosis study and showed 
that TEER values returned to pre-treatment levels (data not shown). 
To better appreciate the transport process involving AC NPs, Caco-2 cell monolayers were 
observed using a confocal microscope following staining to demonstrate ZO-1 and nuclei after 
60 min of apical exposure to the AC NPs. ZO-1 was stained red and nuclei were in blue; AC NPs 
became detectable after the chemical coupling of FITC to chitosan. For blank AC NPs, the green 
fluorescence was mostly co-localised with tight junctions (ZO-1), suggesting the possible effects 
of chitosan (in Figure 4-9d). The observed fluorescence signals from AC NPs-BSA were in a 
similar pattern as unmodified AC NPs, most of them were located on the edge of the cells (Figure 
4-9h). Fluorescent green dots were detected in the cells which had been treated with AC NPs-
ntPE for 60 min. In addition to the co-localisation with ZO-1, some AC NPs-ntPE (Figure 4-9l) 
were found to be in close proximity to nuclei as was observed for fPS NPs-ntPE (Figure 4-5l).  
 
Figure 4-8: Measurement of TEER during the transcytosis of AC NPs. TEER values decreased with 
the addition of AC NPs, but remained above 300 Ω·cm-2 during the experimental course (n=3).     
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Figure 4-9: Representative confocal images of AC NPs on Caco-2 cell monolayers. Green signals from blank AC NPs and AC NPs-BSA 
appeared to associate with the tight junctions (labelled by red) on Caco-2 cell monolayers (in d and h), comparing to them, AC NPs-ntPE 





These studies did not support the contention that ntPE can facilitate the transcytosis of AC 
NPs across Caco-2 cell monolayers. There were, however, a greater amount of AC NPs-ntPE in 
the Caco-2 cell monolayers compared to blank AC NPs and AC NPs-BSA (Figure 4-9). This 
phenomenon might be because the intracellular trafficking required for transcytosis did not occur 
as it would in vivo. One possible reason is that the structure of ntPE was altered by the process 
used to attach it onto NPs. Interestingly, others have noted that compounds which need a carrier-
mediated transport process, showed a lower transport rate when they were tested in Caco-2 cell 
monolayers compared to the test in vivo (248). If this is applicable to this study, might suggesting 
an alternative model is needed.  
 
4.3.4 Circular dichroism spectra of ntPE and AC NPs-ntPE  
      
The measured low transport of ntPE-mediated AC NPs may be due to a loss of transcytosis 
capacity following ntPE’s attachment to AC NPs surface. This might be caused by protein 
denaturation that occurs as part of the chemical coupling.   
The secondary structure of ntPE before and after conjugation was examined using CD 
spectrometry. CD spectra obtained for ntPE prior to and after its coupling to NPs were very similar 
(Figure 4-10), suggesting that conjugation with AC NPs did not change the secondary structure 
of ntPE significantly. These spectra were similar to data published previously (256). The 
 
Figure 4-10: Far-ultraviolet CD spectra of free ntPE and ntPE on the surface of AC NPs. The 
spectra of the two samples were in a very similar pattern, suggesting that the secondary structure 
of ntPE did not change after the chemical conjugations with AC NPs.   
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secondary structure performance index of free ntPE: α-helix, β-sheet, turns and random coil was 
4.8 %, 35.5 %, 18.7 %, 41.0 %, respectively (in Table 4-1) (257), and after conjugating with AC 
NPs, it had the same performance index as ntPE molecules alone.  
 
Table 4-1: Analysis of secondary structure of ntPE and AC NPs-ntPE 
 α-helix β-sheet turns random coil 
ntPE 4.8 % 35.5 % 18.7 % 41.0 % 
AC NPs-ntPE 4.8 % 35.5 % 18.7 % 41.0 % 
 
 
4.3.5 In vitro transcytosis of ntPE-A546 and FITC-BSA 
 
FITC-BSA served as a control for studying the transcytosis of ntPE-A546, and both of them 
have been applied onto the apical compartment of Caco-2 cell monolayers for 120 min incubation. 
The transport rate of FITC-BSA and ntPE-A546 were comparable when corrected for initial 
fluorescence values and final values. Limited amounts of FITC-BSA and ntPE-A546 molecules 
were detected in the basolateral compartments of Caco-2 cell monolayers (Figure 4-11). 0.06 % 
of FITC-BSA molecules were detected from the basolateral compartment after 120 min 
incubation, which had a similar transport outcome as Bies et al. (2004) reported (88). The 
measured transport rate of ntPE-A546 did not show statistically significant difference from 
FTTC-BSA (*p=0.67 > 0.05), with 0.05 % of ntPE-A546 molecules transported from the apical 
to the basolateral side. Comparing to a previous study which showed 6 % of ntPE transported 
from the apical side to basolateral side of Caco-2 cell monolayers, suggesting that the specific 
transport pathway did not occur for ntPE-A546 in this study (229). However, this previous study 
is not totally comparable to the transcytosis study herein, as ELISA (enzyme-linked 
immunosorbent assay) was used to detect the transported ntPE, and this method is more sensitive 




                                     
 
There was little chance for FITC-BSA and ntPE-A546 molecules to go across the barrier via 
the paracellular pathway, as the TEER values were >350 Ω·cm-2 during the transcytosis study 
(Figure 4-12), suggesting sealed cell tight junctions have limited the extent of non-specific 


























Figure 4-11: Transport percentage of FITC-BSA and ntPE-A546 across the Caco-2 cell 
monolayers. The transcytosis rate for FITC-BSA was 0.06 % and for ntPE-A546 was 
0.05 % (*p=0.67 > 0.05, n=3).  
 
Figure 4-12: Measurement of TEER value during the transcytosis of FITC-BSA and ntPE-
A546. The TEER values remained above 350 Ω·cm-2 during the transcytosis study, 
suggesting that tight junctions were kept integral (n=3). 
 





Confocal microscopy showed limited amounts of FITC-BSA molecules associated with Caco-
2 cell monolayer (Figure 4-13), which was consistent with the low transcytosis of FITC-BSA. 
Green fluorescent dots were found in the intercellular spaces. It is possible that FITC-BSA 
molecules interacted with cell membranes specifically, or just remained on the cell surface after 
the rinse in the apical compartment.  
 
 
Albumin is a metabolic transporter in the body, involved in the transport of copper, and fatty 
acid from the intestinal lumen into the capillaries (258, 259). Gp60 is a widely distributed cell-
surface receptor, which has the ability to facilitate the internalisation and subsequent transcytosis 
of albumin across the endothelial cells (260, 261). Besides gp60, cubilin, a multi-ligand receptor 
on the cell membranes, and megalin, a large transmembrane protein, were shown to bind with 
albumin (262, 263). Birn et al.(2000) demonstrated that cubilin, in conjugation with megalin, has 
an essential role in the uptake of albumin (i.e. reabsorption) by the proximal tubules of the kidney 
(262). Since both of these two cell membrane proteins are expressed in the intestinal epithelial 
cells, a similar mechanism for transporting albumin may be involved in the current studies (264). 
 ntPE molecules were tracked by coupling Alexa Fluor® 546 onto the free thiol groups of ntPE, 
and ZO-1 on cell membrane was visualised by staining with FITC (Figure 4-14). Extensive 
amounts of ntPE-A546 molecules were observed to be localised in a peri-nuclear site of Caco-2 
cells, after 120 min application to the apical surface of these cell monolayers.  
 ZO-1 FITC-BSA           DAPI      Merge 
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Figure 4-13 : Representative confocal images of FITC-BSA in Caco-2 cell monolayers. There were few FITC-
BSA molecules associated with Caco-2 cells, and appearing between enteroctyes  (green: FITC-labelled BSA, 





Internalisation and early intercellular trafficking of PE in non-polarised cells is believed to 
involve multiple pathways. Smith et al. (2006) proposed that there are at least two possible 
pathways used by PE to reach the ER (endoplasm reticulum) in HeLa cells that avoid degradation 
in lysosomes (114). One of these is KDEL-receptor mediated pathway (Figure 4-15), where PE 
molecules bind to LPR-1 on the apical membrane and are internalised via clathrin-coated vesicles. 
Following LRP-1-mediated protein endocytosis, PE is subsequently trafficked from the EE (early 
endosomes) to the LE (late endosomes), and further to the TGN (trans-Golgi network). Once in 
the TGN, the C-terminal REDL motif of PE binds to the KDEL receptor and the molecule is 
transported to the ER in a retrograde manner (113, 114).    
              
 
 nt PE-A546 ZO-1 DAPI Merge 
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Figure 4-14: Representative confocal images of ntPE-A546 in Caco-2 cell monolayers. Considerable amounts 
of ntPE-A546 were on Caco-2 cell monolayers, and in close proximity to the nuclei (red: ntPE-A546, green: 
ZO-1, blue: nucleus, scale bar= 25µm). 





The alternative pathway is the lipid-dependent sorting pathway (Figure 4-15). Laurent (2015) 
proposed that this pathway involves ntPE binding to the DRM (detergent-resistant microdomains) 
associated with GM1 ganglioside present on the plasma membrane, as well as to LRP-1 receptors 
in DRM. Whether these bindings occur simultaneously is unknown (2). It is possible, however, 
that ntPE binds to LRP1 (via domain I) and GM1 (via domain II), and the internalised proteins 
were being transported into Golgi and ER via a Rab-6 controlled lipid-dependent sorting pathway 





































Figure 4-15: PE can utilise multiple pathways to move from the plasma membrane to the ER. One 
pathway is KDEL-receptor mediated pathway, where PE molecule is internalised following the 
recognition with LRP-1. Subsequently, PE travels from EE to LE and further to the TGN, where the 
C-terminal REDL motif of PE binds to the KDEL receptor and transports to ER. Lipid-dependent 
sorting pathway involves PE binding to LRP-1 and GM1, and transporting into Golgi and ER via a 
Rab-6 controlled lipid-dependent sorting pathway. PM, plasma membrane; DRM, detergent-
resistant membrane micro-domain; EE, early endosome; LE, late endosome; L, lysosome; TGN, 





In terms of polarised cells, the transport pathway has not been elucidated yet. By comparison 
to other bacterial toxins, like a member of the AB5 toxin family, cholera toxin (CT), we might 
obtain clues regarding the transcytosis pathway of ntPE and better understand the low transcytosis 
measured in this study.  
CT is one of the virulence factors secreted by the intestinal pathogen Vibrio cholera. Using 
polarised monolayers of the human epithelial cell line T84, CT transcytosis was shown to involve 
selected short chain or flexible fatty acid containing forms of GM1. In this case, CT-GM1 
complexes in the Golgi apparatus transport to the ER in a retrograde manner (266).  
Carter (2014) suggested that the transport of ntPE across the polarised Caco-2 cells might be 
influenced by GM1, as the addition of CT considerably reduced the transport of PE across the 
Caco-2 cell monolayers (121). The competition between CT and ntPE binding to GM1 seemed to 
suggest that the intracellular pathway, which involves GM1, is the optimal route for the 
transcytosis of ntPE across the polarised Caco-2 cell monolayers. Further, Pang et al. (2004) 
observed low internalisation of CT in Caco-2 cells and attributed it to the low expression of GM1 
on the plasma membrane (267). This low expression of GM1 might explain the observed low 
transcytosis of ntPE across the Caco-2 cell monolayers reported here, as well as in Laurent’s study 
(2).  
 
4.4 Conclusion  
 
Following the conjugation of ntPE onto fPS NPs and AC NPs in Chapter 3, the ntPE-mediated 
transport ability was tested in an in vitro model: Caco-2 cell monolayers. For stable fPS NPs, 
BSA-coupled fPS NPs showed increased transcytosis compared to unmodified fPS NPs and fPS 
NPs-ntPE. The gp60 proteins on the cell membrane might have facilitated the transport of fPS 
NPs-BSA across Caco-2 cell monolayers in this study. Unmodified fPS NPs and fPS NPs-ntPE 
appeared to transport via a non-specific pathway, there was no suggestion that the paracellular 
barrier was diminished in these studies. 
In general, AC NPs had higher transcytosis rates than fPS NPs, possibly due to the greater 
flexibility of these structures and/or due to the presence of chitosan, which can reversibly open 
tight junctions. A lower than expected transcytosis rate was also observed for AC NPs coupled to 
ntPE. Decreased levels of LRP-1 was tentatively ruled out by western blot analysis, although the 
functional properties of LRP-1 were not examined. Initially, the low transcytosis observed for 
ntPE-mediated NPs was considered due to the alteration of ntPE’s structure after the attachment 
onto NPs. However, CD analysis showed that the secondary structure of ntPE was not 
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dramatically changed by the process used to attach it to NPs. Free ntPE was also observed to have 
a lower than expected transport rate across the Caco-2 cell monolayers. Based upon confocal 
microscopy, it appears that ntPE, whether by itself or attached to NPs, was able to enter Caco-2 
cell monolayers but stopped in the transcytosis process in a peri-nuclear compartment consistent 
with the Golgi apparatus or endoplasmic reticulum. By comparison, BSA by itself or after 
coupling to NPs failed to demonstrate a similar intracellular localisation. 
Based upon all of these findings, it is hypothesised that defects in the intracellular trafficking 
pathways of the Caco-2 cells used in these studies may have led to the lower than expected 
transcytosis of ntPE. Importantly, GM1 was previously shown to affect ntPE transcytosis and its 
low expression in Caco-2 cells resulted in the low transcytosis of CT, which might explain the 
low transcytosis measured for ntPE (121, 267). Rather than perform an extensive series of studies 
in an attempt to understand/correct the trafficking defects observed in these in vitro studies, the 
















Chapter 5    In vivo study of ntPE-coupled nanoparticles 
Overview:   
Aim: To test the transcytosis of nanoparticles mediated by ntPE in a rat model via intraluminal 
administration.  
Methods: Transcytosis of fluorescent polystyrene nanoparticles (fPS NPs) and alginate chitosan 
nanoparticles (AC NPs) was tested in the jejunum region of the small intestine of rats using 
intraluminal injections. After the exposure of NPs on the epithelium for 15 min and 30 min, the 
tissues were isolated and processed by an immunofluorescence protocol. Nuclei in the epithelium 
were stained with DAPI, red fluorescent fPS NPs were observed using a confocal microscope. 
The location of AC NPs-ntPE was determined using immunofluorescence to detect ntPE on the 
surface of AC NPs. Green fluorescent protein (GFP) was used as a model biopharmaceutical (MW 
= 26 kDa; pI = 5.7) loaded into AC NPs-ntPE. GFP-loaded AC NPs were administered following 
the same protocol as previous NPs, and using the fluorescein labelled antibody to track GFP using 
confocal microscopy.  
Results: Localisation of blank fPS NPs or those conjugated with BSA or ntPE was assessed in 
the lamina propria at 15 min and 30 min following the injection of 166 µg fPS NPs-ntPE into the 
intestinal lumen. There were no detected fluorescence signals for blank fPS NPs nor fPS NPs-
BSA in the villi, but fPS NPs-ntPE were found in the lamina propria. AC NPs and GFP-loaded 
AC NPs were also found in the lamina propria of the small intestine in a manner dependent upon 
the coupling of ntPE. Overall, ntPE-mediated NPs showed potential of being a trans-epithelial 













5.1 Introduction  
In chapter 4, the transcytosis of fPS NPs and AC NPs mediated by ntPE was tested in Caco-2 
cell monolayers. Those studies failed to demonstrate a robust transport of these NPs in that in 
vitro model. It was concluded that the Caco-2 monolayer used possibly has low expression of 
GM1, which is important for the transport of ntPE, therefore this cell monolayer, may have not 
provided the normal transcytosis trafficking typically observed in vivo (248). Thus, the feasibility 
of using ntPE to facilitate the trans-epithelial transport of NPs was tested in vivo.  
The anatomy of the intestinal epithelium was introduced in Chapter 1, these tissues will be 
discussed in additional detail here. Intestinal epithelium functions not only as a barrier to 
unwanted solutes, this tissue is also responsible for selectively absorbing nutrients from the 
lumen, as well as maintaining the homeostatic conditions of the small intestine (23). Underneath 
the epithelium is a loose connective tissue called lamina propria that functions to organise blood 
and lymphatic vessels (referring to central lacteal), as well as a wide variety of circulating immune 
cells and resident cells involved in local humoral and adaptive immunity (Figure 5-1). Dendritic 
cells (DCs) are one cell population in the lamina propria involved in antigen presentation, being 
able to extend processes between two adjacent enterocytes and sample bacteria from the lumen 
(268). Overall, the lamina propria is a place for regulating immune function, providing 
nourishment for the epithelium, and processing/passing nutrients absorbed across the epithelium.  
 
Figure 5-1: Illustration of the small intestinal mucosa. The epithelium rests upon an underlying layer of 
connective tissue, lamina propria, which it itself supported by layers of smooth muscles named as muscularis 
mucosa. The finger-like projections are named villi, and the wells between these epithelial-lined villi are 




The intestinal epithelium consists of a 
monolayer of columnar epithelial cells 
covered by a mucus layer (Figure 5-2) 
(33). Enterocytes are the most common 
cells of the intestinal epithelium, with 
microvilli expressed at the apical 
(luminal) surface that are referred to as a 
brush border. Another commonly 
present cell type in the intestinal 
epithelium is the goblet cell. These cells 
produce mucin and release it onto the 
luminal surface of the intestinal epithelium. This mucus layer forms a barrier to help limit the 
invasion of pathogens or noxious substances (33). The mucoadhesive polymers chitosan and 
alginate were used in this study to form NPs, in order to increase interactions with the mucus at 
the surface of the epithelium (126).      
Microfold (M) cells are located individually or in lymphoid follicle-associated epithelium. M 
cells play an important role in the immune response as they internalise antigens from the intestinal 
lumen via endocytosis, and deliver them to underlying lymphoid cells (35). M cells have less 
irregular microvilli and mucus layer compared to the enterocytes, and account for only ~1% of 
the surface area of the epithelium (77). For that reason, Hussain et al.(1997) pointed out that the 
importance of M cells for delivering biopharmaceuticals should not be over-emphasised (82). 
Nevertheless, M cells have attracted considerable interest as a transport route.  
Non-toxic Pseudomonas exotoxin (ntPE) is able to transport across simple columnar epithelial 
cells, such as that present in the small intestine (229). ntPE was attached onto the surface of NPs 
in this work, and the feasibility of using ntPE to facilitate the transport of NPs across the 
epithelium was tested in a rat in vivo model.  
Conventional in vivo studies assess the oral bioavailability of an agent by comparing the 
plasma level vs. time curves following oral administration to that of an intravenous (IV) 
administration (231). Oral gavage was not performed here, because the NPs’ location and 
concentration within the intestine would be uncertain over time. Instead, intraluminal injection 
was performed to allow examination of specific intestinal locations to directly ascertain the 
potential for NP uptake. By using this method, the behaviours of NPs in the epithelium would be 
assessed specifically. Furthermore, intraluminal injection studies would allow the visualisation of 
the transport process, as well as localisation of transported NPs within the lamina propria of the 
small intestine. No IV administrations of the NPs was performed as the goal of these studies was 
to examine ways to facilitate NP delivery to the lamina propria and not the systemic circulation. 
 
Figure 5-2: Image of villi in the small intestine. The villi are 
lined by simple columnar epithelial cells (enterocytes) and 





These in vivo studies also allowed assessment of mucus and intestinal motility on NP uptake, 
aspects that cannot be readily evaluated using polarised epithelial cell monolayer in vitro. 
A non-degradable, commercial NP system (fPS NPs) was initially used to study the ntPE-
mediated transport process. Although fPS NPs do not provide a viable carrier for the delivery of 
biopharmaceuticals, these NPs remain stable during the course of the experiment. By comparison, 
AC NPs are biodegradable and have the capacity to encapsulate biopharmaceuticals. The potential 
of using ntPE-mediated AC NPs for delivering biopharmaceuticals across the epithelium was 




5.2.1 In vivo transcytosis of fPS NPs 
5.2.1.1 In vivo transcytosis assay protocol  
 
Male Wistar rats (250-300 g; approximately 7-9 weeks old, bred in-house) were maintained 
on a 12 h light/day cycle. All experiments were conducted during the light phase. Animals were 
anesthetised under 5 % isoflurane and maintained in an anesthetised state using 4 % isoflurane 
(administered by mask) during surgery. Animals were placed on a warming pad throughout the 
procedure to maintain a stable body temperature. A 4 – 5 cm midline abdominal incision was used 
to expose the small intestine. After selection of a site within the mid-jejunum that contained 
minimal food, fPS NPs (166 µg or 332 µg for fPS NPs-ntPE, 332 µg for blank fPS NPs and fPS 
NPs-BSA) suspended in PBS (pH 7.3, Phosphate-buffered saline, Dulbecco “A” Tablets, 
BR0014G, Oxoid Ltd) were injected into the lumen using a 21 G needle (0.8 × 16 mm, BD 
MicrolanceTM, 304434, Becton Dickinson). The adjacent mesentery was marked with indelible 
ink and the intestinal segment was returned to the abdominal cavity until the tissue to be harvested 
for analysis.  
Concentrations of NPs and exposure times after injection are given in Table 5-1. fPS NPs-
ntPE were used in condition 1 to condition 3, condition 1: 166 µg of with 15 min exposure time; 
condition 2: 166 µg with 30 min exposure time; and condition 3: 332 µg with 15 min exposure 
time. The condition for unmodified fPS NPs and fPS NPS-BSA was 332 µg with 15 min exposure 
time. After 15 or 30 min, the animal was euthanised using CO2 and a 2 cm intestinal section 
encompassing the injection site was isolated. The dissected tissue was cut longitudinally and the 
luminal surface washed with ice-cold PBS prior to placing it (splayed flat) in a cassette with the 




(paraformaldehyde, P6148, Sigma-Aldrich) onto the luminal surface. After 20 min at 4 °C, fixed 
tissue was processed by tissue processor for 18 h (TP 1020, Leica Miscrosystems). Sections of 
small intestine (5 µm) were subsequently cut using a microtome (Biocut 2035, Leica 
Microsystems) and mounted onto polylysine slides (P4981, Thermo Scientific). 
 
Table 5-1: Detailed information of different conditions 
 Type of NPs Concentration Volume Exposure 
time 
Fluorescent tag 
Condition 1 fPS NPs-ntPE 
 
1666 µg/mL 100 µL 15 min FluoSpheres® 
(Ex/Em: 580/605) 
Condition 2 fPS NPs-ntPE 
 
1666 µg/mL 100 µL 30 min FluoSpheres® 
(Ex/Em: 580/605) 
Condition 3 fPS NPs-ntPE 
 
1666 µg/mL 200 µL 15 min FluoSpheres® 
(Ex/Em: 580/605) 
Condition 4 AC NPs-ntPE 86 µg/mL 250 µL 15 min Alexa Fluor® 546 
(Ex/Em: 556/573) 
Condition 5 AC NPs-ntPE 86 µg/mL 250 µL 30 min Alexa Fluor® 546 
(Ex/Em: 556/573) 
Condition 6 GFP-AC NPs-
ntPE 





Slide-mounted cut sections were processed by successive 5 min immersions of Histo-Clear 
(solution 1, HS-200, National Diagnostics), Histo-Clear (solution 2), and 100 %, 90 %, 80 %, 70 
% ethanol solutions (20821.330, VWR chemicals). Tissue sections were then washed three times 
with PBS for 5 min each time. Cell nuclei within the tissue sample were then stained by 30 min 
incubation with DAPI (4’, 6-diamino-2-phenylindole, Dihydrochloride, D1306, Thermo Fisher 
Scientific) at RT. After rinsing with PBS and then water, sections were dehydrated in 70 % and 
100 % ethanol for a few minutes each, followed by immersion in Histo-Clear solution 1 for 5 min 
and 100 % ethanol for a few minutes. Processed tissue sections were mounted using Fluoroshield 
Mounting Medium (ab104135, Abcam) prior to placement of a glass cover slip (12342118, 22×50 
mm, Fisher Scientific). Confocal microscopy, performed using a Zeiss LSM 510 microscope, was 
used to identify and localise fPS NPs in processed tissue sections. The corrected total cryosection 
fluorescence (CTCF) was calculated by analysing 11 images of each condition (269). The 
equation used was: 
CTCF=media of integrated density - (media of area of selected cell × mean fluorescence of 




5.2.2 In vivo study of AC NPs 
 
A volume of 250 µL of AC NPs (suspended in PBS, kept in 4 °C before injection) was 
administered using the same protocol as described above for fPS NPs (in section 5.2.1). Condition 
4: 250 µL of AC NPs-ntPE for 15 min of exposure and condition 5: 250 µL of AC NPs-ntPE for 
30 min of exposure. Following fixation, imbedding, sectioning and mounting onto polylysine 
slides, tissue samples were rehydrated by successive 5 min immersions into Histo-Clear (solution 
1), Histo-Clear (solution 2), and 100 %, 90 %, 80 %, 70 % ethanol solutions and then washed 
three times with PBS for 5 min. AC NPs were tracked in a confocal microscope by using 
immunohistochemistry to stain ntPE. Antigen retrieval was performed by immersing slides in 
boiling 10 mM sodium citrate buffer at pH 6.0 for 10 min. After the antigen retrieval process, 
tissue sections were then permeabilised for 30 min at RT using 0.2 % Triton X-100 (X100-
500ML, Sigma-Aldrich) in PBS and incubated at RT for 2 h in blocking buffer (containing 2 % 
BSA, A7906-100G, Sigma-Aldrich; 2 % donkey serum, D9663-10 mL, Sigma-Aldrich; and 0.1 
% Triton-X 100 in PBS) prior to incubation in primary antibody (rabbit polyclonal anti-
pseudomonas exotoxin A, P2318-1ML, diluted 1:1000) in PBS containing 0.1 % Triton X-100 
and 1% BSA overnight at 4 °C. Excess primary antibody was removed by rinsing in PBS prior to 
incubation at RT for 2 h in a secondary antibody solution (Alexa Fluor® 546-conjugated donkey 
anti-rabbit polyclonal IgG, diluted 1:100, A10040, Life TechnologiesTM) containing 0.1 % Triton 
X-100 in PBS. Afterwards, tissue sections were incubated with DAPI for 30 min at RT and rinsed 
using PBS and then water. After dehydration in 70 % and then 100 % ethanol for a few minutes 
each, tissue sections were exposed to Histo-Clear solution 1 for 5 min and 100 % ethanol for a 
few minutes prior to the addition of Fluoroshield Mounting Medium (ab104135, Abcam). A glass 
cover-slip was placed onto the tissue sample which was then analysed in a Zeiss LSM 510 
microscope. The CTCF was calculated from 16 images of each injection condition.  
 
Examination of CD11c+ dendritic cells by immunohistochemistry staining 
Dendritic cells in the lamina propria of rat jejunum were visualised using immunofluorescence 
staining. After antigen retrieval process, tissue sections were permeabilised for 30 min at RT using 
0.2 % Triton X-100 in PBS and incubated at RT for 2 h in blocking buffer (containing 2 % BSA, 
2 % donkey serum, and 0.1 % Triton-X 100 in PBS) prior to incubation in primary antibody 
(rabbit polyclonal anti-Pseudomonas exotoxin A and mouse monoclonal anti-CD11c antibody, 
diluted 1:1000) in PBS containing 0.1 % Triton X-100 and 1 % BSA overnight at 4 °C. Excess 
primary antibody was removed by rinsing in PBS prior to incubation at RT for 2 h in a secondary 




Fluor® 488 conjugated donkey anti-mouse polyclonal IgG, (ab150109, Abcam) diluted 1:100) 
containing 0.1% Triton X-100 in PBS. Afterwards, tissue sections were incubated with DAPI for 
30 min at RT and rinsed using PBS and then water. After dehydration in 70 % and then 100 % 
ethanol for a few minutes each, tissue sections were exposed to Histo-Clear solution 1 for 5 min 
and 100 % ethanol a few minutes prior to the addition of Fluoroshield Mounting Medium 
(ab104135, Abcam). A glass cover-slip was placed onto the tissue sample, which was then 
analysed in a Zeiss LSM 510 microscope. 
 
5.2.3. In vivo study of GFP-loaded AC NPs  
 
GFP-loaded NPs were prepared by adding GFP into AC NPs suspensions. The details can be 
found in Chapter 2.2.4. A 250 µL volume of GFP-loaded AC NPs-ntPE and GFP-loaded AC NPs-
BSA (suspended in PBS, kept in 4 °C before injection) was injected into the lumen of rat small 
intestine for 30 min. Tissue preparations used for confocal microscopy closely followed the 
protocol described in section 5.2.1.2, the only difference was the immunofluorescence staining 
was performed to determine GFP, refer to Table 5-1. Blocking buffer containing 2 % BSA, 2 % 
goat serum (G9023-10 mL, Sigma-Aldrich), and 0.1 % Triton-X 100 in PBS was used, the 
primary antibody was rabbit polyclonal anti-GFP (ab6556, Abcam) and the secondary antibody 















5.3 Results  
5.3.1 In vivo transcytosis of fPS NPs  
 
Rat jejunum tissues exposed to NPs for different times (15 min and 30 min) and at different 
doses (166 µg and 332 µg) were collected and processed as described in section 5.2. 
Internalisation of fPS NPs occurred shortly after the intraluminal injection (Figure 5-3) shown in 
confocal microscopy. The finger-like structures (in Figure 5-3a, c, d, e and f) were identified as 
villi, and the nuclei of cells were stained by DAPI. Goblet cells can be found between two 
enterocytes (yellow arrows in Figure 5-3a and b). They are responsible for secreting glycoproteins 
named mucins, which generate a protective mucus blanket overlying the epithelial surface (270).  
 
With the treatment of 166 µg fPS NPs-ntPE for 15 min (condition 1) on the luminal side of 
epithelium, some red fluorescence signals were found in the lamina propria (Figure 5-3, white 
arrows) and they were considered to be the accumulation of fPS NPs-ntPE.  
Images in Figure 5-4 show the tissue segments following exposure to fPS NPs-ntPE for an 
increased exposure time of 30 min (condition 2). The same dose of 166 µg as the previous study 
was used. Red fluorescent dots were found in the lamina propria using confocal microscopy 
(Figure 5-4), this outcome was consistent with the 15-min study (Figure 5-3). The observed 
fluorescent signals refer to the accumulated NPs in the tissue, since confocal microscopy is unable 






















Figure 5-3: Representative confocal images of fPS NPs-ntPE in the villi (condition 1: 166 µg for 15 
min). After exposing to NPs for 15 min, red fluorescence suggesting fPS NPs-ntPE were collected in 
the villi. Goblet cells in the epithelium were indicated by yellow arrows in (a) and (b), the internalised 
and collected NPs are pointed in (c), (e), and (f) by white arrows. Images on the right column are 
magnified from the white frame, can be found in the images on the left column (red: fPS NPs, blue: 










Figure 5-4: Representative confocal images of fPS NPs-ntPE (condition 2: 166 µg for 30 min). Red 
fluorescence signals (representing fPS NPs-ntPE) were detected in the lamina propria after exposing 
lumen to fPS NPs-ntPE for 30 min, suggesting the uptake and transport of fPS NPs-ntPE was still 
occurring at 30 min after the intraluminal injection.  fPS NPs-ntPE appeared to be in close proximity 
with the DAPI-stained nuclei in the lamina propria in (d). Images on the right column are magnified 
from the white frame, found in the images on the left column (red: fPS NPs-ntPE, blue: nuclei, scale 





A longer transcytosis study was not carried out, given exposure times longer than 30 min are 
perhaps not meaningful to study; rapid internalisation is preferred for delivering 
biopharmaceuticals via the oral route, considering the harsh environment in the lumen might 
affect the bioactivity of the delivered cargos (271).   
fPS NPs-ntPE were found in the lamina propria regardless of the exposure time (15 min or 30 
min). This outcome showed that fPS NPs had gone across the epithelium, but the transport route 
is unknown. Quantifying these NPs in the lamina propria is desirable, although no standard 
method exists (272). Generally speaking, two approaches have been undertaken to quantify 
measures in fluorescence microscopy images, concrete statistics and abstract statistics. Concrete 
statistics include counting measures such as volume occupied by a structure, and the number of 
structures in a region. While, the abstract statistics measure properties of an image such as 
morphology or texture (273). In this study, concrete statistics was chosen and carried out by 
summing up the red fluorescence intensity in the villi using software Image J (from 11 images). 
The summed values were considered to represent the amounts of fPS NPs found in the villi (274). 
The background fluorescence was subtracted from the fluorescence intensity in each image, and 
the intensity of fluorescence signals was calculated using a reported equation (corrected total 
crysection fluorescence, CTCF) (269).  
The total calculated red fluorescence intensity in the tissue after exposure for 15 min, was in 
a similar range as the isolated tissues after 30 min-treatment (Figure 5-5). This might suggest that 
fPS NPs-ntPE were translocated via the blood or lymphatic vesicles, or were taken up by the 
immune cells in the lamina propria. If there was no translocation of fPS PS-ntPE occurring, more 
and more internalised fPS NPs would be accumulated in the lamina propria rather than in a 
sustained amount as observed. It is unlikely for the internalised NPs to stay in cells/tissues for 30 
min, since this transport study was performed in a living rat. It is important to note that this 
interpretation is only based on the acquired confocal images, which were samples from part of 
the treated tissues. Regarding the dynamic transport process of NPs, a real-time tracking study 





To understand how the transport of fPS NPs might be influenced by concentration, the luminal 
side of the epithelium was exposed to 332 µg of fPS NPs-ntPE (condition 3), which was double 
the amount of NPs compared to the previous two conditions. Red fluorescent dots were the signals 
from the accumulated fPS NPs-ntPE in the villi, after 15 mins of intraluminal injection of NPs 
into the lumen side of small intestine (in Figure 5-6). The associations with these cells might 
suggest that fPS NPs were collected in the cells present in the lamina propria. 
   
 
 
Figure 5-5: Comparison of the red fluorescence intensity from tissues being treated with fPS NPs-
ntPE at different conditions.  Condition 1: 166 µg for 15 min; condition 2: 166 µg for 30 min; and 
condition 3: 332 µg for 30 min. The amounts of red fluorescence intensity suggested the amounts of 
fPS NPs accumulated in the villi, condition 1 and condition 2 was in a similar range. The 
administration of double amounts of fPS NPs into the small intestine seemed to result in double 
amounts of measured red fluorescence intensities collected in the villi, which suggesting the transport 

































   
 
 
Figure 5-6: Representative confocal images of ntPE-coupled fPS NPs (condition 3: 332 µg for 15 min). 
As shown in (b), fPS NPs-ntPE were co-localised with DAPI-stained nuclei cells present in the lamina 
propria. The relatively wide structure found (yellow arrows) in figure (d) was considered to be the Peyer’s 
patch, which has shown the ability to take up NPs. In the magnified image (d), these blue-stained cells 
were considered to be cells present in Peyer’s patch, as they were less organised compared to the stained 
enterocytes in (b) and (f). Images on the right column are magnified from the white frame, which can be 








The thin finger-like structure (indicated by green arrows in Figure 5-6c) was identified as a 
villus, while on the right side of it, the round and wide structure appeared to be a Peyer’s patch 
(yellow arrows in Figure 5-6c). The DAPI-stained cells in Figure 5-6d appeared to be in an 
irregular organisation compared to cells seen in Figure 5-6b and f. They might be M cells present 
in the Peyer’s patches, which are responsible for transporting luminal antigens (and bacteria) to 
the underlying immune cells that either activate or inhibit the immune response (275). It is within 
expectation to see NPs accumulated in the Peyer’s patch, as studies have demonstrated the Peyer’s 
patch is able to absorb and assemble particles < 1 µm (276, 277). It is also possible that these 
irregular shaped cells were caused by the sample processing, particularly the sectioning part.  
Compared to the intestinal tissues treated with 166 µg of fPS NPs-ntPE for 15 min (condition 
1), double amounts of administrated fPS NPs-ntPE seemed to result in double amounts of 
measured fluorescence values (Figure 5-5). It is known that the variable microscope settings in 
different studies would bring difficulties in comparing images (278). Although these measured 
fluorescence values represent accumulated fPS NPs in selected slices of the isolated tissue (150-
200 slices cut, only ~25 slices imaged), it is possible to compare between tissues prepared and 
visualised in the same protocol. The transport of fPS NPs mediated by ntPE appeared to have a 
concentration effect. Higher doses of fPS NPs are needed to be tested in future work, for a more 
comprehensive understanding of ntPE-mediated transport of NPs. 
To investigate the role of ntPE in the transport of fPS NPs, unmodified fPS NPs and fPS NPs-
BSA were also administered to the luminal side of epithelium for 15 min. No red fluorescence 
signals were detected in the villi using a confocal microscope (Figure 5-7a). Following the 
isolation of tissue from the animal, extensive rinsing was carried out to wash away any residues 
on the lumen side, perhaps the unspecific-attached NPs were washed away. It is also possible that 
confocal microscopy is unable to detect these NPs, as they were in small amounts and the 
fluorescence intensity might be below the detection limit of confocal microscopy. In addition, this 
observation cannot exclude the possibility that unmodified fPS NPs and fPS NPs-BSA were 
quickly taken up and translocated, therefore, they could not be detected in the villi any more. fPS 
NPs-BSA were found to accumulate on the edge of the epithelium (Figure 5-7b), although no 
trace of fPS NPs-BSA was detected in the other 10 confocal images for this condition. This 
outcome suggested the importance of ntPE for the internalisation of fPS NPs.   






Following the administration of fPS NPs-ntPE into the lumen of rat small intestine, fPS NPs-
ntPE appeared to accumulate underneath the epithelium observed using confocal microscopy. 
This outcome supports the hypothesis that ntPE is able to facilitate the transport of NPs across the 
epithelium. Therefore, its feasibility to mediate a nano-carrier loaded with biopharmaceutical to 
transport across the intestinal barrier will be tested.  
 
5.3.2 In vivo transcytosis of AC NPs  
 
AC NPs have shown the ability to encapsulate proteins in Chapter 2. Prior to using this nano-
carrier to deliver biopharmaceuticals, the transport of AC NPs mediated by ntPE was tested in 
vivo using the same protocol as fPS NPs-ntPE. Unlike fPS NPs which have impregnated 
fluorophores, AC NPs were visualised using Alexa Fluor® 546-conjugated antibody to track ntPE 
on the surface of NPs. Several attempts were made to visualise the fluorescence labelled AC NPs, 
while no fluorescence signals were detected using confocal microscopy, this might be due to the 
damage brought by the fixation process.   
Red fluorescence dots in the lamina propria represented the accumulation of AC NPs, which 
can also be found on the surface of the epithelium, shown in Figure 5-8. AC NPs appeared to 
accumulate under the basolateral side (yellow arrows, Figure 5-8d), and be collected in a DAPI-
stained cells (white arrows, Figure 5-8).  
 
a b 
Figure 5-7: Representative confocal images of unmodified fPS NPs and fPS NPs-BSA in the villi. (a) No 
red fluorescence was detected in the villi of which lumen side had been exposed to 332 µg of unmodified 
fPS NPs for 15 min; and (b) BSA coupled-fPS NPs seemed to be accumulated on the surface of the 








Figure 5-8: Representative confocal images of AC NPs-ntPE in the villi (condition 4: 250 µL for 15 min). 
Red fluorescent dots in the lamina propria suggested the accumulation of AC NPs-ntPE, red 
fluorescence can also be found on the surface of the epithelium and on the basolateral side of the 
epithelium (yellow arrows). Images on the right column are magnified from the white frame, found in 








After the intraluminal injection of AC NPs-ntPE with 30 min exposure, red fluorescence 
signals were still found in the villi (Figure 5-9). Apart from locating in the lamina propria, some 
collected AC NPs were found in a close proximity to the DAPI-stained nuclei of the enterocytes 
in Figure 5-9b (yellow arrows), and Figure 5-9e (yellow arrows). Mathiowitz et al. (1997) 
demonstrated that NPs (made by polyanhydride copolymer of fumaric and sebacic acid) were 
taken up by the absorptive enterocytes observed using transmission electron microscopy; and NPs 
were visible in the dilated Golgi apparatus and secretory vesicles near the lateral edge of the cells. 
The mechanism of entry was not clear (277).  
Red arrow (in Figure 5-9b) indicates the goblet cell in the epithelium. McDole et al. (2012) 
showed that goblet cells would allow small soluble protein antigens to the lamina propria via the 
goblet cell-associated pathway, and this pathway is size-dependent, as particles bigger than 20 
nm did not enter this pathway (279). For this reason, it was unlikely for AC NPs (~200 nm 
diameter) in this study to undertake the goblet cell-associated pathway. Later on, Howe et al. 
(2014) supported the importance of particle size on the internalisation via goblet cell-associated 
cells, and suggested that NPs (polystyrene, 40 nm) can be taken up by enterocytes via a clathrin-
mediated endocytosis. Besides, Howe et al. (2014) also observed that NPs in the lamina propria 
co-localised with CD11c+ dendritic cells, following 30 min of exposure after intraluminal 
injection (280).  
CD 11c are membrane proteins expressed in dendritic cells, macrophages and neutrophils 
(281, 282). AC NPs’ accumulation appeared to co-localise with CD 11c+ cells using a 
fluorescence antibody bound to CD 11c (Figure 5-10). It is well known that dendritic cells play a 
key role in the regulation of the intestinal immune response (283). Farache et al. (2013) showed 
dendritic cells can sample antigen directly from the intestinal lumen, likely using tight junction 
proteins to penetrate the epithelium (284). This uptake route might also occurred in the transport 
of AC NPs-ntPE herein, considering CD 11c is highly expressed in dendritic cells. Green 
fluorescent signals (for CD 11 c+) were found in the enterocyte and between two adjacent 
enterocytes (white arrows, in Figure 5-10b), this might suggest that these immune cells travel 
across the intraepithelial route to take up antigens from the lumen, particularly dendritic cells 
(285). An attempt to understand the role of macrophages in the uptake of NPs was not performed, 








Figure 5-9: Representative confocal images of AC NPs-ntPE in the villi (condition 5: 250 µL for 30 min). 
AC NPs-ntPE (red fluorescence) were still detectable after 30 min of exposure time. AC NPs-ntPE 
accumulated on the basolateral sides of epithelium, and were also in close proximity to the enterocytes 
(yellow arrows). Images on the right column are magnified from the white frame, can be found in the 










The red fluorescence intensity in the villi after 15 min- and 30 min- treatment with AC NPs-
ntPE was measured and summed up from 16 images (Figure 5-11). The tissue exposed to AC 
NPs-ntPE for 30 min seemed to have lower fluorescence values compared to 15min tissue-
exposure time. It is consistent with the observation from the confocal images, that fewer red 
fluorescence signals were found on the surface of the epithelium for 30-min treatment. Although 
confocal images may not represent the whole uptake and trans-epithelium process of AC NPs-
ntPE, at least it showed that AC NPs-ntPE can be taken up and translocated within 15 min. In 
terms of delivering biopharmaceuticals, a short exposure time to the harsh environment is 
beneficial for preserving the structure of biopharmaceuticals (23). 
 
 
              
 
 
Figure 5-10: Representative confocal images of AC NPs-ntPE in the villi co-localising with CD 11c+ cells. 
AC NPs-ntPE were stained by the red fluorescence, cells expressing CD 11c were presented by green 
fluorescence, and nuclei were in blue. The accumulated AC NPs-ntPE were found to be co-localised with 
CD 11c+ cells. Green fluorescence labelled CD 11c+ cells can also be found on the surface of the 
epithelium and between two enterocytes, suggesting these immune cells were in the process of taking up 






5.3.3 In vivo transcytosis of GFP loaded AC NPs  
 
ntPE seemed to facilitate AC NPs transport across the epithelium, thus to evaluate whether 
these ntPE-coupled nano-carriers are able to deliver biopharmaceuticals or not, GFP was loaded 
into AC NPs. The GFP-loaded AC NPs were prepared and administered into rat small intestine 
by intraluminal injection, and the transport was evaluated by tracking GFP using a fluorescein-
labelled secondary antibody using confocal microscopy.  
Although GFP is auto-fluorescent, the fixation process damaged the fluorescent signals, so 
that GFP was tracked by using a fluorescent antibody. The confocal images in Figure 5-12 
captured the moment of transporting GFP-loaded AC NPs-ntPE across the epithelium. Green 
fluorescence signals representing the accumulated AC NPs, can be found on the surface of 
epithelium (yellow arrows, Figure 5-12f and c) and inside of the enterocytes (red arrows, Figure 
5-12b and Figure 5-12c); and some were located in the lamina propria (white arrows). 
It is understood that the detection of GFP in the confocal microscopy does not necessarily 
indicate these proteins were still encapsulated in AC NPs. Furthermore, the bioactivity of the 
delivered proteins needs to be evaluated in the future.  
 
 
Figure 5-11: Comparison of the fluorescence intensity of AC NPs-ntPE in two isolated 
tissues. Condition 4 was for tissue of which lumen side was exposed to 250 µL AC NPs-ntPE 
for 15 min, and condition 5 was for 30 min. The uptake of AC NPs-ntPE occurred quickly 





An equivalent negative control was prepared by loading GFP into AC NPs-BSA and was 







Figure 5-12: Representative confocal images of GFP-loaded AC NPs (condition 6: 250 µL for 30 min). 
Green fluorescent dots (representing the accumulated GFP-loaded AC NPs) can be found on the surface 
of the epithelium (yellow arrows); inside of the enterocytes (red arrows); and in the lamina propria. 
Images on the right column are magnified from the white frame, can be found in the images on the left 




fluorescent signals (perhaps from GFP-loaded AC NPs-BSA) were located outside of the villi 
(white arrows in Figure 5-13b) and some were associated with the epithelium (yellow arrows in 
Figure 5-13). No accumulation of AC NPs was detected in the villi, this might suggest that these 
NPs did not travel across the epithelium (as ntPE-coupled NPs did) or that they had been 
internalised and were no longer located in the villi. Certainly, more quantification strategies are 
needed to assess the ntPE-mediated transport and evaluate its feasibility as a carrier for trans-
epithelial drug delivery in the future. It is also important to note that the detected fluorescence 
signals only represent the location of GFP, might not always indicate the location of AC NPs.  
 
5.4 Conclusion  
 
This study has supported the hypothesis that ntPE attached to the surface of NPs can facilitate 
the delivery of NPs to a selected cell population within the lamina propria. NPs conjugated with 
BSA, a molecule with similar physicochemical properties as ntPE, or unmodified NPs failed to 
demonstrate similar delivery to the lamina propria. These control samples have been tested 
closely following the protocol used for ntPE coupled NPs. While this study was carried out in 
rats, Pseudomonas aeruginosa is known to be a human pathogen and the actions of ntPE could 
therefore be considered in potential clinical applications. These studies were restricted to the 
jejunum, but it is quite possible for ntPE to similarly facilitate the delivery of NPs to other 
segments of the small intestine and possibly the large intestine as well. 
 
 
Figure 5-13: Representative confocal images of GFP-loaded AC NPs-BSA in the villi. Green 
fluorescence representing the accumulation of GFP-loaded AC NPs-BSA was found on the surface of 
the epithelium or in the luminal side, indicating that AC NPs-BSA did not carry GFP across the 





The size of the NPs used in these studies were restricted to ~200 nm in diameter or less. LRP-
1 has shown to be the surface receptor for ntPE and the internalisation of ntPE is reported to be 
via clathrin-mediated vesicle endocytosis (226). Clathrin-coated endosomes are very consistent 
in size due to the geometry of organised triskelion proteins, resulting in a size limitation up to 200 
nm diameter (286). Larger NPs could enter cells via pathways involving phagocytosis or 
pinocytosis without the involvement of clathrin (287). Such uptake is more commonplace in M-
cells where the microfold characteristic is more accommodating to larger particles (224).  
NPs (~ 100 – 200 nm in diameter) were very difficult to observe individually by the confocal 
microscope available for these studies. Individual NPs crossing the epithelium of rat small 
intestine could not be observed since they are not visible until they were collected into locations, 
such as in phagocytic/antigen presentation cells present in the lamina propria. This was validated 
using an antibody to detect CD 11c, which is highly expressed in dendritic cells. Thus, the 
transport of NPs across rat epithelium was only inferred by the detection of clustered NPs after 
their delivery to the lamina propria. Future studies with a higher resolution confocal, and 
detection of antigens specific to vesicle compartments that define the various intracellular 
trafficking routes, would provide valuable information regarding the transcytosis route of these 
NPs.  
The quantity of fPS NPs detected in the lamina propria was observed at 15 and 30 min, and it 
correlated with high levels of NPs applied to the luminal surface of the epithelium. NPs were 
observed to be collecting in discrete cells of the lamina propria by 15 min, and these clustered 
NPs were more prominent 30 min after their introduction into the intestinal lumen. These 
observations suggest that ntPE-mediated NPs transport rat epithelium can occur shortly after the 
injection. Such a transport timeline is consistent with the other transcytosis processes that utilise 
ATP to ensure directed, rather than random, movement of vesicles within the cell.  
Overall, these in vivo studies showed the importance of ntPE for the transport of NPs across 
the intestinal epithelium, and these ntPE-coupled NPs are worthy of continued research. Stable 
fPS NPs-ntPE appear to provide a tool for future studies to better define the route of NPs across 
the intestinal epithelium and fate within the lamina propria. The demonstration of GFP delivery 
to the lamina propria using GFP-loaded AC NPs-ntPE, however, shows the potential 
pharmaceutical promise of this approach. While future studies with fPS NPs-ntPE might be more 
amenable for pharmacokinetic types of outcomes, therapeutic protein-loaded AC NPs-ntPE 
should provide opportunities to examine outcomes associated with the pharmacodynamics of this 
oral route of administration.   




Chapter 6    General discussion and future work  
 
The aim of this thesis was to develop a nano-carrier that could be used for the delivery of 
biopharmaceuticals across the intestinal epithelium, following oral administration in a dosage 
form that would protect the material during passage through the stomach. Specifically, the 
strategy presented herein was organised to identify and validate a polymeric biodegradable NP, 
which could be chemically conjugated at its surface with a non-toxic form of a bacterial exotoxin 
that had been previously suggested to traffic across polarised intestinal epithelia. To achieve and 
evaluate this strategy the following steps were performed: (a) biodegradable NPs using alginate 
and chitosan (AC NPs) were prepared and their characteristics to favour uptake and transcytosis 
were optimised; (b) these NPs were chemically conjugated to a non-toxic version of Pseudomonas 
aeruginosa toxin (ntPE); (c) transcytosis of the ntPE-coupled NPs was evaluated in vitro using 
Caco-2 cell monolayers; (d) the trans-epithelial transport of the ntPE-coupled NPs in vivo was 
tested by direct injection into the rat small intestine; and finally (e) the potential of these NPs to 
deliver biopharmaceuticals across the intestinal epithelium was evaluated, by examining the 
loading of a model protein (green fluorescent protein; GFP) into AC NPs. The following 
discussion is based upon key aspects and outcomes of these studies.   
 
Characteristics of nanoparticles 
Nano-carrier size is an important property that can directly affect their interactions with and 
trafficking within polarised intestinal epithelial cells. As expected, size measurement in DLS and 
TEM were different for the NPs prepared in these studies. Size measured by DLS was considered 
to be more relevant for these studies, since both alginate and chitosan are hydrophilic polymers 
and their application would be affected by their properties in a hydrated environment. Thus, the 
hydrodynamic size measured by DLS should best represent the physiological conditions for their 
ultimate use in vivo.  
Based upon information available for the transport of NPs in intestinal epithelial cells, 100 – 
200 nm is the optimal size range. It is anticipated that NPs conjugated at their surface with ntPE 
would utilise the transport route involving clathrin-coated vesicle entry, which restricts entering 
materials to a size of < 200 nm in diameter.  
The characteristics of NPs were affected by changes in preparation parameters. For instance, 
the concentration and ratio of the polymers used had a direct impact on NP size, while the pH had 
great influence on NP size and surface charge as assessed by zeta potential measurement. 




ionisation state of the polymers used and their solution conformation. In this regard, the present 
studies identified pH 4.5 as optimal to produce NPs in the desired size range of 100 – 200 nm. 
Higher or lower pH conditions led to solubility problems of chitosan or alginate that compromised 
the ability to generate NPs with the desired characteristics. 
Surface charge has also been demonstrated as a parameter that affects NP transcytosis. While 
this would be affected to some extent by the surface coupling of ntPE, we assumed this 
physicochemical property to not be extensively affected. BSA-coupled NPs were prepared with 
similar characteristics as ntPE-coupled NPs. Due to difficulties with the Caco-2 cell monolayer 
model that was used to examine this question in vitro, a definitive outcome regarding the effects 
of surface charge on NP transcytosis was not obtainable. Studies performed with Caco-2 
monolayers resulted in apical uptake of NPs but their transcytosis was halted within the cells at a 
location consistent with the Golgi network or endoplasm reticulum.  
Density of transport ligands on the NP surface is another important factor. As different ligand 
density would lead to different characteristics of NPs as discussed earlier, ultimately this would 
have impacts on cell uptake and transport. It is challenging to report a precise ligand density, due 
to the lack of an accurate method of counting NPs, which is important information to determine 
the number of ligands on each NP. Future work on quantification of NPs would upgrade the 
understanding of the ligand-coupled NPs to a more sophisticated level.    
 
In vitro and in vivo studies 
The attachment of ntPE onto AC NPs was carried out to test the hypothesis that NPs could be 
ferried across intact, polarised intestinal epithelium using the transcytosis pathway utilised by this 
exotoxin. While this could not be readily assessed in vitro due to technical problems with the 
Caco-2 monolayers, in vivo studies were successful.  
It remains unclear why the Caco-2 monolayers performed so poorly as an in vitro model for 
NP transcytosis in these studies. The Caco-2 monolayers used were verified to express LRP1, the 
receptor known to be used by PE (and ntPE) to enter cells. Its presence was consistent with the 
finding that ntPE-NPs entered into these monolayers, but they simply failed to complete the 
process of transcytosis and appeared to become trapped in an intracellular compartment. Some 
unpublished studies have suggested that PE (and ntPE) also engages the ganglioside GM1 as part 
of the transcytosis pathway utilised by this exotoxin. Since the nature of this potential interaction 
is still poorly understood, the issue of GM1 levels or GM1 localisation within polarised epithelial 
cells was not followed up.  




In vivo studies demonstrated that BSA-coupled NPs were poorly absorbed compared to ntPE-
coupled NPs at 15 and 30 min after intraluminal injection into rat jejunum. BSA has comparable 
physicochemical properties to ntPE and was used as a protein that could be coupled to the surface 
of NPs, as a control for presence of a surface-coupled protein. NtPE-coupled NPs were observed 
to accumulate in the lamina propria of rat small intestine, ntPE-NPs strikingly out-performed the 
BSA-NPs in terms of the number of particles undergoing transcytosis and the extent of cells in 
the lamina propria which had concentrated these NPs after transcytosis. Importantly, these studies 
supported the concept that ntPE-NPs moved across intestinal epithelial cells in a time course and 
via intracellular locations that are consistent with a receptor-mediated, energy-driven, vesicular 
pathway.   
For ntPE-coupled NPs, it appeared that they were sequestered in the immune cells (i.e. 
macrophage and dendritic cells) present in the lamina propria. There are two main reasons for 
this assumption. Firstly, macrophages function to clear particles from a tissue, and dendritic cells 
are antigen-presenting cells and patrol the lamina propria. Secondly, PE (and ntPE) are known to 
target macrophage and dendritic cells, since the receptor (LRP1) for PE (and ntPE) is expressed 
by these cells. Future work on identifying the location of ntPE in the lamina propria is worth 
pursuing.  
It is important to state that confocal microscopy is a qualitative, but not quantitative method 
to detect the NPs tested in these studies. Further, the extent of NPs that have undergone 
transcytosis is assessed by their presence in the epithelial cells and retention in the lamina propria. 
While the data presented suggests that ntPE-NPs were much more efficiently transported than 
BSA-NPs, it is possible that large amounts of BSA-NPs could have crossed the epithelium and 
were removed from the lamina propria by vascular and/or lymphatic vessels. For accurate 
tracking of individual NPs at a systemic level (in vivo), more precise equipment, such as an IVIS® 
Imaging System with high resolution, would be necessary.  
A fluorescent dye was used to localise NPs during their transcytosis and fate within the lamina 
propria. When GFP loaded into AC NPs-ntPE was detected, it suggested that this model protein 
was being transported across the intestinal epithelium and sequestered into the lamina propria. 
Whether the GFP molecules detected were still encapsulated inside the NPs is unknown. GFP 
signal was localised within enterocytes as well as within cells of the lamina propria. This was 
consistent with the transcytosis and macrophage fate previously observed for markers used to 
define the NPs coupled with ntPE. Interestingly, in the case of BSA-coupled NPs both the NPs 






Oral delivery of biopharmaceuticals 
     Nano-carriers have the potential to facilitate the delivery of biopharmaceuticals via the oral 
route.  While extensive studies have been carried out in this field, there are still many challenges 
that need to be addressed.  
     Protein stability is critical for maintaining its specific functions. In this regard, nano-carriers 
can be used to protect loaded biopharmaceuticals. A conjugated surface ligand, in this case ntPE, 
is also a component that must remain stable. While the general size of AC NPs prepared here 
remained the same for 7 days, longer storage studies that include different conditions need to be 
considered in the future to ensure stability. Means of improving the stability of these nano-carriers 
would be valuable for the future work, as some precipitation was noticed in the suspension after 
24 h storage.   
The relatively large surface area of NPs offers the advantage of high drug loading, related to 
this the control of accurate dose appears to be fundamental. Even though the reproducibility of 
NP formation and biopharmaceutical loading/encapsulation can be solved, the reproducibility in 
the release of loaded drugs must be also studied for developing a final oral formulation.  
Overall, this work has provided data to support the hypothesis that a novel strategy using 
bacterial toxin-coupled NPs to transport biopharmaceuticals across the intestinal epithelium is 
feasible. These NPs were shown to transport across the intestinal epithelium and accumulate in 
the lamina propria of the rat small intestine. There are still, however, many challenges (such as 
stability, release, toxicity and dose uniformity) for developing this strategy into a feasible oral 
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Appendix 1 Protocol for Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis 
 
Recipes: 
Reducing sample buffer 2X (1 mL): 500 µL of 4X NuPAGE® LDS buffer, 200 µL of NuPAGER 
reducing agent 200, and 300 µL of MQ H2O. 
Running buffer (Tris-Glycine) 10X (1 L): 30.3 g of Tris, 144 g of glycine, and 10 g of sodium 
dodecyl sulphate.  
Staining solution (1 L): 500 mg of Coomassie Brilliant Blue R-250, 400 mL of ethanol, 100 mL 
of glacial acetic acid, and 500 mL of MQ H2O.  
Destain Solution (1 L): 100 mL of methanol, 70 mL of glacial acetic acid, and 830 mL of MQ 
H2O.  
Recipes for 10 polyacrylamide gels. 12% Bio-Tris acrylamide, 1 mm thick gels: 
Resolving gel: 16.8 mL of 40 % Bis-Tris acrylamide, 14.0 mL of 1.5 M Tris-HCl pH 8.8, 560 µL 
of 10% SDS, 560 µL of 10% ammonium persulfate, 56 µL of tetramethylethylenediamine, and 
24.0 mL of MQ H2O.  
Stacking gel: 3.0 mL of 40% Bis-Tris acrylamide, 5.0 mL of 0.5 M Tris-HCl pH 6.8, 200 µL of 
10% SDS, 200 µL of 10% ammonium persulfate, 20 µL of tetramethylethylenediamine and 11.6 
mL of MQ H2O.  
The mixtures for resolving gel were poured into gel cassettes to about 75 % total volume. Butanol 
was used to fill up the gel cassettes, in order to ensure that the gel set flat and without bubbles. 
Gels were allow to polymerise for 45 min at room temperature. Later on, the butanol was 
discarded and the stacking gel solution was applied. Gel combs containing 12 wells were inserted 
into the stacking gel at the top of the cassette prior to polymerisation and gels were left to set for 
another 30 min.   
Procedures: 
10 µL of samples (collected protein fractions) were mixed with 50 µL of reducing sample buffer 
and 20 µL of the mixture were loaded onto polymerised gel which was placed on an XCellTM Sure 
lock® Mini-cell tank with running buffer.  
The first well was filled with 15 µL of a standard protein ladder (10-170 KDa). Gels were allowed 




Coomassie stain solution on a rocking platform. Finally, protein bands were observed after the 





























 Appendix 2 Ellman’s reagent reaction 
 
Materials preparation:  
Reaction buffer: 0.1 M sodium phosphate, 1 mM EDTA, and 50 mL of MQ H2O, at pH 8.0. 
Ellman’s Reagent solution: 4 mg Ellman’s reagent were dissolved in 1 mL of reaction buffer.  
0.15 mM cysteine solution (dissolved in PBS) was prepared as positive control. 
Measurement: 
50µL of Ellman’s Reagent solution and 2.5 mL of reaction buffer were added into a 5 mL 
Eppendorf tubes. 250 µL of unknown sample was added into tube 1, 250 µL of reaction buffer 
was added to a tube 2 as a blank, and 250 µL of 0.15mM cysteine solution was added into tube 3 
as a positive control. All these solutions were mixed and incubated at RT for 15 min. Absorbance 
of each sample was measured at the wavelength of 412nm using a spectrophotometer. The 
concentration of the free thiol groups in the unknown sample was calculated using the adapted 
equation follows: 𝑐 =
11.2𝐴
𝑏𝐸
, where A=absorbance, b=path length in centimetres, E= molar 
extinction coefficient, which is 14,150 M-1cm-1. 
 
 
 
